[biotech-news] BIOCHEMISTRY: Mad Cow Mechanism May Be Integral to Storing Memory

[famouswba]

BIOCHEMISTRY: PRIONS : ARTICLE: Mad Cow Mechanism May Be Integral to
Storing Memory

Whitehead Institute Contacts: Kelli Whitlock or David Cameron
Phone: 617.258.5183
E-mail: newsroom @ wi.mit.edu

Columbia University Contact: Annie Bayne
Phone: 212.305.3900
E-mail: as862 @ columbia.edu

Mad Cow Mechanism May Be Integral to Storing Memory


"CAMBRIDGE, Mass. (Dec. 24, 2003)  Scientists have discovered a new 
process for how memories might be stored, a finding that could help 
explain one of the least-understood activities of the brain. Whats 
more, the key player in this process is a protein that acts just 
like a prion a class of proteins that includes the deadly agents 
involved in neurodegenerative conditions such as mad cow disease.

The study, published as two papers in the Dec. 26 issue of the 
journal Cell, suggests that this protein does its good work while in 
a prion state, contradicting a widely held belief that a protein 
that has prion activity is toxic or at least doesnt function 
properly.

For a while weve known quite a bit about how memory works, but weve 
had no clear concept of what the key storage device is, says 
Whitehead Institute for Biomedical Research Director Susan 
Lindquist, who coauthored the study with neurobiologist Eric Kandel 
at Columbia University. This study suggests what the storage device 
might be  but its such a surprising suggestion to find that a prion-
like activity may be involved.

Central to a proteins function is its shape, and most proteins 
maintain only one shape throughout their lifetime. Prions, on the 
other hand, are proteins that can suddenly alter their shape, or 
misfold. But more than just misfolding themselves, they influence 
other proteins of the same type to do the same. In all known cases, 
the proteins in these misfolded clusters cease their normal function 
and either die or are deadly to the cell  and ultimately to the 
organism.

For this reason, Kausik Si, a postdoc in Kandels lab, was surprised 
to find that a protein related to maintaining long-term memory 
contained certain distinct prion signatures. The protein, CPEB, 
resides in central-nervous-system synapses, the junctions that 
connect neurons in the brain. Memories are contained within that 
intricate network of approximately 1 trillion neurons and their 
synapses. With experience and learning, new junctions form and 
others are strengthened. CPEB synthesizes proteins that strengthen 
such synapses as memories are formed, enabling the synapses to 
retain those memories over long periods.

For the study, the team extracted the CPEB protein from a sea slug. 
This lowly creature has achieved high status in neurobiology because 
its neurons are so big, they can be manipulated and turned into 
unusually powerful investigative tools. The researchers fused this 
CPEB to other proteins that would serve as reporters of activity, 
and then observed its behavior in a variety of yeast models. The 
researchers discovered that CPEB altered its form and caused other 
proteins to follow functioning exactly like a prion. A second 
unexpected finding was that CPEB carried out its normal function  
protein synthesis  when it was in its prion state.

This is remarkable not just because the protein executes a positive 
function in its prion-like state, says Lindquist, who also is 
professor of biology at the Massachusetts Institute of Technology. 
It also indicates that prions arent just oddballs of nature but 
might participate in fundamental processes."

--

The full article may be read at the URL above.

A list or resources and links related to this research report is 
provided at the end of this document.

Sincerely,
David Dillard
Temple University
(215) 204 - 4584






 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 


http://www.arizonabiotech.com/ >Arizona Biotech
http://groups.yahoo.com/group/biotech-news/ >Biotech News
http://www.arizonaentrepreneurs.com/ >Arizona Entrepreneurs
http://www.azhttp.com/ >Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[biotech-news] Biotechnology News and Information - Seattle Genetics Appoints Biotechnology Exp

[famouswba]

Seattle Genetics Appoints Biotechnology Expert Franklin Berger to
Board of Directors

  BOTHELL, Wash.--(BUSINESS WIRE)--July 1, 2004--Seattle 
Genetics, Inc.
(Nasdaq:SGEN) announced today that Franklin M. Berger, CFA, a 
biotechnology
industry analyst with over 25 years of experience in capital markets 
and
financial analysis, has been appointed to the company's Board of 
Directors.


  "Franklin's financial expertise and extensive knowledge of the
biotechnology industry will provide a valuable perspective to the 
company,"
stated Clay B. Siegall, Ph.D., President, Chief Executive Officer and
Interim Chairman of the Board of Seattle Genetics. "His appointment 
reflects
our ongoing commitment to foster a Board that includes highly 
qualified
independent directors to oversee Seattle Genetics' continued growth."

  Franklin Berger served most recently as Managing Director, 
Equity
Research and Senior Biotechnology Analyst at J.P. Morgan Securities 
from
1998 to 2003. In this position, he initiated team coverage of 26
biotechnology companies and was responsible for technical, 
scientific and
clinical due diligence as well as company selection. Previously, 
Berger
served in similar capacities at Salomon Smith Barney from 1997 to 
1998 and
Josephthal & Co. from 1991 to 1997. Prior to his work as a 
biotechnology
analyst, he managed Pantagruel Partners, a firm that developed early-
stage
pharmaceutical compounds for sale to drug companies and venture 
capital
firms. Berger holds an M.B.A. from the Harvard Graduate School of 
Business
Administration and an M.A. in International Economics and a B.A. in
International Relations both from Johns Hopkins University.

  About Seattle Genetics

  Seattle Genetics discovers and develops monoclonal antibody-
based
therapeutics to treat cancer and other human diseases. The company 
has built
a diverse portfolio of product candidates targeted to many types of 
cancer,
including three being tested in multiple ongoing clinical trials, 
SGN-30,
SGN-15 and SGN-40, and three in preclinical development, SGN-35, SGN-
75 and
SGN-17/19. The product candidates encompass three platform 
technologies:
genetically engineered monoclonal antibodies, antibody-drug 
conjugates
(ADCs) and antibody-directed enzyme prodrug therapy (ADEPT). Seattle
Genetics has developed leading ADC technology comprised of highly 
potent
synthetic drugs and stable linkers for attaching the drugs to 
monoclonal
antibodies. The company currently has license agreements for its ADC
technology with Genentech, Celltech Group, Protein Design Labs and 
CuraGen
and for its ADEPT technology with Genencor International. More 
information
about Seattle Genetics can be found at www.seattlegenetics.com.

  Certain of the statements made in this press release are
forward-looking. Actual results or developments may differ 
materially from
those projected or implied in these forward-looking statements.
Specifically, statements regarding the Company's continued growth are
forward-looking and actual results may differ materially from these
statements for various reasons. Factors that may cause such a 
difference
include risks related to adverse clinical results as our product 
candidates
move into and advance in clinical trials, risks inherent in early 
stage
development and failure by Seattle Genetics to secure collaborators 
or
failure of those collaborators to perform their contractual 
obligations.
More information about the risks and uncertainties faced by Seattle 
Genetics
is contained in the Company's filings with the Securities and 
Exchange
Commission. Seattle Genetics disclaims any intention or obligation 
to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.







 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 


http://www.arizonabiotech.com/ >Arizona Biotech
http://groups.yahoo.com/group/biotech-news/ >Biotech News
http://www.arizonaentrepreneurs.com/ >Arizona Entrepreneurs
http://www.azhttp.com/ >Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[biotech-news] Biotech News - Biotech Raises Nearly $15 Billion in First Half of 2004

[famouswba]

Biotech Raises Nearly $15 Billion in First Half of 2004

... turning in another strong quarter, biotech is poised for an 
excellent
year

SAN FRANCISCO, July 7 "In the history of the biotechnology industry, 
the prospects for long term success have never been greater,"
stated G. Steven Burrill, CEO of Burrill & Company, a San Francisco-
based life sciences merchant bank.  "You could sense the growing 
enthusiasm for this industry at BIO 2004 where nearly 20,000 people 
poured into the Moscone Center in San Francisco to network, 
showcase, educate, and learn about the latest advances," he 
said.  "Leaders from science, industry and governments from
all over the world attended ... a huge change from the last time the 
convention met in San Francisco in 1995 when 2,700 people came," 
Burrill noted.
"The numbers also tell a heartening tale," continued 
Burrill.  "Last year at this time, the industry had raised a total 
of nearly $8.9 billion, with $5.4 billion coming from financings and 
some $3.5 billion from partnering transactions.  This year, we've 
raised $14.5 billion with $10.2 billion from financings (almost 
double last year's numbers) and $4.3 billion from
partnering deals," he noted.  "Certainly a portion of the increase 
is coming
from the 21 IPOs that have gotten done in 2004 which have raised a 
total of
more than $1.2 billion.  While the performance of the majority of 
these
companies has been relatively flat, Eyetech, which entered the 
market in
January, has seen a spectacular increase in value ... up 104%," 
Burrill
said.
Eyetech and Pfizer announced on June 17 that they had completed the 
filing
of
a New Drug Application with the FDA for Macugen(TM) as a treatment 
for wet
age-related macular degeneration, the leading cause of adult 
blindness in
the
US.
Another newcomer, Pharmion, has enjoyed an even more dramatic 
ascent
with
shares up nearly 250% since its IPO in November 2003.  The company's 
main
focus is on the development and commercialization of treatments for
haematology and oncology patients.  Pharmion owns the development 
rights for
thrombosis medications, Innohep and Refludan and also purchased 
rights to
both
myelodysplastic syndrome treatment Vidaza (from Pharmacia) and blood 
cancer
treatment thalidomide from Celegene.  On June 3, the company 
announced that
its thalidomide medication was approved in Turkey for the treatment 
of
multiple myeloma after failure of standard therapies as well as for 
the
treatment of a severe and debilitating complication of leprosy.  
Turkey is
the
third country outside the US to approve thalidomide, following the
registrations in Australia and New Zealand for the same indications 
in Q4
03.
"It's clear that investors have changed considerably since the 
genomics
bubble of 1999-2000," noted Burrill.  "The companies that are 
entering the
market today are all more mature with strong product stories to 
tell, and
yet
only two have really taken off.  When you look at the performance of 
the
companies that forced open the IPO window in 1999, there's a sharp
contrast,"
he explained. The four companies that debuted in the final days of 
the last
century all enjoyed amazing rides, experiencing phenomenal gains on 
Wall
Street during their first six months.  Symyx saw shares rise 204% 
from
November 17, 1999 to June 30, 2000.  Likewise, shares of Tularik 
rose 111%,
Caliper's share values jumped 188% and Maxygen's shares rose 255% -- 
all in
the same time period.  But this IPO window is different, with 
average share
prices up only 29% since entering the market.
"There are two big reasons that we're not seeing the same kind of
momentum
today," explained Burrill. "One is that the general markets are 
skittish and
extremely discerning, with both the DJIA and NASDAQ treading water.  
The
other
reason is that biotech investors are very tentative and risk 
adverse ...
investors are only backing firms with products that have either 
reached the
market or are in late stage clinical trials.  You can see that there 
is far
less in the way of risk taking this time around," Burrill noted.

Financings

IPOs
The biotech IPO window was tight in Q2 04. but open nonetheless, 
with 12
new biotech firms entering the publicly traded market, bringing the 
total of
new entrants to the publicly traded biotech market from the IPO 
class of
2003-
2004 to 28 (7 in 2003, 21 so far this year).   In 2Q 04, all but two
companies
-- Barrier Therapeutics and Cytokinetics -- had to discount their 
paper in
order to get aloft.  Four delivered reasonably good returns since 
their
IPO --
Memory Pharmaceuticals, up 30%; Cytokinetics, up 14%; Alnylam, up 
26% and
Momenta Pharma, up 36%.
In April, five companies completed IPOs -- Memory 
Pharmaceuticals which
develops drugs for the treatment of central nervous system disorders 
raised
$40 million and has seen its shares increase 30% since its debut on 
April 4.
Corcept Therapeutics which develops drugs for tr

[biotech-news] Foundation for Stem Cell Research

[famouswba]

Foundation for Stem Cell Research 
  

PALO ALTO, Calif., May 6  In response to the site selection of the 
new Headquarters for the California Institute for Regenerative 
Medicine (CIRM), the Following Statement was Made by Susan 
DeLaurentis, Chief Executive Officer of the Foundation for Stem Cell 
Research:

"Now that the real estate competition is over, we must focus our
collective energy on supporting the critical work of stem cell 
research; finding cures for diseases and saving lives."

About the Foundation for Stem Cell Research

The Foundation for Stem Cell Research (FSCR) is dedicated to 
educating the public about the importance and potential benefits of 
stem cell research, promoting regenerative medicine, expediting the 
discovery of cures and treatments for patients with chronic disease 
and injuries, investigating best practices for the conduct of 
medical research and clinical trials, and advocating the realization 
of the goals of Proposition 71.

 CONTACT
 Susan DeLaurentis
 (650) 283 - 8349


SOURCE Foundation for Stem Cell Research









 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 


http://www.arizonabiotech.com/ >Arizona Biotech
http://groups.yahoo.com/group/biotech-news/ >Biotech News
http://www.arizonaentrepreneurs.com/ >Arizona Entrepreneurs
http://www.azhttp.com/ >Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[biotech-news] Bone Care International Announces Advancement of LR-103 Into Human Patients With

[famouswba]

Bone Care International Announces Advancement of LR-103 Into Human 
Patients With Stage 5 Chronic Kidney Disease

- New Vitamin D Hormone Replacement Therapy for Chronic Kidney 
Disease - 



Following the successful filing of the Investigational New Drug 
(IND) Application in March, 2005, Bone Care International (Nasdaq: 
BCII - News) announces plans to move the novel Vitamin D hormone, LR-
103, into human subjects with Chronic Kidney Disease (CKD).
The recently accepted IND focuses on the use of LR-103 to treat 
secondary hyperparathyroidism in patients with CKD. Data available 
from pre-clinical research indicate that LR-103 has the same potency 
as calcitriol, but much lower toxicity. "Early safety data from an 
ongoing Phase I clinical study with LR-103 in cancer patients 
support the expanded testing of LR-103 in patients with chronic 
kidney disease," said Charles W. Bishop Ph.D., Chief Scientific 
Officer at Bone Care International. The initial study with LR-103 in 
CKD will be a Phase I/II dose-ranging efficacy and safety study in 
patients with Stage 5 CKD or end-stage renal disease. Additionally, 
a separate study is being planned to study LR-103 in earlier stages 
of CKD.

According to the National Kidney Foundation, more than 20 million 
Americans have CKD and an additional 20 million are at risk.

About Bone Care International

Bone Care International (http://www.bonecare.com) is a specialty 
pharmaceutical company engaged in the discovery, development and 
commercialization of innovative therapeutic products to treat the 
unmet medical needs of patients with debilitating conditions and 
life-threatening diseases. Our current commercial and therapeutic 
focus is in nephrology, utilizing Hectorol®, a novel vitamin D 
hormone therapy, to treat secondary hyperparathyroidism in patients 
with moderate to severe chronic kidney disease and end-stage renal 
disease. In addition to chronic kidney disease, the company is 
developing vitamin D hormone therapies to treat hyperproliferative 
disorders such as cancer and psoriasis.


Contact:

 Bone Care International, Inc.
 Brian J. Hayden
 Chief Financial Officer
 (608) 662-7800

This press release contains forward-looking statements. Statements 
relating to future sales, costs of sales, other expenses, 
profitability, financial resources, or products and production 
schedules, or statements that predict or indicate future events and 
trends and which do not relate solely to historical matters identify 
forward-looking statements. Forward-looking statements are made 
pursuant to the safe harbor provisions of Section 27A of the 
Securities Act of 1933 and Section 21E of the Securities Exchange 
Act of 1934 and are based on management's beliefs as well as 
assumptions made by and information currently available to 
management. Accordingly, the Company's actual results may differ 
materially from those expressed or implied in such forward-looking 
statements due to known and unknown risks and uncertainties that 
exist in the Company's operations and business environment, 
including, among other factors, the ability of the Company and each 
of its suppliers of doxercalciferol, Hectorol® Injection and 
Hectorol® Capsules to meet the Company's anticipated production 
schedules, technical risks associated with the development of new 
products, regulatory policies in the United States and other 
countries, risks associated with our ability to avoid or minimize 
delays in/or interruption of the manufacture and supply of our 
products, including the approvals of regulatory authorities in 
connection therewith, reimbursement policies of public and private 
health care payors, introduction and acceptance of new drug 
therapies, competition from existing products and from new products 
or technologies, the failure by the Company to produce anticipated 
cost savings or improve productivity, the timing and magnitude of 
capital expenditures and acquisitions, currency exchange risks, 
economic and market conditions in the United States, Europe and the 
rest of the world, and other risks associated with the Company's 
operations. The Company disclaims any obligation to update any such 
factors or to publicly announce any revisions to any of the forward-
looking statements contained herein to reflect future events or 
developments.




-
---
Source: Bone Care International






 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 


http://www.arizonabiotech.com/ >Arizona Biotech
http://groups.yahoo.com/group/biotech-news/ >Biotech News
http://www.arizonaentrepreneurs.com/ >Arizona Entrepreneurs
http://www.

[biotech-news] Large Scale Biology Corporation and Planet Biotechnology Inc., Announce

[famouswba]

Large Scale Biology Corporation and Planet Biotechnology Inc., 
Announce Biomanufacturing Agreement
07/15/2004 -- Large Scale Biology
Corporation (NASDAQ: LSBC) and privately held Planet Biotechnology 
Inc., (Planet) of Hayward, California, today announced initiation of 
a biomanufacturing agreement to extract and purify Planet's lead 
product, CaroRxT, a plant-made antibody to control dental caries.

Planet's CaroRxT is the world's first recombinant plant-made 
antibody to be clinically tested, and has been shown to prevent the 
adhesion of tooth decay causing bacteria to the tooth surface. 
Planet's tobacco plants expressing CaroRxT secretory IgA will be 
extracted by LSBC at its Owensboro, Kentucky, manufacturing 
facility. CaroRxT has completed Phase I clinical trials under
an approved U.S. FDA Investigational New Drug (IND) application.

"The experience and manufacturing capabilities that LSBC offers in 
the area of plant-produced recombinant protein extraction 
complements our proprietary gene expression and product development 
technologies," stated Elliott Fineman, President and CEO of Planet 
Biotechnology. "Larger quantities of CaroRxT are needed for our 
expanded clinical trials, and testing of formulations for the 
European market. We are happy to be working with LSBC during the 
scale-up phase of product development," Mr. Fineman added.

"We are pleased to be working with Planet, a true pioneer in the 
development of plant-produced antibodies, as they expand their 
development program for their exciting new product, CaroRxT," said 
Kevin Ryan, LSBC's President and CEO. "Our new agreement with Planet 
further exemplifies LSBC's leadership role in the manufacture of 
plant-made pharmaceuticals and demonstrates the versatility of our 
Owensboro manufacturing facility in the extraction of a wide range 
of products," Mr. Ryan added.

About Large Scale Biology Corporation

Large Scale Biology uses its proprietary gene expression, molecular
engineering and bioprocessing technologies to develop and manufacture
therapeutic and industrial proteins, vaccines and diagnostic 
products for
effective characterization and treatment of disease. Corporate 
offices, R&D
laboratories and Eclipse Diagnostics Inc. are headquartered in 
Vacaville,
California, and the Company's commercial-scale biomanufacturing 
facility is
located in Owensboro, Kentucky. For more information about Large 
Scale
Biology Corporation, visit the Company's website at www.lsbc.com.

About Planet Biotechnology, Inc.

Planet Biotechnology, Inc. is a privately held, clinical-stage 
company whose
mission is to discover, develop and commercialize new
monoclonal-antibody-based therapeutic and preventative products to 
meet
significantly underserved medical needs. The Company's unique plant-
derived
antibody-based products ("plantibodies") have been produced through
cultivation of genetically modified tobacco. Planet's headquarters 
and
product development laboratories are located in Hayward, California. 
For
additional information on Planet Biotechnology Inc. please visit the
Company's website at www.planetbiotechnology.com.

This release contains forward-looking statements about applications 
of
LSBC's technologies and potential markets for product of one of our
collaborators. These forward-looking statements involve risks, 
uncertainties
and situations that may cause our actual results to differ 
materially from
those implied by these statements, including our ability to 
commercialize
one of our products, the ability of our collaborators to sell 
products we
extract or make for them, the effectiveness of our and our 
collaborators'
technologies to produce specific products and/or in a cost-effective 
manner,
any difficulties or delays in obtaining regulatory approval to test 
and
market such products, and the requirement of substantial funding for 
us to
preserve our technology base and product pipeline. We cannot 
guarantee
future results. You should not place undue reliance on these forward-
looking
statements, which apply only as of the date of this release. For a 
further
list and description of such risks and uncertainties see the reports 
filed
by Large Scale Biology Corporation with the Securities and Exchange
Commission, including our reports on Forms 10-K and 10-Q. Except as 
required
by law, we do not undertake to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.

LSBCT, our logo and GENEWARE® are trademarks of Large Scale Biology
Corporation. Planet and CaroRx are trademarks of Planet 
Biotechnology, Inc.








 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/

[biotech-news] Biotechnology Industry Trends the Focus at BIO VentureForum East 2005

[famouswba]

Biotechnology Industry Trends the Focus at BIO VentureForum East 2005

May 4, the Biotechnology Industry Organization (BIO) announced 
additional speakers at BIO VentureForum East 2005, scheduled May 9-
11 at the Intercontinental Hotel-Buckhead in Atlanta, Georgia.
BIO VentureForum East is the largest annual East Coast regional 
investor conference for venture stage biotechnology and healthcare 
firms. It features plenary sessions and workshops on financing and 
partnering trends in the biotechnology industry, networking 
receptions, and presentations by more than 90 biotech companies 
which have been selected by an advisory board of leading equity 
capital leaders.

The plenary session from 8 - 9:45am on Wednesday, May 11th, will be 
a roundtable discussion on Industry Trends for In-licensing and 
Partnering. Pharmaceutical and biotech executives will discuss 
pipeline sustainability and examine the value of collaboration. 
Panelists will also discuss partnership strategies and consequences. 
Kristopher D. Ford, Corporate Strategy and Business Development for 
UCB Pharma Inc., will moderate. Panelists include:


--  Donald L. Drakeman, President & CEO, Medarex, Inc.;
--  Robert J. Gould, PhD, Vice President of Licensing and 
External
 Research, Merck Research Labs;
--  John D. Mendlein, PhD, JD, Chairman & CEO, Affinium 
Pharmaceuticals;
--  Herbert S. Ormsbee, PhD, Senior Director of Licensing & 
Development,
 Pfizer Inc.;
--  John P. Richard, President, BioGrowth.

Thomas H. McLain will present the luncheon keynote address "Managing 
Transformative Growth" from 12 - 1:30pm on May 11th. McLain is 
Chairman, CEO and President of Nabi Biopharmaceuticals as well as 
Chairman of BioFlorida. Headquartered in Florida, Nabi 
Biopharmaceuticals ended 2004 with $103 million in cash assets and 
positive cash flow from operations.

For more information about BIO VentureForum East, please visit 
http://bvf-east.bio.org/ Registration is complimentary for 
credentialed members of the news media. Reporters and editors 
working full-time for print or broadcast news organizations may 
register onsite with valid media credentials.

BIO represents more than 1,100 biotechnology companies, academic 
institutions, state biotechnology centers and related organizations 
across the United States and in 31 other nations. BIO members are 
involved in the research and development of healthcare, 
agricultural, industrial and environmental biotechnology products.




-
---
Source: Biotechnology Industry Organization


http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/";>Arizona High Tech






 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[biotech-news] Arizona Technology Council and Arizona BioIndustry Association Sign Partnership

[famouswba]

Arizona Technology Council and Arizona BioIndustry Association Sign 
Partnership Deal  
TEMPE, Ariz. – October 12, 2004 –The Arizona Technology Council and 
the Arizona BioIndustry Association today announced a strategic 
alliance in serving their respective memberships. Working to provide 
Arizona's technology community with optimal business development 
options, public policy progress and overall leadership, the Arizona 
Technology Council and the Arizona BioIndustry Association will work 
together on matters of mutual interest, including: Cross-cluster 
cooperation in Arizona, promotion of the Arizona biotechnology and 
pharmaceutical industries, communications with national, state and 
local government, venture capital resource development, integrated 
supply chain development, technology transfer program development 
from university and private research, and promotion of K-20 
education for Arizona with emphasis on the sciences. 

The technology associations will also co-sponsor events as part of 
the strategic alliance, cross promoting to their respective 
memberships. In an effort to further solidify the open communication 
between constituencies, one member of the Board of Directors from 
each organization will sit as a non-voting delegate on the Board of 
Directors of the other organization.
 
"This partnership represents one of true mutual benefit in that both 
organizations' missions are the same: growing the tech sector in 
Arizona," said Jon McGarity, Arizona BioIndustry Association 
Chairman. "The clear objective is to build the biotech and 
pharmaceutical industries in Arizona as part of a strategic vision 
to have Arizona recognized as a top- tier center for innovation and 
technology based industries."

"The Tech Council has always included bioscience in our cadre of 
representation, but the reach will now be deeper," said Todd 
Bankofier, President and CEO of the Arizona Technology 
Council, "This partnership speaks directly to Arizona's greatest 
competitive challenge and that is its ability to build 
collaborations that eliminate duplication and serve the greater 
good."
About the Arizona Technology Council
Since its inception in 2002, the Arizona Technology Council has 
stood as the largest association of technology companies in Arizona, 
whose shared vision is for the state to be recognized as a top-tier 
center for technology-based businesses. The Council works to carry 
out this vision by driving partnerships, policies and programs that 
advance the business climate for Arizona's technology community and 
by representing, supporting and advocating for member companies 
through initiatives, advocacy, networking and effective 
communications. 

The Arizona Technology Council represents 30,000-plus employees at 
more than 400 of the leading technology companies across Arizona. 
Represented industries include advanced manufacturing, aerospace, 
biotechnology, e-learning, environmental technology, software, 
Internet applications, semiconductors, and telecommunications.

About the Arizona BioIndustry Association
The Arizona BioIndustry Association is the statewide affiliate of 
the Washington, D.C. based national organization, Bio that promotes 
the growth of bioindustry in the areas of public policy, member 
services, education, business networking, and entrepreneurial 
endeavors.  The Arizona BioIndustry Association also has a 
partnership arrangement with BIO-SA, the biotechnology association 
serving Southern Arizona and works with Northern BIOPARTNERS in 
Flagstaff. 

The Arizona BioIndustry Association currently has over 200 members 
and is growing rapidly in membership as the commitment to developing 
the biotech and pharmaceutical industries in Arizona continues to 
evolve. To learn more about the Arizona BioIndustry Association, 
visit www.azbioindustry.org.

 







 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Phoenix, Arizona Biocluster Seeks Business & Research Opportunities

[famouswba]

Phoenix, Arizona Biocluster Seeks Business & Research Opportunities 
With European Biotech Companies

Wednesday March 23, 2005

Vibrant Urban Setting Creates Unique Ambiance for 28-Acre Biocenter 


PHOENIX, AZ

The City of Phoenix has officially become the nation's newest 
biotech cluster with the grand opening of its Downtown Biomedical 
Center and worldwide headquarters for TGen (Translational Genomics 
Institute) and IGC (International Genomics Consortium). The City of 
Phoenix and State of Arizona have invested and laid the foundation 
for becoming one of the industry's foremost research centers with 
regards to neurogenomics and related research areas of alzheimer's, 
autism, cancer, and diabetes. The city seeks to attract biotech and 
related companies to Phoenix and Arizona from Europe for business 
opportunities in R&D, collaboration, partnering, and office 
expansion.
Source: City of Phoenix  


 
The Phoenix Biomedical Center provides a unique, urban environment 
for cutting edge companies to expand offices or open R&D centers. 
The $46 million TGen/IGC building forms the foundation of the PBC, a 
28-acre development area planned near the epicenter of Copper 
Square -- a thriving and rejuvenated section of Phoenix featuring 
sports, music, theatre, restaurants and other entertainment and 
cultural venues. The futuristic, 173,000-square-foot TGen/IGC 
building is owned by the City of Phoenix.

"Building our biotech industry is very important for the state's 
future economic growth and will benefit all its citizens," said 
Arizona Governor Janet Napolitano. "We are committed to investing 
resources, and fostering a positive investment climate in 
partnership with our universities, to make Arizona more attractive 
to out of state companies wishing to open or expand offices here."

"Now that we've completely moved into our state-of-the-art facility, 
I'm looking forward to the next stages and milestones we will 
accomplish in the scientific community," says Dr. Jeffrey M. Trent, 
TGen's President and Scientific Director. "The research conducted 
here will be valuable to companies and organizations worldwide."

"In addition to our rich cultural and entertainment venues, Downtown 
Phoenix has the resources and infrastructure necessary to attract 
and sustain world-class organizations and companies," said Phil 
Gordon, Mayor of Phoenix. "We're excited to have TGen, IGC, and 
NIDDK in our midst, and we invite biotech companies from out of 
state and around the world to investigate the business opportunities 
for R&D, collaboration, and expansion that we offer."

Building Grand Opening Features Leaders from Government and 
Scientific Community

A ribbon-cutting ceremony will be attended by Arizona State 
Governor, Janet Napolitano, City of Phoenix Mayor, Phil Gordon, U.S. 
Senator, Jon Kyl, and TGen President & Scientific Director, Dr. 
Jeffrey M. Trent. A keynote speech will be delivered by Francis S. 
Collins, M.D., Ph.D. Director, National Human Genome Research 
Institute. Thousands are expected to attend. The celebration also 
includes a Health & Research Fair from 7:30 a.m. - noon with exhibit 
booths from more than 40 biotech and related partner organizations.

About the Phoenix Biomedical Center The PBC is the keystone of the 
state-wide bioscience initiative and is expected to have a 
significant impact on biomedical discoveries, the quality of health 
care for Arizona's residents, and the expansion and diversification 
of the state's economy. Other planned developments for the PBC area 
include the Arizona Biomedical Collaborative (a three university 
teaching facility), a College of Medicine, a College of Pharmacy, 
and a College of Nursing.

Major Regional Biotech Organizations & Resources

--  Arizona Heart Institute
--  Arizona State University
--  Banner Health
--  Barrow Neurological Institute
--  Mayo Clinic
--  NIDDK
--  Scottsdale Healthcare
--  St. Joseph's Hospital
--  The Biodesign Institute of ASU
--  University of Arizona
Phoenix Region Facts

Population: 3.4 million
Bio-Related Companies:  1,000+
Major Airport:  23 major airlines, 7th busiest airport in 
the world
Higher Education:   25 institutions of higher learning, 277,000
enrolled students
Weather:Average temperature 73F.  300+ sunny days a 
year
Entertainment:  52 theatres, 40 museums, 200 art galleries, 
4 pro
sports teams
About TGen

The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a relatively new field 
employing innovative advances arising from the Human Genome Project 
and applying them to the development of diagnostics, prognostics and 
therapies for cancer, neurological disorders, diabetes and other 
complex diseases. TGen is focused on personalized medicine and plans 
to accomplish its goals 

[ biotech news ] One Billionth Biotechnology Acre and Counting

[famouswba]

One Billionth Biotechnology Acre and Counting 
  The one billionth acre using genetically enhanced crops has been 
planted this spring. Dean Kleckner, former president of American 
Farm Bureau and now chairman of a not for profit group Truth About 
Trade and Technology is a national and international leader in 
agriculture. Kleckner and the Truth About Trade and Technology 
organization have developed a sophisticated monitoring system for 
counting the acres and the one billionth acre is expected to be 
planted this spring.

May 11, 2005 -- Remember how McDonald's used to boast beneath the 
golden arches about how many billions of hamburgers it had sold?

Well, it's time for someone to raise a sign on behalf of 
agricultural biotechnology, because somewhere in the world this week 
a farmer planted the 1 billionth acre of genetically enhanced crops.

This is a huge milestone for the world. Just ten years ago, biotech 
crops became commercially available for the first time. Since then, 
they've been adopted with astonishing speed. In the United States, 
about 85 percent of all soybeans, 75 percent of all cotton and 
nearly half of all corn is biotech enhanced.

Just how big is a billion acres? Let's start by recalling that the 
traditional understanding of a single acre is the amount of land a 
yoke of oxen can plow in a day. In German, the word "Acker" means, 
literally, "a field."

Today, of course, we need more precise measurements--and so a square 
acre measures precisely 208.75 feet per side.

A billion acres is a lot of territory. It would take more than 27 
land masses the size of Iowa to fill up that much space.

If you lined up a billion square acres, they would circle the planet 
at the equator more than 1587 times. They would reach to the moon 
and back 164 times. They would go all the way to the sun and all the 
way back--and still have some length left to spare.

Some years ago, it was possible to say that biotech crops were a 
newfangled concept. Today, with a billion acres of them now planted, 
they are a conventional source of food.

There are those who will continue to hurl insults by calling 
them "Frankenfood" and the like, but these shrill voices are 
increasingly out of step with mainstream methods of food production. 
How many more acres must we plant, harvest, and consume before these 
radical naysayers admit that biotech enhanced crops are a proven 
technology? Must we go all the way to the sun and back before 
they'll see the light?

The simple fact is this - biotech crops are the latest developments 
in an ancient line of agricultural innovation. Farmers are the 
world's original genetic enhancers--they've been crossbreeding 
plants for thousands of years. In the wild, there's never been any 
such thing as a juicy tomato. But there have been little red berries 
that farmers, across generations, have turned into a staple crop.

Something similar could be said of virtually everything we eat, and 
biotech crops are a part of this heritage. Farmers have chosen to 
adopt them so rapidly because they produce more food at lower costs. 
On a planet populated by over 6 billion people--and the number is 
growing every day--this is an essential characteristic.

Farmers have also rapidly adopted biotech because we care about the 
environment. Biotech crops help the environment in a variety of 
ways. Yielding more food on existing farmland reduces the pressure 
to cut down rainforests in Brazil and elsewhere. Since 1980, farmers 
around the world have increased our corn production by 45 percent 
but it was accomplished by adding less than 5 percent more acres to 
our fields. That additional corn was produced on the equivalent of 
130 million acres of rainforest that has not been cut down!

Moreover, biotech crops protect our environment by allowing us to 
use farming techniques that save topsoil and use our resources much 
more effectively.

Finally, and perhaps most importantly, biotech crops are approved 
for commercial use only after regulators at the Department of 
Agriculture, the Food and Drug Administration, and the Environmental 
Protection Agency have tested them repeatedly and registered their 
approval.

The bottom line is that they're perfectly safe to eat. There's never 
been a case anywhere of a biotech plant causing a human being so 
much as to sneeze.

In the future, it will become increasingly clear that biotech crops 
aren't merely acceptable to eat--they'll be preferable to eat, as 
plant breeder's research ways to produce crops that add essential 
vitamins and nutrients to our diets. The research is going on right 
now and it promises to transform the ways in which we think about 
keeping ourselves healthy.

So today, we celebrate a billion acres. At some point in the future, 
like McDonald's, so many billions will have been "served" that we'll 
quit counting these biotech acres altogether.

Dean Kleckner is chairman of Truth About Trade and Technology, an 
Iowa farmer and a 

[ biotech news ] Bioscience Industry News at Maricopa Community Colleges Center for Workforce Dev

[famouswba]

http://www.maricopa.edu/workforce/bionews.html";>Bioscience 
Industry News

Maricopa Community Colleges Center for Workforce Development 
Division of Academic Affairs  Bioscience Industry News



Research

Biotech corn OK'd for feed, not food 
Arizona Republic

Ribomed sees success 
Arizona Republic

Arizona nanobiotechnology 
firm scores 108th patent
The Business Journal of Phoenix

Big deal for Ariz. firm
Arizona Republic

Biotech firm spun off from UA 
research hopes to stunt tumors
Arizona Republic

Phoenix biotech firm gets 
grant to detect airborne pathogens
Arizona Republic

Valley joins organic food boom
Arizona Republic

Medtronics granted approval 
to sell new pacemaker
The Business Journal of Phoenix

State scientists reach out to Mexico
The Business Journal of Phoenix

Ribomed signs $3M deal 
for bioterrorism device
The Business Journal of Phoenix

Genetically engineered crops up 15 percent 
Arizona Republic

Arizona Biodesign Institute 
selected for arthritis tests
The Business Journal of Phoenix

Barrow, UA get nicotine-research grants
Arizona Republic

Advanced technology helps Tempe 
biotech firm land $3.7M in grants
The Business Journal of Phoenix

TGen announces Mexican collaboration
The Business Journal of Phoenix

Ribomed receives funding 
for research on smallpox
The Business Journal of Phoenix

Scientists of very small 
draw disciplines together
The New York Times

Gene Expression and Cancer: 
Getting It Together
Nature Genetics

General Industry Information

Human Genome to cut 20% of staff
CNN/money

Cluster Marketing Research: Bio-Industry
Greater Phoenix Economic Council

What is Bioindustry?
Arizona BioIndustry Association

Biotech not everywhere, 
despite claims to the contrary
The Site Selection

Best Practices

Phoenix looks at Canada 
to help build bioindustry
The Business Journal of Phoenix

San Diego provides biotech model for Phoenix
The Business Journal of Phoenix

Georgia schools building 
big base for research labs
The Business Journal of Phoenix


Workforce and Education

Biotech law draws interest 
Arizona Republic 

ASU to offer 1st master's 
degree in biotech, genomics law 
Arizona Republic 

Five colleges get $5 million for biotech 
AACC, Community College Times 

Three key sciences making 
an impact on Arizona's economy
The Business Journal of Phoenix

Utah firm signs research deal 
with Arizona Biodesign Institute
The Business Journal of Phoenix

Promoting bioscience puts 
cooperation first among cities
The Business Journal of Phoenix

'Big thinker' to direct ASU's biodesign unit
Arizona Republic

Phoenix, UA lobby for funds 
for downtown medical campus
Arizona Republic

ASU researchers to get seed money
The Business Journal of Phoenix

Universities shift tech transfer 
efforts toward commercialization
The Business Journal of Phoenix

Phoenix, ASU sign pact to 
build biomedical campus
The Business Journal of Phoenix

Kitchell to build research facility for NAU
The Business Journal of Phoenix

Biodesign institute starts 
phase 2 on ASU campus
The Business Journal of Phoenix

Chandler develops biomed 
center, adds 270 jobs
The Business Journal of Phoenix

Five biomedical campus plans 
prepared for Regents review
The Business Journal of Phoenix

Staffing needs seen in biotech industry
San Diego Union Tribune

ASU reaches out to tech, biotech startups
The Business Journal of Phoenix

Phoenix Union, TGen coming 
together for biotech high school
The Business Journal of Phoenix

DeVry adds biomedical 
engineering degree program
The Business Journal of Phoenix

IBM installing super computer for genomics
The Business Journal of Phoenix

Plans expand for biotech center
The Business Journal of Phoenix

ASU opens nanoscience center
East Valley Tribune

Plans expand for biotech center 
The Business Journal of Phoenix 

College district pledges 
$1.5 million to biotech industry 
The Business Journal of Phoenix 

Maricopa Community Colleges 
make workforce training 
commitment to biotech industry 
PRESS RELEASE 
Read EdCetera article

Biotech training gaining support 
The Business Journal of Phoenix 

Colleges train workers for biotech companies
AACC, Community College Times

ASU, Tempe team on biotech 
The Business Journal of Phoenix

Biotech training gaining support
The Business Journal of Phoenix

New federal support for UA Institute for Biomedical Science and 
Biotechnology 
UA News.org

Arizona colleges commit 
$2.5m to lure genomics group 
AACC, Community College Times 

Maricopa Community College District 
puts big bucks into biotechnology 
East Valley Tribune 

 


Local Bioscience Industry

Biosciences, health care expected 
to drive economy into the future 
The Business Journal of Phoenix 

Boost in state's biotech efforts 
Arizona Republic 

States, cities court biotech, 
but is it worth it? 
East Valley Tribune 

Myths, realities of Arizona's 
bioscience strategy 
The Business Journal of Phoenix 

Arizona biotech industry makes strides, 
but venture capital is lacki

[ biotech news ] CryoPort Updates Shareholders on Development of Disposable Cryogenic Shipper

[famouswba]

CryoPort Updates Shareholders on Development of Disposable Cryogenic 
Shipper

CryoPort, Inc. (OTC.PK: CYRX) announced today new information 
regarding the development of its one-way, one time use, disposable 
cryogenic shipper. Initially, this revolutionary new shipper was not 
expected to be ready for client use until the spring of 2006, with 
clinical trials commencing during the summer of 2006. However, due 
to an accelerated R&D schedule as the result of additional funding, 
the development stage of the "phase one" shipper is now complete. 
Prototype models of the new disposable cryogenic shipper are 
scheduled to be made available to select clients as early as July 
2005. 

CryoPort is currently working with a number of biotech and 
pharmaceutical companies who have a high level of interest in the 
disposable cryogenic shipper for use in drug delivery. Several of 
these companies are already using CryoPort's reusable cryogenic 
shipper which is currently being used to successfully ship product 
in ongoing clinical trials. 

Cell Genesys, recently purchased 100 of CryoPort's reusable 
lightweight shippers with a projected need over the coming months 
for several hundred more. This initial order is intended to serve as 
a "Proof of Concept" for the technology that will be incorporated 
into the soon to be released disposable shipper. 

The use of a cryogenic shipping protocol, rather than a dry ice 
protocol, helped Cell Genesys avoid significant logistical problems 
that they would have faced had they been forced to use traditional 
dry ice shipping methods. Dry ice shippers can maintain temperatures 
of negative seventy-eight degrees Celsius for a maximum of 48 hours 
before the shipment must be handled and repackaged. If not 
repackaged on fresh dry ice within a small time frame, the frozen 
material risks thawing and becoming unusable. CryoPort's cryogenic 
shippers maintain negative one hundred and ninety six degrees 
Celsius and can maintain this same level of temperature for up to a 
period of 2 weeks, depending on the application. Additionally, dry 
ice emits gas vapors, which result in its classification as a 
hazardous material. CryoPort's shippers, including the new one-way 
shipper, are non-hazardous and can even be shipped using traditional 
postal services. 

Once the new disposable shipper completes its initial testing phase 
with select clients during the summer of 2005, large scale 
manufacturing is expected to commence in early 2006 in an effort to 
meet the anticipated demand from biotech and pharmaceutical 
companies worldwide. 

"SAFE HARBOR": 

Certain statements contained herein constitute "forward-looking 
statements" within the meaning of the Private Securities Litigation 
Reform Act of 1995. These forward-looking statements are based on 
current expectations, estimates and projections about the Company's 
industry, management's beliefs and certain assumptions made by 
management. Readers are cautioned that any such forward-looking 
statements are not guarantees of future performance and are subject 
to certain risks, uncertainties and assumptions that are difficult 
to predict. Since such statements involve risks and uncertainties, 
the actual results and performance of the Company may turn out to be 
materially different from the results expressed or implied by such 
forward-looking statements. Given these uncertainties, readers are 
cautioned not to place undue reliance on such forward-looking 
statements. Unless otherwise required by law, the Company also 
disclaims any obligation to update its view of any such risks or 
uncertainties or to announce publicly the result of any revisions to 
the forward-looking statements made herein; however, readers should 
carefully review reports or documents the Company files from time to 
time with the Securities and Exchange Commission. 

SOURCE: CryoPort, Inc. 

CryoPort, Inc is a featured Company on BiodefenseStocks.com, 
HomelandDefenseStocks.com









 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Fraunhofer USA's Center for Molecular Biotechnology Receives Grant

[famouswba]

Fraunhofer USA's Center for Molecular Biotechnology Receives Grant 
from Bill & Melinda Gates Foundation for Trypanosomiasis Research

Fraunhofer USA's Center for Molecular Biotechnology (CMB), a non-
profit research organization based in Newark, Delaware, has received 
a $1.2 million grant from the Bill & Melinda Gates Foundation for 
pre-clinical studies towards the development of a vaccine against 
African trypanosomiasis.

The disease, known in cattle as Nagana and in humans as Sleeping 
Sickness, is spread by the bite of the tsetse fly and is fatal if 
left untreated. It occurs in 36 countries of sub-Saharan Africa. It 
is reaching epidemic proportions and is having a devastating impact 
on local economies there.

CMB will apply its newly developed suite of technologies to 
engineer, produce and evaluate candidate vaccines to combat this 
disease. This project is a collaborative effort between CMB, the 
Institute of Parasitology at McGill University in Canada, and 
Makerere University in Uganda.

The new plant-based technology developed at CMB has the potential to 
provide safe, effective and affordable vaccines against a variety of 
pathogens.

"Our plant-based approach is highly time-efficient and ensures 
economic production of vaccines," said Vidadi Yusibov, Executive 
Director of CMB.

"An affordable vaccine against trypanosomiasis could prevent tens of 
thousands of deaths each year," said Dr. Douglas Holtzman, senior 
program officer for the Infectious Diseases Program of the Bill & 
Melinda Gates Foundation. "We're pleased that the Fraunhofer USA 
Center for Molecular Biotechnology is applying its unique expertise 
to this critical research."

About Fraunhofer USA CMB

Fraunhofer USA Center for Molecular Biotechnology (CMB) is a non-
profit research organization that is part of Fraunhofer USA, Inc., a 
Rhode Island incorporated, with Headquarters in Plymouth, MI. CMB is 
located at the Delaware Technology Park in Newark, Delaware, and is 
a unique institution conducting research in the area of plant 
biotechnology, utilizing newly developed/developing cutting edge 
technologies to assist the diagnosis, prevention and treatment of 
human and animal diseases.

Web site: http://www.fraunhofer-cmb.org




-
---
Source: Fraunhofer USA CMB








 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Bolder BioTechnology, Inc wins National Institutes of Health Grant

[famouswba]

Bolder BioTechnology, Inc. announced that it has been awarded a 
$99,000 Phase I Small Business Innovation Research (SBIR) grant from 
the National Institute of Allergy and Infectious Diseases (NIAID) of 
The National Institutes of Health. The grant supports research to 
improve the pharmacological properties of a human protein, gamma 
interferon, to enhance its ability to stimulate the body's immune 
system to fight infections. The optimized gamma interferon protein 
may prove useful for the treatment of viral infections, 
immunodeficiencies and various cancers.




Bolder BioTechnology, Inc. announced that it has been awarded a 
$99,000 Phase I Small Business Innovation Research (SBIR) grant from 
the National Institute of Allergy and Infectious Diseases (NIAID) of 
The National Institutes of Health. The grant supports research to 
improve the pharmacological properties of a human protein, gamma 
interferon, to enhance its ability to stimulate the body's immune 
system to fight infections. The optimized gamma interferon protein 
may prove useful for the treatment of viral infections, 
immunodeficiencies and various cancers.

The SBIR program is a peer-reviewed grant program that provides 
research support to small businesses to discover and develop 
innovative biomedical products for the treatment of serious unmet 
medical needs. Companies that successfully meet the goals of the 
Phase I grant are eligible to apply for an additional $750,000 in 
Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering 
technologies to create proprietary, long-acting human protein 
pharmaceuticals for the treatment of hematopoietic and endocrine 
disorders, cancer and infectious diseases. For additional 
information about Bolder BioTechnology, Inc., please visit our web 
site at http://www.bolderbio.com/.

Statements contained herein that are not historical facts are 
forward-looking statements that are subject to a variety of risks 
and uncertainties. There are a number of important factors that 
could cause actual results to differ materially from those expressed 
in any forward-looking statements made by the Company. These factors 
include, but are not limited to: (1) the Company's ability to 
successfully complete product research and development, including 
pre-clinical and clinical studies, and commercialization; (2) the 
Company's ability to obtain required government approvals; (3) the 
Company's ability to attract and/or maintain manufacturing, sales, 
distribution and marketing partners; and (4) the Company's ability 
to develop and commercialize its products before its competitors.

Web site: http://www.bolderbio.com/




http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/";>Arizona High Tech





 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] TGen s Von Hoff, colleagues, publish comprehensive pancreatic cancer textbook

[famouswba]

TGen's Von Hoff, colleagues, publish comprehensive pancreatic cancer 
textbook 


54 chapters and commentary from over 100 international experts in 
the field 

05-23-2005

Phoenix, Arizona, May 23, 2005--The Translational Genomics Research 
Institute's (TGen) Daniel Von Hoff, MD, and colleagues at M. D. 
Anderson Cancer Center and Johns Hopkins have edited and published 
the first comprehensive reference book on pancreatic cancer. The 
text, entitled Pancreatic Cancer, features contributions from over 
100 international experts in the field and boasts 54 chapters and 
supporting commentaries that provide expert analysis and 
counterpoint on selected topics. 
Until now, physicians and researchers interested in pancreatic 
cancer had to track down and gather each individual scientific paper 
on the subject. 

"Our goal was to create a definitive text that will allow current 
and future researchers entering the field to get up to speed in a 
short period of time," says Dr. Von Hoff, Senior Investigator and 
head of TGen's Pancreatic Cancer Research Division. 

The book offers a knowledge base to anyone with an interest in 
pancreatic cancer, from a young surgeon to scientists to patients 
and their families, says Dr. Von Hoff, one of the world's leading 
experts on pancreatic cancer. 

In 2005, an estimated 32,000 individuals in the U.S. will be 
diagnosed with pancreatic cancer. As the fourth leading cause of 
death from cancer in the US, the disease is the most deadly of all 
cancers with the 1-year survival rate of only 24 percent and the 5-
year survival rate of approximately 4 percent. 

Published by Jones and Bartlett Publishers, the groundbreaking new 
text is dedicated to improving these statistics by providing 
comprehensive information about the epidemiology, molecular biology 
and pathogenesis of the disease. 

The Heriette Pickelner Fund for Pancreatic Cancer Research at the 
University of Texas M.D. Anderson Cancer Center donated the funding 
to colorize the graphic elements including photos, charts and MRI 
scans. 

"I hope patients, their families and healthcare professionals will 
use this book as a knowledge instrument," explains Von Hoff. 

In addition to Von Hoff, Douglas B. Evans, MD, a distinguished 
professor of surgery at the University of Texas M.D. Anderson Cancer 
Center, and Ralph H. Hruban, MD, a professor of pathology and 
oncology at the Sol Goldman Pancreatic Cancer Research Center at 
Johns Hopkins, edited the book. 

To purchase the book, contact Jones and Bartlett Publishers at 800-
832-0034 or [EMAIL PROTECTED] 








 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Targeted Genetics Expands AAV Vector Patent Portfolio

[famouswba]

BioTech News at Arizona Biotech: 
http://www.arizonabiotech.com/2005/05/targeted-genetics-expands-aav-vector.html";>Targeted
 Genetics Expands AAV Vector Patent Portfolio

http://www.arizonabiotech.com/2005/05/targeted-genetics-expands-aav-vector.html

Targeted Genetics Expands AAV Vector Patent Portfolio

Targeted Genetics Corporation (Nasdaq: TGEN - News) today announced 
the issuance of an additional patent related to its adeno-associated 
virus (AAV) vector technology. U.S. patent #6,893,865, 
titled "Methods, Compositions and Cells for Encapsidating Recombinant 
Vectors in AAV Particles," expands Targeted Genetics' AAV vector 
systems used for gene delivery. Targeted Genetics' leading gene 
delivery vehicle, AAV, is used to deliver a gene of interest into 
cells of the patient to impact disease. 






 Yahoo! Groups Sponsor ~--> 
What would our lives be like without music, dance, and theater?
Donate or volunteer in the arts today at Network for Good!
http://us.click.yahoo.com/TzSHvD/SOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech Forum in Eorope - Windhover Information Euro-Biotech Forum

[famouswba]

http://www.eurobiotechforum.com/EB2005/Main.asp";>Windhover 
Information's Euro-Biotech Forum


Windhover Information's Euro-Biotech Forum is the industry's most 
important and prestigious venue for bringing together senior 
biotechnology and pharmaceutical executives from around the world to 
meet, discuss and explore potential collaboration opportunities.

Now in its 12th year, Euro-Biotech features corporate presentations 
from a select group of American and European biotechs providing the 
information you need for understanding what each company offers - 
and expects - as a potential partner. 

Biotech presenters in 2004 included some of the most interesting 
newer firms, like Ambrx, Rinat Neuroscience, Saegis Pharmaceuticals 
and Neuro3d SA, as well as more established players like Biogen 
IDEC, BioVitrum and Abgenix. Last year's meeting attracted more than 
450 participants from the top European and American pharmaceutical 
companies as well as many dozen biotechs.

http://www.eurobiotechforum.com/EB2005/Main.asp





http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech




 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] BioLink USA-Ireland - Ireland-USA Biotechnology Initiative

[famouswba]

Ireland-USA Biotechnology Initiative

Blood, Sweat and Tears -- History repeats itself? Using contemporary 
building blocks for a different type of Infrastructure -- the Irish 
are building an amazing Life Science Linkage between the USA and 
Ireland.

BioLink USA-Ireland, an educational networking organization 
responsible for connecting and fostering relationships between Life 
Scientists in the US and Ireland, announces its 3rd Annual Life 
Science Conference, entitled "International Innovation and 
Entrepreneurship."

The conference will be held June 16th-17th in Boston, Massachusetts 
at the Boston Sheraton Hotel. Sponsored by Enterprise Ireland, the 
Trade and Technology Board of the Irish Government, the conference 
will focus on Life Science Governance, Cutting Edge Technologies and 
Commercialization of Research from IP to IPO. Topics range 
from "Stem Cell Research and Bio Ethics" to "Global Life Science 
Investing."

Attending the conference will enable you to:

-- Understand new regulations and industry trends

-- Learn about the emergence of a world class life science research 
environment

-- Identify funding opportunities for doing research and starting a 
business in the US and Ireland

-- Meet Ireland's emerging entrepreneurs and discuss opportunities 
for partnering -- over 13 Irish companies will be participating

-- Network with leading life scientists from the European Union and 
the United States

-- Follow-up research, licensing, contracting, partnering, 
investment, and employment opportunities

According to BioLink President, Dr. Denis Headon of the Rice 
University in Texas, "The past two conferences have produced 
agreements that currently translate to over $5 million in 
investments with a later funding potential of over $10 million 
between small indigenous Irish companies and their larger US 
counterparts. This year's Third Annual Conference promises even 
greater returns for its participants."

BioLink USA-Ireland has, during its short existence, launched a 
network of over 700 scientists, engineers and life science business 
professionals in the United States. Over 300 participated in its two 
previous conferences that were held in New York and San Francisco. A 
number of strong national and international delegates are expected 
to attend this year's conference.

Speakers at the Boston conference will include high level 
representatives from the Irish government and biotech start-ups, as 
well as top level speakers from the US academic, governmental and 
industrial biospace. These include, on the U.S. side, Dr. Lester 
Crawford, Commissioner Designate of the FDA, Mr. Tom Finneran, 
President of the Massachusetts Biotechnology Council, Dr. Frances 
Toneguzzo, Director of Corporate Sponsored Research and Licensing at 
Massachusetts General Hospital, Mr. Thomas O'Toole, Chief Licensing 
Officer for the Centers for Disease Control and Dr. Donald Black, 
Global Head of R&D for GE Healthcare, among others.

Representatives from Ireland include the Honorable Isolde Moylan, 
Consul General of Ireland in Boston, Mr. Alan Dixon, Director of 
Life Sciences for Enterprise Ireland, and Mr. Pat O'Mahony, Director 
of the Irish Medicines Board and thirteen CEO's of indigenous Irish 
biotechnology companies.

In coordination with Irish America Magazine, there is a very 
exciting component to this year's conference: The Irish America Top 
15 Life Science Awards, where renowned individuals who have made a 
significant contribution to the Lifescience sector will be honored. 
Awardees include Tommy Thompson, Former Secretary of Health and 
Human Services, Dr. Lester Crawford, Commissioner of FDA, Dr. Garret 
Fitzgerald of the University of Pennsylvania, Dr. Donald Black, 
Global Head of R&D for GE Healthcare, and Mr. James Lenehan, Former 
Worldwide Chairman of Johnson and Johnson, amongst others.

A full agenda, lists of speakers and awardees, registration form and 
information on chapters across the US are available at 
www.biolinkusaireland.org or through email, 
[EMAIL PROTECTED] Registration fee is $300 for members and 
$500 for nonmembers, with student pricing set at $175. Registration 
includes one year's membership in BioLink USA-Ireland.


 For more information, please contact:
 Conference Coordinator
 Ms. Edel McCarville, [EMAIL PROTECTED], 
212-546-0470
 For general information on the BioLink USA-Ireland 
organization, please
 contact: [EMAIL PROTECTED]

 Follow on Interviews
 Dr. Denis Headon, President, BioLink USA-Ireland, 
[EMAIL PROTECTED]

About BioLink USA-Ireland:
BioLink USA-Ireland (www.biolinkusaireland.org) is an association of 
scientists, engineers and business professionals from Ireland 
working in the life sciences in the USA, and others who are 
similarly engaged and who support the aims of the organization. The 
aims of BioLink USA-Ireland are connecting and fostering relations 
and interactions among members for mutual benefit, and p

[ biotech news ] National Geographic & IBM Unveil Unprecedented Global Study Genographic Project

[famouswba]

National Geographic and IBM Unveil Unprecedented Global Study of the 
Human Species - Genographic Project

The National Geographic Society and IBM have launched a 
groundbreaking five-year international study in Washington DC that 
will trace the history of the human species with more depth than 
ever before and is expected to reveal unprecedented information 
about how the earth was populated. 

Scientists of The Genographic Project will set up ten centers around 
the world and study more than 100,000 DNA samples from a variety of 
populations, including indigenous groups and the general public. The 
resulting database will be home to one of the largest, most valuable 
collections of human population genetic information ever assembled.

Public Encouraged to Participate By Anonymously Donating Cheek Swabs

The National Geographic Society and IBM have launched a 
groundbreaking five-year international study in Washington DC that 
will trace the history of the human pecies with more depth than ever 
before. 

The five-year research partnership is expected to reveal 
unprecedented information about how the earth was populated. 
Scientists will set up ten centers around the world and study more 
than 100,000 DNA samples from a variety of populations, including 
indigenous groups and the general public. The resulting database 
will be home to one of the largest collections of human population 
genetic information ever assembled and will serve as a vital 
resource for scientists, historians and anthropologists.

The centers will be located in Philadelphia at the University of 
Pennsylvania, as well as in China, Russia, India, Lebanon, Brazil, 
South Africa, Britain, France and Australia. 

Members of the general public will be able to become a part of 
history by participating in the study. By purchasing a participation 
kit and submitting their own cheek swab samples, everyday 
individuals will be able to track their own migratory history as 
well as the overall progress of the project. Personal results will 
be stored securely and anonymously to ensure privacy. 

To learn more or to purchase a participation kit, go to 
www.nationalgeographic.com/genographic

-
---

Produced for National Geographic



http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech






 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Electronic Forum on Biotechnology in Food and Agriculture

[famouswba]

Electronic Forum on Biotechnology in Food and Agriculture
http://www.fao.org/biotech/forum.htm
This site from the Food and Agriculture Organization of the United 
Nations (FAO) provides a series of email conferences: the Electronic 
Forum on Biotechnology in Food and Agriculture. The conferences 
discuss biotechnologies presently available in the crop, forestry, 
animal, and fish sectors (respectively) for food production and 
agriculture in developing countries. Users can sign up to join 
conferences. A glossary of biotechnology terminology and contact 
information is also provided.

Conference 13 runs from 6 June to 3 July 2005 and is dedicated 
to "The role of biotechnology for the characterisation and 
conservation of crop, forest, animal and fishery genetic resources 
in developing countries". The conference, as usual, is open to 
everyone, is free and will be moderated. Instructions for 
registering are given.

http://www.fao.org/biotech/conf13.htm



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/









 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech financings bog down in slow season

[famouswba]

Biotech financings bog down in slow season

http://www.biv.com/subscriber/tech.asp";>Business in 
Vancouver May 31-June 6, 2005; issue 814

Biotech financings bog down in slow season

Soft U.S. market, aggressive short-selling blamed for slowdown in 
fundraising

Glenn Drexhage

A pair of biotech financings from local companies underlines the 
tough market conditions besetting the sector, a situation that 
onlookers expect to continue over coming months.

"I think the market conditions are very difficult," said Carolyn 
Cross, president and CEO of Vancouver's Ondine Biopharma Corp., one 
of the firms to raise funds.

"This is not a time of the year when investors are ready to put more 
money to work. Rather, they go into the summer months knowing that 
the markets tend to trail off, go soggy until September.

"I think we are going to see interest in the biotech sector, but not 
until later on this year."

On May 18, Ondine (OBP:TSX, AIM) -- which develops non-antibiotic 
therapies for a range of infections -- announced the pricing for a 
$12-million equity financing via agents Canaccord Capital Corp. and 
Sprott Securities Inc.

A day earlier, MIGENIX Inc. (MGI:TSX; MGIFF:OTC), a Vancouver drug 
development firm, said it had reduced the size of its previously 
announced unit offering to $5 million from $15 million, citing 
market conditions. There's also an option to raise the offering by 
up to $3 million.



http://www.arizonabiotech.com/
http://smsac.blogspot.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/




 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Ribomed Recognized by Frost & Sullivan for Excellence in Biological Detection

[famouswba]

Ribomed's innovative technology has been recognized by the leading 
market research firm, Frost & Sullivan, with its award to Ribomed of 
the Biological Detection Technologies Excellence in Research of the 
Year Award for 2005. 

Ribomed Recognized by Frost & Sullivan for Excellence in Biological 
Detection Technologies Research

Naples, Fla. — May 25, 2005 — Frost & Sullivan will present Ribomed 
Biotechnologies, Inc. with
the 2005 Biological Detection Technologies Excellence in Research of 
the Year Award at
tonight's Excellence in Industrial Technologies Banquet.
Ribomed receives the Award for its excellence in research and 
development (R&D) and for its
introduction of the Abscription® process that detects both disease 
cells and germs that serve as
biological warfare agents.
Abscription, a contraction of abortive transcription, is a rapid, 
robust, isothermal, polymerase
chain reaction (PCR)-free method for detecting and quantifying 
target proteins and nucleic acids.
It is an integral part of Ribomed's RiboMaker® Detection System.
Abscription's development was driven by four major requirements in 
clinical, and later, biological
defense detection systems. The first was the inadequacy of 
conventional detection systems in
terms of time, efficiency, and practicality. The second was the 
rising cost of healthcare, which
created a need to improve diagnosis and drug development.
The third factor was the U.S. Government's apprehension about 
national security from biological
attacks both at home and abroad. Lastly, the growth of molecular 
genetics promotes molecular
detection of diseases and the development of disease- and patient-
specific drugs.
"Abscription uses the reiterative synthesis of short RNA Abscripts®, 
which are produced by the
RiboMaker® Abscriptase® enzyme, to rapidly generate thousands of 
detectable and quantifiable
signals per target per minute," says Frost & Sullivan research 
analyst Michael Valenti.
"Abscripts® are generated from an artificially created start site 
for Abscription, called an
Abscriptase ® Promoter Cassette (APC)."
Modular RiboMaker® APCs can be linked to targeted molecules such as 
RNA, DNA, or protein,
and, since Abscription is linear, the amount of Abscripts® generated 
is directly proportional to the
number of target molecules present.
Abscripts® can be tagged with reporters, affinity tags, or haptens 
during the Abscription process
by incorporating Ribomed's proprietary tagged Ribonucleotide analogs 
(RiboLogs®). They are
then fed into several different secondary signaling systems, leading 
to the rapid production of
millions of signals per target. Moreover, Abscription is highly 
conducive to multiplexing, and can
create more than 20 APCs, each producing a unique product.
By being able to identify infectious agents accurately in real time 
using the Abscription-based
RiboMaker detection tests, physicians can treat patients at their 
point-of-care, saving 72 hours of
culturing to pick an appropriate treatment.
"This time saving can be critical in determining whether persons are 
victims of a biological attack
and in devising the most appropriate method of treating them," notes 
Valenti. "It has also sparked
the funding by several agencies of the federal government in 
bioterrorism applications."
The National Institutes of Health (NIH/NCI, NIAID), the U.S. 
Department of Defense (DARPA),
and the Department of Homeland Security (HSARPA) have supported the 
development of
Abscription.
"Ribomed continues to exploit the robustness of the Abscription® 
process by developing a bloodbased
test for rapid development of vaccines to deadly viruses and 
bacteria," observes Valenti.
7550 IH 10 West, Suite 400
San Antonio, TX 78229
Tel. 210.348.1000 Fax 210.348.1003
www.frost.com
"The company has a novel approach to identifying both airborne and 
blood-transmitted pathogens
and early disease biomarkers, and has proved its superiority in R&D 
with its revolutionary
technologies for biological detection."
Frost & Sullivan presents its Excellence in Research of the Year 
Award to the company that has
carried out new, disruptive research in its industry. The Award 
recognizes a company's R&D
program that Frost & Sullivan expects will bring significant 
contributions to the industry in terms of
adoption, change, and competitive posture. The results of this 
research may already have altered
or will potentially impact certain market sectors.
Held in Naples, Fla., the Frost & Sullivan Excellence in Industrial 
Technologies Awards Banquet
honors world-class companies for outstanding performance and 
achievements in their industries.
An annual event, the banquet recognizes the quality and merit of 
distinguished individuals and
companies.
About Ribomed Biotechnologies, Inc.
Ribomed Biotechnologies, Inc. is a molecular diagnostics company 
developing rapid, specific and
robust tests for the early detection and characterization of 
diseases and their causative agents,
and the screening o

[ biotech news ] Conference Highlights N.C.'S Biotech Community; Biotech 2005 Draws Experts from

[famouswba]

Conference Highlights N.C.'S Biotech Community; Biotech 2005 Draws 
Experts from Medicine, Finance and Government to Explore Future 
Potential of Life Science Sector


RESEARCH TRIANGLE PARK, N.C. May 25, 2005 - The Council for 
Entrepreneurial Development (CED), along with the North Carolina 
Biotechnology Center, the North Carolina Biosciences Organization 
(NCBIO) and the Biotechnology Industry Organization (BIO), hosted 
the 14th annual Biotech conference on Tuesday and Wednesday with 
more than 800 people participating in total. Held at the RTP's 
Sheraton Imperial Hotel and Convention Center, Biotech 2005: Fusing 
Science, Technology and Industry Leadership showcased the state's 
position as a global player in the life science sector. 

The conference kicked off Tuesday afternoon with comments from Dr. 
Henri Meier, Chairman of the Board of Directors, HBM Partners AG and 
HBM BioVentures AG. Dr. Meier shared his experience investing 
globally in life science companies. He noted that North Carolina was 
uniquely positioned to take advantage of biotechnology's explosive 
growth moving forward. 


 
"North Carolina is a great place to do business. I can't imagine a 
more inviting place to do a deal," Dr. Meier told Biotech 2005 
attendees. "North Carolina must continue to leverage its collegial 
spirit and collaborative nature of doing business." 

Dr. Victor Dzau, Chancellor for Health Affairs, Duke University and 
President and CEO, Duke University Health System, also spoke Tuesday 
afternoon at the conference. Dr. Dzau emphasized the importance of 
bold, strategic collaborations to improve the pipeline of innovation 
and commercialization. 

On Wednesday morning, the conference featured opening remarks from 
Leslie Alexandre, President and CEO of the N.C. Biotechnology 
Center; Lieutenant Governor Beverly Perdue; and Dr. Tanja Popovic, 
Acting Associate Director for Science, The Centers for Disease 
Control and Prevention (CDC). 

Following these comments, the conference offered six concurrent 
panels that highlighted trends in late-stage financing, early-stage 
financing, global biotech, government partnerships, personalized 
medicines and technology convergence. 

During lunch on Wednesday, Walter E. Daniels of Daniels Daniels & 
Verdonik received the 3rd annual Charles Hamner Leadership Award in 
recognition of extraordinary contributions and service in the 
region's life science sector. 

David Malakoff, technology and science correspondent for National 
Public Radio (NPR), wrapped up the conference with a luncheon 
keynote address. Through humorous anecdotes, Malakoff explained the 
implications of fragmented media, the public's perception of media, 
journalists' role as advocates/critics, and the occasional "clash of 
cultures" between scientists and journalists. 

After Malakoff's comments, Biotech 2005 Conference Co-Chair Murray 
Spruill of Alston & Bird encouraged conference attendees to work 
diligently to support life sciences in North Carolina. 

"I'm proud of the biotech community in North Carolina," Spruill 
said. "I challenge everyone to go out and continue to do great 
things for North Carolina's life science economy." 

About CED: The Council for Entrepreneurial Development, located in 
Research Triangle Park, NC, is a private, non-profit organization 
formed in 1984 to stimulate the creation and growth of high-impact 
companies in the greater Research Triangle region. CED provides 
education, mentoring and capital formation resources to new and 
existing high-growth entrepreneurs through annual conferences, 
seminars, workshops and monthly programs on entrepreneurial 
management and finance. CED, which celebrates its 20th anniversary 
in 2004, is the largest entrepreneurial support organization in the 
nation with more than 3,500 members representing 1,000 
entrepreneurial companies, financiers and professional firms. 
www.cednc.org 

About the North Carolina Biotechnology Center: The North Carolina 
Biotechnology Center is a private, non-profit corporation funded 
primarily by the state's General Assembly. Its mission is to provide 
long-term economic and societal benefits to North Carolina by 
supporting biotechnology research, business and education statewide. 
www.ncbiotech.org 

About the North Carolina Biosciences Organization: NCBIO is a trade 
organization promoting the development of the biosciences industry 
in North Carolina. NCBIO provides cost-effective, organized 
legislative and advocacy efforts on behalf of the industry at the 
state and federal levels. 

About the Biotechnology Industry Organization: The Biotechnology 
represents more than 1,000 biotechnology companies, academic 
institutions, state biotechnology centers and related organizations 
in all 50 U.S. states and 33 other nations. BIO members are involved 
in the research and development of healthcare, agricultural, 
industrial and environmental biotechnology products. www.bio.org 


http://www.arizonabiot

[ biotech news ] Why Biotech Stocks Are Sedated

[famouswba]

http://www.businessweek.com/magazine/content/05_24/b3937006_mz001.htm";>Why
 Biotech Stocks Are Sedated

Why Biotech Stocks Are Sedated 

Judging from Genentech Inc.'s (DNA ) stellar performance on Wall 
Street this year, biotech might seem like a can't-miss investing 
opportunity. Since January, Genentech's shares have rocketed 49.2%, 
to $81.25, fueled by positive news about its drugs to treat cancer 
and macular degeneration, a major cause of blindness. A strong 
showing from a sector leader often sends capital flooding into 
similar companies, lifting the whole group. Advertisement

Elsewhere, though, investors are spitting out biotech stocks as if 
they were spoiled medicine. The American Stock Exchange 
Biotechnology Index, which counts Genentech among its members, has 
risen just 1.1% since January. The broader NASDAQ Biotechnology 
Index is down 11.7%. Even sexy-sounding biotech upstarts are 
struggling to find love on Wall Street: The 40 or so that have gone 
public since 2003 have dropped an average of 7% since their IPOs, 
according to Burrill & Co., a merchant banker covering life sciences.




http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://home.att.net/~quotations/
http://www.azhttp.com/




 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Report Shows Biotech Booming in Greater Philadelphia

[famouswba]

Report Shows Biotech Booming in Greater Philadelphia 

19th Annual Ernst & Young Industry Survey Calls Greater Philadelphia 
A Top 10 Region for Biotech

PHILADELPHIA, 

Select Greater Philadelphia applauded the announcement that the 
Greater Philadelphia region ranks in the top 10 in biotech business, 
according to the new Ernst & Young industry report.  The report 
showcases the region's growing stature as a "biotech boomtown" as 
final preparations are underway for the BIO 2005 convention, to be 
held in Philadelphia June 19 - 22.

The 19th annual Ernst & Young industry report showed Greater 
Philadelphia had 13 public biotech companies in 2004.  That's up 26 
percent from the previous year, and positions Greater Philadelphia 
as the number 10 region in terms of public biotech firms.

E&Y counted a combined 68 public and private biotech companies in the
region, also ranking Greater Philadelphia 10th.

"Philadelphia has always been a major player in the biotech world, 
and I don't see that changing," Mike Hildrith, Americas 
Biotechnology director at Ernst & Young told The Philadelphia 
Inquirer.  "There is an active venture capital community, a robust 
academic research community and entrepreneurial spirit."

The report also shows that Greater Philadelphia ranks:

-- 9th in biotech market value ($6.2 Billion)
-- 8th in biotech revenue ($1.2 Billion)
-- 8th in short-term investments ($1.5 Billion)

The 11-county Greater Philadelphia region stacks up favorably 
against other regions in the Top 10 when you consider that many of 
the other regions are considerably larger.  For instance, the New 
England region includes five entire states; the Southeast region is 
comprised of eight states.

Additionally, Ernst & Young did not count pharmaceutical 
companies, many of which are heavily invested in biotech research 
and development.  Eighty of the world's largest pharmaceutical 
companies have a presence in the region.

"When you consider that we are being compared to regions so much 
larger in size, it's easy to see that Greater Philadelphia is a 
hotbed of biotech activity," said Jim Shannon, Chief Marketing 
Officer for Select Greater Philadelphia.  "The biosciences industry 
is a critical segment of our regional economy, and a major reason 
why this region is thriving."

Select Greater Philadelphia is a business marketing organization 
dedicated to building the economy of the tri-state Greater 
Philadelphia region by enhancing the region's profile and image in 
order to attract and retain businesses.  It is a private, nonprofit 
organization.

Select Greater Philadelphia markets the region nationally and 
globally in order to establish Greater Philadelphia as a top-tier 
place to do business.

The Greater Philadelphia region encompasses Southeastern 
Pennsylvania, Southern New Jersey and Northern Delaware.



SOURCE Select Greater Philadelphia


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/








 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Junior High School Kids Learn Biotech 101

[famouswba]

http://www.rednova.com/news/science/154217/junior_high_school_k
ids_learn_biotech_101/">RedNova News - Science - Junior High School 
Kids Learn Biotech 101

Junior High School Kids Learn Biotech 101
BREMERTON, Wash. -- A genetic experiment is part of the curriculum 
in the classroom of science teacher Cathy Nitchman, a former 
research oceanographer. 

But the high-tech learning experience doesn't come cheap. The 
experiment is part of a science kit that can cost up to $10,000. 

Scattered around Nitchman's classroom are all the biotech 
paraphernalia in the kit _ micropipets that look like giant plastic 
hypodermic needles that the students use to inject chemicals onto 
cultures, small jars of chemicals and a large Styrofoam incubator. 

Nitchman holds up a little glass bottle to the class. "This plasmid 
costs $500," she says, exhorting them to handle the small, DNA-
containing element carefully. 

The students will inject the plasmid into a colony of harmless E. 
coli bacteria and then "shock" the bacteria into accepting the 
foreign DNA into its cell. 

If the experiment is successful, the students will have given some 
ordinary run-of-the-mill laboratory bacteria two new traits: a gene 
that makes a protein to turn the colony blue and a gene for 
ampicillin resistance. 

"The students are learning how genes can be transferred from one 
organism to another," Nitchman says, "and how genes cause traits 
such as blue eyes. They are also learning proper laboratory 
techniques."

The science kits are provided by the Fred Hutchinson Cancer Research 
Center in Seattle. Last year, more than 100 teachers in Washington 
used the kits in science classes. 

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/








 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Phoenix, Arizona Biocluster Seeks Business & Research Opportunities With Europea

[famouswba]

Phoenix, Arizona Biocluster Seeks Business & Research Opportunities 
With European Biotech Companies

Vibrant Urban Setting Creates Unique Ambiance for 28-Acre Biocenter 

PHOENIX, AZ -- 03/23/2005

The City of Phoenix has officially become the nation's newest 
biotech cluster with the grand opening of its Downtown Biomedical 
Center and worldwide headquarters for TGen (Translational Genomics 
Institute) and IGC (International Genomics Consortium). The City of 
Phoenix and State of Arizona have invested and laid the foundation 
for becoming one of the industry's foremost research centers with 
regards to neurogenomics and related research areas of alzheimer's, 
autism, cancer, and diabetes. The city seeks to attract biotech and 
related companies to Phoenix and Arizona from Europe for business 
opportunities in R&D, collaboration, partnering, and office 
expansion. 

The Phoenix Biomedical Center provides a unique, urban environment 
for cutting edge companies to expand offices or open R&D centers. 
The $46 million TGen/IGC building forms the foundation of the PBC, a 
28-acre development area planned near the epicenter of Copper 
Square -- a thriving and rejuvenated section of Phoenix featuring 
sports, music, theatre, restaurants and other entertainment and 
cultural venues. The futuristic, 173,000-square-foot TGen/IGC 
building is owned by the City of Phoenix. 


Arizona Governor Janet Napolitano cuts the ribbon to
officially open the new TGen building and Downtown 
Phoenix Biomedical Center. (L-R Front Row) Phoenix 
Mayor Phil Gordon, Speaker of the House James P. 
Weiers, Arizona Governor Janet Napolitano, TGen 
President and Scientific Director Jeffrey M. Trent,
and Phoenix Councilman Greg Stanton."Building our biotech industry 
is very important for the state's future economic growth and will 
benefit all its citizens," said Arizona Governor Janet 
Napolitano. "We are committed to investing resources, and fostering 
a positive investment climate in partnership with our universities, 
to make Arizona more attractive to out of state companies wishing to 
open or expand offices here." 

"Now that we've completely moved into our state-of-the-art facility, 
I'm looking forward to the next stages and milestones we will 
accomplish in the scientific community," says Dr. Jeffrey M. Trent, 
TGen's President and Scientific Director. "The research conducted 
here will be valuable to companies and organizations worldwide." 

"In addition to our rich cultural and entertainment venues, Downtown 
Phoenix has the resources and infrastructure necessary to attract 
and sustain world-class organizations and companies," said Phil 
Gordon, Mayor of Phoenix. "We're excited to have TGen, IGC, and 
NIDDK in our midst, and we invite biotech companies from out of 
state and around the world to investigate the business opportunities 
for R&D, collaboration, and expansion that we offer." 

Building Grand Opening Features Leaders from Government and 
Scientific Community 

A ribbon-cutting ceremony will be attended by Arizona State 
Governor, Janet Napolitano, City of Phoenix Mayor, Phil Gordon, U.S. 
Senator, Jon Kyl, and TGen President & Scientific Director, Dr. 
Jeffrey M. Trent. A keynote speech will be delivered by Francis S. 
Collins, M.D., Ph.D. Director, National Human Genome Research 
Institute. Thousands are expected to attend. The celebration also 
includes a Health & Research Fair from 7:30 a.m. - noon with exhibit 
booths from more than 40 biotech and related partner organizations. 

About the Phoenix Biomedical Center The PBC is the keystone of the 
state-wide bioscience initiative and is expected to have a 
significant impact on biomedical discoveries, the quality of health 
care for Arizona's residents, and the expansion and diversification 
of the state's economy. Other planned developments for the PBC area 
include the Arizona Biomedical Collaborative (a three university 
teaching facility), a College of Medicine, a College of Pharmacy, 
and a College of Nursing. 

Major Regional Biotech Organizations & Resources 

--  Arizona Heart Institute
--  Arizona State University
--  Banner Health
--  Barrow Neurological Institute
--  Mayo Clinic
--  NIDDK
--  Scottsdale Healthcare
--  St. Joseph's Hospital
--  The Biodesign Institute of ASU
--  University of Arizona

Phoenix Region Facts 
Population: 3.4 million
Bio-Related Companies:  1,000+
Major Airport:  23 major airlines, 7th busiest airport in 
the world
Higher Education:   25 institutions of higher learning, 277,000
enrolled students
Weather:Average temperature 73F.  300+ sunny days a 
year
Entertainment:  52 theatres, 40 museums, 200 art galleries, 
4 pro
sports teams

About TGen 
The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a re

[ biotech news ] Maryland Biotechnology Companies to Show Up in Force on the Biotechnology Indust

[famouswba]

Maryland Biotechnology Companies to Show Up in Force on the 
Biotechnology Industry Organization Show Floor 
  
 

Maryland's biotechnology community has united and will turn out en 
masse at the Biotechnology Industry Organization's (BIO) 2005 Annual 
International Convention in Philadelphia, June 19-22, 2005 at the 
Pennsylvania Convention Center.

The Maryland Pavilion will have nearly 5,000 square feet of 
exhibit space in Exhibit Hall C and feature 36 exhibitors at the 
world's largest biotechnology event.  More than 18,000 biotech 
executives, investors, journalists, policy makers and scientists 
from more than 60 countries are expected to attend the three-day 
meeting.

The biotechnology community in Maryland, including the Tech 
Council of Maryland, the Maryland Department of Business and 
Economic Development, the Montgomery County Department of Economic 
Development, and MDBio has helped elevate Maryland's vibrant family 
of biotech companies by constructing one of the show's largest state 
pavilions.

"The Maryland Pavilion will feature the broadest range of the 
most progressive technologies anywhere on the Bio show floor," said 
Edward M. Rudnic, Chairman, President and CEO of Advancis 
Pharmaceuticals and Chair of the Tech Council of Maryland's 
BioAlliance.  "This pavilion has small, medium and large 
biotechnology firms and will showcase why it is so important for 
companies to move their operations or invest in Maryland 
biotechnology," he said.

According to a recent study conducted by Pfizer, the 
Biotechnology and Pharmaceutical industry created more than 33,000 
new jobs in 2003 and contributed to an average salary range nearly 
70 percent higher than the state average.  The Pfizer survey also 
demonstrated that the biotechnology and pharmaceutical industries 
contributed nearly $146 million in income, sales and property taxes 
to Maryland in 2003.

The Maryland Pavilion is located in Hall C of the Philadelphia 
Convention Center in booths 124 through 344.  Smaller pavilions from 
Malaysia, Florida, and Minnesota flank the Maryland Pavilion.



We also encourage you to visit these progressive Maryland 
biotechnology companies featured at the Maryland Pavilion:

Gene Logic Inc. -- Booths 242, 243, 143, and 145
Gene Logic's partnership-based philosophy has guided our 
emergence as a leading provider of products and services across the 
entire drug development value chain: drug discovery, pre-clinical, 
and clinical.  Our portfolio of offerings covers this spectrum with 
capabilities in Genomics & Toxicogenomics, Preclinical Services, 
Drug Repositioning & Selection, and Clinical Pharmacogenomics.
Contact: Jennifer R. Garms, [EMAIL PROTECTED]

Advanced Product Enterprises LLC -- Booths 242, 243, 143, and 145
Advanced Product Enterprises LLC is a Maryland based 
biotechnology company involved in the identification, testing, 
development, and sell of biomolecular products.  Additionally, 
Advanced Product Enterprises provides its expertise to the 
scientific community via numerous scientific services that are
available to both government and privately funded investigators.
Contact: Joseph N. Garner, Ph.D., [EMAIL PROTECTED]

Fort Detrick Business Development Office -- Booths 242, 243, 
143, and 145 The Fort Detrick Business Development Office 
enhances collaboration and business activity between Fort Detrick 
and private industry.  We serve, at no cost to the user, as a bridge 
to opportunity for our customers by helping them make the right 
connections, develop new business and initiate cooperative
research.
Contact: Darryl Rekemeyer, [EMAIL PROTECTED]

A&G Pharmaceutical, Inc. -- Booths 242, 243, 143, and 145
Our Precision Antibody(TM) service rapidly develops customized, 
high-affinity monoclonal antibodies to your target antigen in as 
little as 30 days with a success rate over 90%.
Contact: Michael Keefe, [EMAIL PROTECTED]

Trophogen, Inc. -- Booths 242, 243, 143, and 145
Trophogen, Inc, was founded in 2001 by the management team and 
inventors, Drs. Bruce Weintraub, Mariusz Szkudlinski, and Toucan 
Capital.  Trophogen's unique protein engineering platform technology 
allows design of more potent and efficacious analogs of glycoprotein 
hormones and related growth factors to address several large 
therapeutic markets including infertility.
Contact: Bruce D. Weintraub M.D., [EMAIL PROTECTED]

Protiveris, Inc. -- Booths 242, 243, 143, and 145
Protiveris Inc. is a nanotechnology company dedicated to the
commercialization of cantilever systems for research, drug 
discovery, bio-defense and diagnostic applications.  The VeriScan(TM)
3000 biosensor and nano-cantilever array chips deliver label-free, 
real-time data that provides a unique, high value insight into the 
binding interactions of cells, proteins, antibodies and drug 
candidates.
Contact: Robert G. Menzi, [EMAIL P

[ biotech news ] Arizona Biotech is now listed in Science > Biology > Biotechnology in the Ya

[famouswba]

http://dir.yahoo.com/Science/Biology/Biotechnology/";>Arizona 
Biotech is now listed in Science > Biology > Biotechnology in the 
Yahoo! Directory


http://dir.yahoo.com/new/20050609/Science/";>Ariona 
Biotech Yahoo! Directory - New Additions in Science for Thursday 
Jun 9, 2005

Directory > Science
Directory > Biology > Biotechnology
http://www.arizonabiotech.com/";>Arizona Biotech - 
includes news and information on Arizona Biotechnology, genomics, 
biotech companies, genetic engineering, biotech research, and biology. 

http://www.arizonabiotech.com/ >Arizona Biotech



http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech




 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech Research Breakthroughs, Collaborations, and Economic Incentives

[famouswba]

Biotech Research Breakthroughs, Collaborations, and Economic 
Incentives to Be Announced at BIO 2005 
  
 

A number of state and international economic development agencies 
and private companies will make announcements to the press at a 
special venue during the BIO 2005 Annual International Convention, 
June 19-22 at the Pennsylvania Convention Center in Philadelphia.

The press conferences will spotlight scientific advancements, new 
research agreements, and biotech business opportunities around the 
world.  The schedule of press conferences, listed in chronological 
order, includes the following:

* Government of India -- Recent Policy Developments
  Will Make India a Hotbed for Biotech
  Kapil Sibal, Indian Minister for Science & Technology,
  Amar Singh, Member of Parliament, and others will
  outline why India is fast emerging as a significant
  biotechnology hotbed in the Asia-Pacific region.
  Sunday, June 19 at 10:00 am, Room 203B
  Contact: Kapil Sibal, 24 64 1074

* Queensland, Australia -- Biotechnology Breakthroughs
  The Honourable Peter Beattie, MP, Premier of
  Queensland, will announce breakthroughs in research and
  development within Queensland's biotechnology industry.
  His announcement will highlight R&D funding
  commitments, new industry partnerships, new research
  collaborations, and significant policy decisions, such as the
  Biodiscovery Bill.
  Monday, June 20 at 9:00 am, Room 203B
  Contact: Tina Radburn, (213) 346-0090, 
[EMAIL PROTECTED]

* BioAdvance -- Greater Philadelphia Life Sciences
  Study Findings
  BioAdvance will announce findings of a first-ever look at
  the Greater Philadelphia area's competitive position within
  the life sciences industry.  BioAdvance will release a June
  2005 Milken Institute study, titled "The Greater
  Philadelphia Life Sciences Cluster: An Economic and
  Competitive Assessment."
  Monday, June 20 at 10:00 am, Room 203B
  Contact: Ellen Semple, (215) 966-6207, [EMAIL PROTECTED]

* Victoria, Australia -- New Biomedical Announcements,
  Plus Latest Results in the Kangaroo Genomics Project
  Victoria Government Premier Steve Bracks, Treasurer
  John Brumby and Minister for Health Bronwyn Pike will
  deliver major biomedical announcements and the latest
  results in kangaroo genomics research projects.  Victoria is
  partnering with the US NIH on sequencing the kangaroo genome.
  Monday, June 20 at 10:00 am, Room 204A
  Contact: Trish Vardon, +61 (0)3 9651 9236, 
[EMAIL PROTECTED]

* British Columbia -- Hot Opportunities in North America
  British Columbia Premier Gordon Campbell will announce
  economic development incentives for the biotechnology
  industry in Canada.
  Monday, June 20 at 11:00 am, Room 203B
  Contact: Linda Thorstad, (604) 761-5046, 
[EMAIL PROTECTED]

* Singapore -- The Biopolis of Asia
  Singapore is dedicated to enhancing human healthcare as
  one of the world's most preeminent life sciences hubs.  The
  Singapore Economic Development Board will emphasize
  opportunities that currently exist in Singapore as a base for
  R&D investment and as a strategic location for Biomedical
  Sciences manufacturing.
  Monday, June 20 at 12:00 pm, Room 203B
  Contact: Daphne Teo, +65 6235 4495, [EMAIL PROTECTED]

* Invitrogen -- A New System for Disease Research
  Invitrogen will announce new research technologies geared
  toward specific disease models and pathways.  Invitrogen
  will introduce a system that ties its technologies together to
  target applications and pathways.
  Monday, June 20 at 2:00 pm, Room 203B
  Contact: Gregory L. Geissman, (760) 476-7032,
  [EMAIL PROTECTED]

* Wyeth & Dublin City University -- Collaboration on
  Advanced Technologies for Protein Expression
  Wyeth and Dublin City University have entered into a
  collaborative research agreement, with funding support
  from the Science Foundation of Ireland, to investigate gene
  expression pathways of cultured mammalian cells relevant
  to their industrial use in biopharmaceutical production.  The
  project will involve the use of genomics and proteomics
  technologies in the identification of genes expressed in
  Chinese hamster ovary cells that are important in
  supporting outstanding cell growth and protein
  productivity in production bioreactor cultures.
  Tuesday, June 21 at 11:00 am, Room 203B
  Contact: Gerald V. Burr, (484) 865-5138, [EMAIL PROTECTED]

* Commonwealth of Massachusetts -- Joint Scientific
  Research Collaborations between Massachusetts and
  the Ministry Of Education, University, and Research of
  the Italian Republic
  Massachusetts Governor Mitt Romney will sign a
  Memorandum of Understanding

[ biotech news ] Supreme Court Protects Pharmaceutical Research

[famouswba]

Supreme Court Protects Pharmaceutical Research

Heller Ehrman Represented Merck KGaA In a Victory That Will Have an 
Enormous Impact on the Pharmaceutical Industry 


NEW YORK, June 13 -- The U.S. Supreme Court ruled today that the 
pharmaceutical companies have a broad immunity from patent 
infringement claims when they engage in research on promising new 
drug candidates. In a unanimous opinion authored by Justice Antonin 
Scalia, the Supreme Court held that the Federal Circuit had erred 
when it drastically limited the protection of the FDA safe harbor, 
applying it only to the late-stage testing on human patients.

"This was a grand slam homerun for patients and for drug innovators. 
The Supreme Court gave drug companies and researchers enormous 
latitude to conduct the testing necessary to bring promising 
therapies to needy patients. It means that researchers will not have 
to sit on their hands for a decade when they have discovered a 
promising drug, but rather, without skipping a beat, can conduct the 
experiments they need to conduct to make sure the drug gets to sick 
patients as soon after patent expiration as possible."



-- E. Joshua Rosenkranz, Heller Ehrman LLP

The case, Merck KGaA v Inegra LifeSciences is the most significant 
patent infringement ruling to confront the biotech and 
pharmaceutical industries in a generation.

WHO:   Attorney E. Joshua Rosenkranz
*  Attorney E. Joshua Rosenkranz presented the oral argument, on 
behalf of Merck KGaA, before the U.S. Supreme Court in April 2005.


http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/







 Yahoo! Groups Sponsor ~--> 
In low income neighborhoods, 84% do not own computers.
At Network for Good, help bridge the Digital Divide!
http://us.click.yahoo.com/EA3HyD/3MnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Pennsylvania Department of Community and Economic Development

[famouswba]

Pennsylvania Department of Community and Economic Development 


PA DCED Secretary Announces Five Economic Development and Technology 
Investment Projects That Will Create Nearly 500 Biosciences Jobs in 
Pennsylvania

HARRISBURG, Pa., June 13 

Pennsylvania Department of Community and Economic Development (DCED) 
Secretary Dennis Yablonsky today announced Governor's Action Team 
(GAT) projects for five Biosciences companies that were offered 
approximately $5 million in state assistance to create and retain 
nearly 500 jobs in Pennsylvania.

 
"The bioscience industry is transforming the commonwealth's economy 
by supporting new companies, creating jobs and contributing to 
community growth," Yablonsky said. "Today's announcements 
demonstrate the commonwealth's commitment and tradition to 
innovation through our forward thinking and dedication to the life 
sciences industry. Projects like these ensure our continued growth 
and success in this constantly evolving industry throughout 
Pennsylvania and beyond."

Yablonsky announced the following GAT projects:

Agentase LLC is expanding its Allegheny County operations by 
relocating to a new facility in Harmar Township. The chemical 
engineering company completed the Research & Development (R&D) phase 
for its new products and needs to relocate to a facility with wet 
chemistry lab space. At least 54 jobs will be created within three 
years and 22 existing employees will be retained. The Governor's 
Action Team (GAT), economic development professionals who report 
directly to Gov. Edward G. Rendell and Yablonsky, and the Allegheny 
County Department of Economic Development worked with Agentase on 
this project. DCED offered the company a $328,300 funding package 
that includes: a $200,000 Small Business First (SBF) loan; a $50,000 
Opportunity Grant; $24,300 in Job Training Assistance (JTA); and 
$54,000 in Job Creation Tax Credits (JCTC). Agentase is focused on 
the development and implementation of biocatalysts. Its products 
include anti-chemical warfare/terrorism sensors and pesticide 
remediation.

Charles River Laboratories has outgrown its current Exton facility 
and plans to relocate to a new 60,000-80,000-square-foot facility in 
southeastern Pennsylvania. A location has not yet been determined. 
The company, a provider of solutions that advance the drug discovery 
and development process, will create at least 36 jobs within three 
years and retain 92 existing employees. DCED offered the company a 
$1.08 million financial package that includes: $450,000 Machinery 
and Equipment Loan Fund (MELF); $300,000 Opportunity Grant; $150,000 
JTA; and $180,000 JCTC. Charles River Laboratories' products and 
services are designed to enable its clients to bring drugs to market 
faster and more efficiently.

Integrated BioSciences Inc. (IBS) is expanding its existing 
Lewisberry, York County facilities and infrastructure by purchasing 
additional equipment and hiring new employees. At least 65 jobs will 
be created within three years and the company, which is a complete 
contract manufacturer of medical devices, automated equipment 
and "box build" electronics, will retain 22 existing employees. DCED 
offered the company a $705,000 funding package that includes: a 
$500,000 loan through MELF; a $75,000 Opportunity Grant; and 
$130,000 JCTC. IBS is an FDA registered, ISO 9001:2000 certified 
manufacturer that offers total project management for class I and II 
medical devices for companies looking to outsource the manufacture 
of their products, automated equipment or entire manufacturing 
programs.

Isolagen Inc. has expanded operations by relocating its Texas 
headquarters and R&D to its existing Exton, Chester County, 
facility. The company, which specializes in the development and 
commercialization of cellular therapies for soft and hard tissue 
regeneration, will create at least 140 new jobs within three years. 
DCED offered Isolagen a $1.7 million financial package that 
includes: a $500,000 loan through MELF: a $400,000 Opportunity 
Grant; $100,000 JTA; and $700,000 JCTC. The company's technology 
process has potential applications in cosmetic dermatology, cosmetic 
surgery, periodontal disease, reconstructive dentistry and other 
therapies. Isolagen has five secured patents and five additional 
patents pending.

NanoDynamics Inc. has four existing business units and is creating a 
new division in the City of Pittsburgh - ND Life - in collaboration 
with the McGowan Institute of Regenerative Tissue. At least 50 jobs 
will be created by the company, which will leverage existing 
expertise in nanotechnology-based products to address needs and 
opportunities in the life sciences marketplace. DCED offered 
NanoDynamics a $1.15 million funding package that includes: a 
$500,000 loan through MELF; a $200,000 loan through SBF; a $200,000 
Opportunity Grant; $100,000 JTA; and $150,000 JCTC. NanoDynamics is 
a leading manufacturer of nanomaterials to improve the fo

[ biotech news ] Biotechnology Laboratory Technician Certificate

[famouswba]

Biotechnology Laboratory Technician Certificate 
http://www.csusm-es.org/biotech/

CSUSM - Extended Studies - Biotechnology Laboratory Technician 
Certificate Program

 Train for a New Career in Biotechnology! Program begins January 18, 
2005. 

National and local trends indicate that there is a promising 
employment picture for individuals with specific training in 
biotechnology. While biotech-related jobs in 2003 jumped more than 
12.4% over the previous year, it is projected that the San Diego 
biotech workforce will grow on a faster-than-average basis (17.5%) 
for this decade (San Diego Economic Bulletin, December 2003 and 
Nature, December 11, 2003). Inherent in this workforce growth is the 
increasing need for qualified laboratory technicians. 

This specialized Biotechnology Laboratory Technician Certificate 
program is designed to:

Provide students with a foundation in the knowledge and techniques 
needed to earn entry-level positions as lab technicians in the 
growing biotechnology field
Train laboratory personnel for careers and jobs as laboratory 
technicians and/or research assistants
Concentrate on the laboratory techniques most commonly used by firms 
in their research,manufacturing, and quality control laboratories
Provide industry employers with a workforce-ready pool of well-
trained lab technicians, Quality Assurance and research / 
manufacturing assistant 
 

 
 
 
 
This program provides an overview of the industry and the functions 
of biotechnology and pharmaceutical laboratories in research, 
manufacturing and quality control. Emphasis on the industry, the 
role of biotechnology companies and the process of discovery and 
development of new products. Also covered are federal regulations 
with emphasis on Good Laboratory Practices (GLP) and Good 
Manufacturing Practices (GMP).

The 17-semester unit certificate can be completed in one full year, 
provided necessary prerequisites
have been completed. Courses are drawn from the regular Cal State 
San Marcos catalog and include:

BIOL 359 Biotech/Pharmaceutical Industry Labs (3 units) 
BIOL 355 Molecular Biotechnology (4 units) 
BIOL 356 Cellular Biotechnology (4 units) 
CHEM 351 Biochemistry (3 units) 
BIOL 358 Computer Skills for Biotechnology (3 units) 
Biotech/Pharma Industry Laboratories (BIOL 359) 

This exciting new course will provide you with a comprehensive 
overview of the industry and the functions of biotechnology and 
pharmaceutical laboratories in research, manufacturing and quality 
control. Emphasis is on the industry, the role of biotechnology 
companies and the process of discovering and developing new 
products. Also covered are federal regulations with emphases on Good 
Laboratory Practices (GLP) and Good Manufacturing Practices 
(GMP).This course may be taken as a "stand alone" course for 
individuals who simply want an introduction to the biotech/pharma 
industry, or as the first course in the Biotechnology Laboratory 
Technician Certificate of Competence. No prerequisites; no program 
application required. May be used as an elective for the CSUSM 
biology degree.

Course No: BIOL 359 
Fee: $600 
Dates: Tuesdays, January 18 ? April 5 
Saturdays, January 22 and April 16 
Times: 5:30 am - 8:30 pm (Tuesdays) and 8:30-3:00 pm (Saturdays) 
Units: Three Semester Units (degree applicable) 
Location: Please call the Extended Studies office at (760) 750-4020 
for classroom location. 
Facilitator: Al Kern, Director of Biotechnology, Cal State San 
Marcos 
Instructors: Program features a wide variety of industry leaders and 
content experts. 

For more information on the certificate program and to receive an 
application packet, contact Extended Studies at (760) 750-4020. 
 

http://www.arizonabiotech.com/

http://groups.yahoo.com/group/biotech-news/

http://smsac.blogspot.com/



 







 Yahoo! Groups Sponsor ~--> 
Has someone you know been affected by illness or disease?
Network for Good is THE place to support health awareness efforts!
http://us.click.yahoo.com/RzSHvD/UOnJAA/79vVAA/H4xqlB/TM
~-> 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] More than 45 Delegates from the New Zealand Biotechnology Industry Highlight New

[famouswba]

More than 45 Delegates from the New Zealand Biotechnology Industry 
Highlight New Zealand Innovation and Global Connectedness at BIO 
2005 

 BIO 2005 Annual Convention 


  Over 150 Years of Life Sciences R&D Has Produced a Rapidly Growing 
Biotech Industry Addressed to Health and Wellness, Industrial 
Biotech, Agriculture, Forestry and More

More than 150 years of life sciences research and technological 
innovation, combined with strong global partnerships, and a public-
private collaborative approach to business have given New Zealand 
one of the world's fastest growing biotechnology industries. Today 
New Zealand biotechnology applications range beyond agriculture to 
add medicine, human health, wellness and performance, industrial 
biotechnology, forestry, biosecurity, and environmental 
applications. 

To promote awareness of New Zealand's growing global presence in 
biotechnology, the Honorable Pete Hodgson, New Zealand Minister of 
Commerce and ex-Minister of Research, Science and Technology will 
lead a delegation of 47 companies and organizations to the BIO 2005 
conference, taking place in Philadelphia, PA from June 19 - 22. 
Through its internationally oriented biotechnology industry and its 
presence at BIO 2005, New Zealand is reaching out to partner with 
leading U.S. and international research institutions and 
universities, companies, and state agencies. 

New Zealand Pavilion 

The New Zealand Government's economic development agency New Zealand 
Trade and Enterprise (NZTE) will host a pavilion in the BIO 2005 
Exhibition Hall. The pavilion will showcase a variety of New Zealand 
research initiatives and companies in the areas of human medicine, 
health and wellness, agricultural biotechnology, industrial 
biotechnology and support organizations. The pavilion will include a 
meeting area for networking and one-on-one meetings during the 
conference. NZTE will co-host with the Australian Pavilion a special 
exhibit hall event on Tuesday June 21, 2:00 - 4:00 pm, featuring 
fine wines from New Zealand and Australia. The New Zealand Pavilion 
is located in Hall C, Stands 749-856. 

New Zealand Country Seminar 

On Sunday June 19, International Day presenters for New Zealand will 
include Minister Hodgson, along with Chris Boalch, Director of 
Biotechnology, NZTE; Richard Furneux, Ph.D., CEO of GlycoSyn, an 
Industrial Research Ltd company focused on glycobiology; Larry 
Ellingson, CEO of Protemix USA, a New Zealand founded 
biopharmaceutical company; and Howard Moore, Executive Director of 
the recently founded venture firm, BioPacificVentures. Together they 
will provide an overview of the New Zealand biotech industry and 
business environment, including government initiatives planned to 
grow the industry, as well as the New Zealand industry's expanding 
international linkages. 

The New Zealand Minister of Commerce, Hon. Pete Hodgson, said, "Much 
of New Zealand's wealth has been built on a proven ability to add 
value to natural resources by applying biological knowledge. Now 
unique approaches to biotechnology pioneered in New Zealand are set 
to have a major impact on the way we all deal with health and 
environmental issues. 

"The New Zealand biotech sector has firm backing from the New 
Zealand Government which recognises its importance to the economy. 
It is working with the New Zealand biotechnology community to 
implement a detailed strategy to put in place the necessary 
infrastructure to promote success on a global scale." 

New Zealand Companies at BIO2005 

Representatives of some of New Zealand's leading biotechnology 
companies, as well as scientists from cutting edge research programs 
at the country's Crown Research Institutes and Universities, will 
represent the nation's outstanding capabilities and global research 
at BIO2005. Just a few of the New Zealand companies represented at 
BIO include: 

-- Proacta and Protemix are two companies that illustrate well the 
global connectedness of New Zealand biotechnology. Taking advantage 
of New Zealand innovation, scientific know-how and low cost of 
research, these two companies are among those who have expanded 
operations to the United States for access to larger patient 
populations and markets. Proacta is developing treatments for cancer 
that take advantage of the oxygen-poor environment in tumors. 
Protemix is engaged in the development of a novel treatment to 
repair heart damage in patients with diabetes, as well as other 
therapies for cardiovascular disease, diabetes and other metabolic 
conditions. 

-- Lactopharma and Ovita are two companies whose research 
demonstrates New Zealand's ability to mine leading agricultural 
research for new human therapeutic applications. Lactopharma is 
developing applications of lactoferrin, a milk-derived protein with 
both anti-inflammatory properties and the ability to promote bone 
formation and inhibit bone absorption. Ovita's research on muscle 
development and twinn

[ biotech news ] Generex Biotechnology Presents Oral-lyn(TM) Clinical Trial Results

[famouswba]

Generex Biotechnology Presents Oral-lyn(TM) Clinical Trial Results

Company presents at the American Diabetes Association 65th 
Scientific Sessions 

TORONTO, 

Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in 
the area of buccal drug delivery, today announced clinical trial 
results in respect of Oral-lyn(TM), the Company's proprietary oral 
insulin buccal spray formulation, presented at the 65th Annual 
Meeting & Scientific Sessions of the American Diabetes Association 
held June 10 - 14, 2005 in San Diego.
 
Generex clinician Dr. Jaime Guevara-Aguirre presented a poster in 
the Clinical Therapeutics/New Technology -- Insulin Delivery Systems 
category titled "A Series of Open-Label Studies Comparing Various 
Formulations of Oral-lyn(TM) Propellant Spray in Patients with Type-
1 Diabetes Mellitus" (co-authored with M. Guevara and J. Saavedra).

During the normal drug development process and besides evaluating 
Oral-lyn(TM) against its active comparator, it was necessary to test 
preparations with different insulin concentrations or different 
ratios of the excipients included in the Oral-lyn(TM) formulation. 
In Dr. Guevara's study, the glucodyanmic (GD) profiles induced by 
single pre-prandial versus pre- and post-prandial split doses of 
Oral-lyn(TM) were compared to the GD profile of Humulin-R in a 3-day 
(4 hours per day) open-label study performed in patients with Type-1 
diabetes. In a second experiment, Dr. Guevara tested the relative 
efficacy of various Oral-lyn(TM) preparations in a series of similar 
4-hour open label studies performed in the same individuals with a 
view to determining the most appropriate Oral-lyn(TM) preparation 
for longer term trials.

In the first experiment, Oral-lyn(TM), in either a single pre-
prandial dose or in a split-dose fashion, was administered to 6 
patients with Type-1 diabetes. The corresponding GD profiles were 
compared to the GD profiles induced by the administration of the 
active comparator (subcutaneous injection of Humlin-R) 30 minutes 
prior to the same test meal. The study determined that a pre- and 
post-prandial split-dose of Oral-lyn(TM) was better than a pre-
prandial single dose and comparable to the GD profile induced by 
Humulin-R.

The second experiment included a series of open-label studies at 
which the same 6 patients with Type-1 diabetes received, in 
different days, single does of each preparation of Oral-lyn(TM) in a 
split-dose regimen with 5 puffs before and 5 puffs after the test 
meal. After evaluation of the GD profiles of the various 
preparations, Dr. Guevara was able to identify the preparation that 
exhibited the best GD profile for use in longer term trials.

In addition, Generex clinician Professor Itamar Raz published a 
paper in the Abstract Book for the 65th Annual Scientific Sessions 
titled "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type-
2 Diabetes Maintained on Glargine + Meformin -- A Comparison with 
Placebo" (co-authored with A. Dubinsky, M. Kidron and J. Wainstein).

The purpose of the Professor Raz study was to determine the 
metabolic effect of Oral-lyn(TM) at mealtime on a long-term basis 
(12 weeks) in patients with Type-2 diabetes maintained on once-a-day 
subcutaneous Glargine insulin injection therapy at bedtime and 
Metformin. The primary hypothesis was that Oral-lyn(TM) can be used 
safely at mealtimes and will improve 7 point glucose profiles, 
fructosamine and the baseline HbA1c levels 12 weeks after treatment.

This was a randomized, double-blind, long-term (12 weeks) study in 
26 patients with Type-2 diabetes (male or female) with poorly 
controlled blood glucose maintained on once a day s.c. Glargine and 
Metformin. After the initial screening visit, subjects maintained 
their regular treatment for two weeks as a run-in period. Following 
the training of the Oral-lyn(TM) device operation and dosing 
schedules, they were divided into two groups. One group had 7 puffs 
of Oral-lyn(TM) TID, and the other group had 7 puffs of placebo TID. 
Both groups took the puffs 10 minutes before mealtime in addition to 
their regular treatment. In cases where self-glucose values were 
above 12mmol/L before any meal or before bedtime, an additional 7 
puffs were added. Each subject had routine blood chemistry and HbA1c 
as well as fructosamine levels at the beginning of the study and at 
the end of every month during the study period. Beginning with the 
initial screening visit, each subject had to monitor his/her blood 
glucose at least three times a day and once a week for a 7-point 
profile.

The interim results, after 8 weeks of treatment, showed no change in 
fasting glucose while in post-prandial glucose there was a 15.4% 
reduction in the Oral-lyn(TM) group versus 3.9% elevation in the 
placebo group. Furthermore, the study found a reduction of 
fructosamine in the Oral-lyn(TM) group of 6.4% versus 3.6% in the 
placebo group and for HbA1c there was a 6.6% reduction in the Oral

[ biotech news ] Kreatech Biotechnology Launches a Series of ULS arrayCGH Labeling Kits Array Bas

[famouswba]

Kreatech Biotechnology Launches a Series of ULS arrayCGH Labeling 
Kits Array Based Comparative Genomic Hybridization (CGH) Analysis 
  
AMSTERDAM, 

New "ULS(TM) arrayCGH Labeling Kits" for Direct, Non-enzymatic 
labeling of genomic DNA for microarray based comparative genomic 
hybridization (arrayCGH) analysis

Kreatech Biotechnology BV announces the launch of a series of ULS
arrayCGH labeling kits offering its' proprietary ULS labeling 
molecule bound to a choice of fluorescent dye pairs that have been 
licensed by Kreatech including dyes from GE Healthcare/Amersham 
(CyDyes), Perkin Elmer (Cyanine Dyes) and Dyomics (DYDyes). The 
complete labeling kits include unique purification columns 
(KREApure), blocking buffer (KREAblock) and hybridization buffers.

The ULS labeling of nucleic acids is a robust, one-step 
procedure that is completed within 30 minutes. "The possibility of 
analyzing genomic DNA directly without the need to amplify is a very 
attractive feature to many researchers, not only does it save time 
but it also removes the potentially biasing enzymatic step that is 
currently required in order to label genomic samples" according to 
Ted van der Lende, Director of product development.

The Universal Linkage System - ULS(TM) - is a proprietary 
labeling technology that has been optimized for arrayCGH analysis on 
DNA arrays. The ULS arrayCGH labeling kit has the unique feature of 
allowing the user to label genomic DNA directly in a one step 
labeling reaction (30 minutes), avoiding the need for a potentially 
biasing enzymatic step. This results in more accurate data as well 
as saving time and money. The ULS labeling efficiency is independent 
of fragment length making it ideal for use with archival DNA. Where 
samples are limiting and amplification is required, this is carried 
out using natural unmodified nucleotides which is then followed by
the one step ULS labeling.

Brent Keller, acting Commercial Director for Kreatech states "Our
decision to make available arrayCGH labeling kits that offers a 
choice of fluorescent dye pairs from the leading dye manufacturers 
is consistent with our strategy to offer ULS technology independent 
of array platform used and the labels that researchers work with. In 
this way, ULS can be the ubiquitous choice of researchers for their 
labeling needs, eliminating the concern over matching arrays and 
labels with the offering of every manufacturer."

Kreatech earlier this year launched a line of aRNA labeling kits 
for expression arrays with dye pairs from GE Healthcare, Perkin 
Elmer, Dyomics and a Biotin system for Affymetrix users.

For more information on the ULS labeling kits visit 
http://www.kreatech.com



SOURCE Kreatech Biotechnology B.V.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] MilkenInstitute.Org > Publications > The Greater Philadelphia Life Sciences Clus

[famouswba]

http://www.milkeninstitute.org/publications/publications.taf?
function=Þtail&ID=E4&cat==ResRep

MilkenInstitute.Org > Publications > The Greater Philadelphia Life 
Sciences Cluster: An Economic and Comparative Assessment

The Greater Philadelphia Life Sciences Cluster: An Economic and 
Comparative Assessment
Ross DeVol, Rob Koepp, Lorna Wallace, Armen Bedroussian and Daniela 
Murphy
June 2005 



Price:$ 35.00*

As you order, the number of items in your shopping cart will appear 
in the upper right corner. You may make changes at checkout. 


The life sciences industry is an emerging powerhouse for U.S. global 
economic competitiveness in the 21st century. So which metropolitan 
areas are in the lead for this important engine of economic growth? 

According to this study, Boston, the San Francisco Bay Area and 
Greater Philadelphia have the most dynamic life sciences clusters in 
the country.

Encompassing biotechnology, pharmaceuticals, medical devices, 
associated research and development activities, and supporting 
infrastructure – including research universities, teaching 
hospitals, medical laboratories and venture capital firms – life 
sciences is one of the most knowledge-intensive and research-rich 
sectors of the U.S. economy. It directly and indirectly supports 
millions of jobs and pays above-average wages to life science 
industry workers.

The study was sponsored by BioAdvance, PricewaterhouseCoopers, 
Pennsylvania BIO and the Greater Philadelphia Chamber of Commerce's 
CEO Council for Growth, which asked the Institute to undertake the 
study to gauge the Greater Philadelphia region's standing compared 
to the other leading life sciences clusters in the U.S.

Researchers benchmark and assess the current position of the Greater 
Philadelphia life sciences sector relative to 10 other leading 
centers – Greater New York, Boston, Greater Raleigh Durham, 
Minneapolis, Chicago, Dallas, Greater San Francisco, Seattle, 
Greater Los Angeles and San Diego – and estimate the total impact on 
the region's economy by calculating the multiple ripple effects, 
evaluate how it is positioned for future growth by investigating its 
ongoing ability to innovate, and formulate an overall composite for 
the life sciences. 

The Greater Philadelphia life sciences cluster ranks among the elite 
centers in the country. Its life sciences industry is a clear 
potential source of comparative advantage for the region's economy 
over the long term and it ranks among the largest clusters in the 
country. 

The study includes detailed statistics from the dozens of 
measurements examined by researchers in each of the 11 clusters

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/





http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] BIO Ventures for Global Health Announces Bill & Melinda Gates Foundation Grant t

[famouswba]

BIO Ventures for Global Health Announces Bill & Melinda Gates 
Foundation Grant to Expand Biotech Industry's Role in Fight Against 
Neglected Diseases

Four-year, $5.4 Million Grant Will Help Companies Overcome Market 
and Funding Barriers 


PHILADELPHIA, June 21 BIO Ventures for Global Health today announced 
it will expand its efforts to enlist biotechnology companies in the 
fight to improve global health, with a new $5.4 million grant from 
the Bill & Melinda Gates Foundation. BVGH is a nonprofit venture 
founded last year by the Biotechnology Industry Organization, with 
support from the Gates Foundation and the Rockefeller Foundation. 
The announcement was made at BIO 2005, the biotech industry's annual 
convention.
 
"The biotech industry has tremendous potential for developing new 
therapeutics, vaccines and diagnostics against diseases of the 
developing world," said Richard Klausner, MD, executive director of 
the Gates Foundation's Global Health program. "For too long, 
funding, market, and information barriers have prevented biotech 
companies from realizing this potential. We believe that BIO 
Ventures for Global Health will provide the means to help industry 
overcome some of these barriers. We congratulate BVGH in taking 
leadership in helping to bring the potential of biotechnology to 
improving health equity in our world."

The new grant will help BVGH launch a series of business cases to 
assess and build market opportunities for neglected diseases. 
Companies are deterred by an insufficient understanding of 
developing world markets and many lack the capacity to generate this 
knowledge on their own. To evaluate whether to invest in a 
technology, they need information on potential market demand and 
pathways to get products tested, licensed and distributed. BVGH will 
fill that gap. The business cases, a tool used regularly by 
industry, will explore new models for tapping into emerging markets. 
BVGH's first business case will evaluate the market opportunity for 
tuberculosis vaccines.

"This grant represents a historic shift in thinking about how to 
engage the biopharma sector in addressing the unmet health needs of 
people in developing countries," said Rob Chess, Chairman of 
BVGH. "We understand the business of biotech and are seeking ways to 
translate that knowledge into solutions that improve the lives of 
individuals in the poorest regions of the world."

For markets that are too small to compete with other industry 
opportunities, BVGH will pursue market incentives to enhance the 
underlying market and "pull" new industry investment. Over the last 
year, BVGH has reached out aggressively to biotechnology companies 
and has represented the industry in talks with the World Bank and 
the finance ministers of the G7 countries to design advance market 
commitments to spur biotech innovation for critical products such as 
AIDS and malaria vaccines.

"BVGH is uniquely placed, with access to -- and intellectual support 
from -- the most innovative biopharma companies -- large and small," 
said Jim Greenwood, President of the Biotechnology Industry 
Organization. "BVGH has treated global health as a business from the 
outset, and funding for their efforts should have a catalytic impact 
on industry's response to these immense global challenges."

Currently, less than 10 percent of health research funding is 
targeted to diseases that account for 90 percent of the global 
disease burden. BVGH aims to radically change that equation.

"The biopharma industry is ready and willing to tackle the tough 
scientific and technical challenges in global health, but the market 
has to be there," said BVGH Executive Director Wendy Taylor. "We're 
creating the business roadmap -- through improved markets and 
creative new business models -- that will lead industry to those 
much-needed solutions."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH) is a global, non-profit entity 
that seeks to break traditional barriers to global health product 
development, bridging the gap between biotechnology's immense 
promise and the enormous unmet health needs of the developing world. 
By uncovering and building new market opportunities -- through 
better market information, creative business models and new market 
incentives -- BVGH aims to catalyze industry investment in global 
health innovations to address the unmet health needs of the poorest 
regions of the world. More information is online at 
http://www.bvgh.org.




-
---
Source: BIO Ventures for Global Health; Biotechnology Industry 
Organization


http://www.arizonabiotech.com/
http://smsac.blogspot.com/
http://groups.yahoo.com/group/biotech-news/






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.ariz

[ biotech news ] Berna Biotech Enters Australia, Swiss Cooperations

[famouswba]

Berna Biotech Enters Australia, Swiss Cooperations


Swiss biotechnology company Berna Biotech AG (BBIN.EB) Wednesday 
said it entered new cooperations with Australia-based CSL Ltd 
(CSL.AU) and Swiss company Apoxis. 
 
Berna Biotech entered an exclusive commercialization and licence 
agreement for Aerugen in Australia and New Zealand with CSL. Aerugen 
is a vaccine for the prophylaxis of Pseudomonas aeruginosa 
infections in cystic fibrosis patients and is expected to be 
launched in Europe in the year 2007. 

Melbourne-based CSL is a biopharmaceutical company that develops, 
manufactures and markets products to treat and prevent serious human 
medical conditions. 

With Apoxis an agreement for clinical-grade, recombinant protein 
production and supply was signed. Berna Biotech will help in the 
production of Apoxis' produce recombinant MegaFasL product for phase 
I clinical trials in oncology. 

Apoxis develops novel therapeutic proteins able to modulate 
apoptotic cell death, or cell suicide. Apoptosis plays a central 
role in the regulation of cancer and autoimmune disease and its 
control, through agonistic or antagonistic molecules, holds great 
promise for the treatment of life-threatening diseases. 

http://www.bernabiotech.com 



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] FierceBiotech Honors Xencor as One of the ``Fierce 15'' Biotech Companies of 200

[famouswba]

FierceBiotech Honors Xencor as One of the ``Fierce 15'' Biotech 
Companies of 2005 

Xencor, Inc., a company engineering superior biotherapeutics using 
its Protein Design Automation(R) technology, announced today that it 
has been selected as one of the "Fierce 15" for 2005 by 
FierceBiotech, an internationally recognized publication for the 
biotech industry covering the biotechnology and pharmaceutical 
markets. Xencor was chosen as one of the top emerging biotechnology 
companies for the company's innovative Protein Design Automation (PDA
(R)) technologies, including Xencor's XmAb(TM) technology that 
improves the potency of monoclonal antibodies. 


"The beauty of Xencor's work is that it focuses on the constant 
region of an antibody, redesigning a segment that helps it more 
effectively attack a target cell by improving an antibody's natural 
immune system recruitment," says John Carroll, of 
FierceBiotech. "Like the other swiftly developing companies on this 
year's Fierce 15 list, we'll be watching Xencor closely in the years 
ahead." 

"Xencor's PDA technology has allowed the company to generate an 
outstanding roster of industrial collaborators and grow an internal 
pipeline of biotherapeutics, with our lead candidate for the 
treatment of rheumatoid arthritis, DN-TNF, expected to enter human 
trials in 2006," said Bassil Dahiyat, President and CEO of 
Xencor. "Xencor is honored to be chosen for this distinction by 
FierceBiotech, a recognized leader in the industry for advancing an 
understanding of biotechnology companies and the life science 
community." 

The Fierce 15 celebrates the spirit of being "fierce" -- championing 
innovation and creativity, even in the face of intense competition. 
The list of Fierce 15 companies is available in today's issue of 
FierceBiotech and on the FierceBiotech Web site at 
http://www.fiercebiotech.com. 

About FierceBiotech 

FierceBiotech, an internationally recognized email newsletter for 
the biotech industry, provides more than 35,000 executives a must-
read briefing on the day's top stories in the biotech and 
pharmaceutical industries. Visit http://www.fiercebiotech.com for 
additional information. 

About Xencor 

Xencor, Inc., engineers biotherapeutics including protein 
therapeutic candidates and XmAb(TM) antibody drug candidates using 
its proprietary Protein Design Automation(R) technology platform. 
The company is internally advancing several therapeutics against 
biologically validated targets, including a protein therapeutic drug 
candidate for the treatment of arthritis and other rheumatic 
disorders and antibody candidates for the treatment of cancer. With 
multiple partners such as industry leaders Genentech and Roche, 
Xencor applies its suite of XmAb antibody Fc domains to improve 
antibody drug candidates for traits such as potency, affinity, and 
stability. Xencor also develops therapeutic protein variants in 
collaboration with major pharmaceutical partners. For more 
information, please visit www.xencor.com.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech Breakthrough Will Favorably Impact the U.S. Chemical Industry

[famouswba]

Biotech Breakthrough Will Favorably Impact the U.S. Chemical Industry

Codexis and Cargill, members of the Biotechnology Industry 
Organization's (BIO) Industrial and Environmental Section, today 
announced a breakthrough in developing a novel microbial process 
that will convert corn sugar to a chemical intermediate. This 
process is an important milestone in the development of a new 
renewable chemical platform. When fully commercialized, the 
industrial biotech process will convert dextrose derived from corn 
to a chemical intermediate known as 3, hydroxyproprionic acid (3HP).
 
The new process will utilize very low-cost, clean agricultural 
feedstocks instead of petroleum to produce 3HP. 3HP is a key 
intermediate for several commercially important chemicals. The 
chemicals that can be produced from 3HP include acrylic acid, 
acrylamide and 1,3 propanediol. Acrylic acid and its derivatives are 
used to create a wide range of polymer-based consumer and industrial 
products, such as adhesives, paints, polishes, protective coatings, 
and sealants. This new process is cheaper and more environmentally 
friendly than the old process that uses petroleum as a feedstock.

"Industrial biotechnology converges seamlessly with other scientific 
disciplines and is a powerful source of innovation for new products 
and processes," stated Brent Erickson, executive vice president for 
BIO's Industrial and Environmental Section. "The global acrylic acid 
market is worth over $4 billion. This breakthrough is going to shake 
up the chemical industry and it will help U.S. companies that adopt 
it to be more competitive in the global marketplace."

"With natural gas and crude oil prices going through the roof, the 
commercialization of this renewable chemical platform should be 
great news for the chemical industry. The chemical industry needs 
new feedstocks to stay competitive, and this chemical platform will 
be based on corn, not foreign oil. Furthermore, the biobased economy 
that is evolving is about more than just ethanol," Erickson 
added. "The interface between industrial biotechnology and 
agricultural production provides the ability to produce inexpensive, 
natural raw materials -- such as sugars and lipids -- for 
manufacturing biobased products. Sugars and lipids from agricultural 
crops can be used in many products, replacing increasingly expensive 
oil and natural gas, which are currently the main feedstocks of the 
chemical industry," Erickson continued.

BIO represents more than 1,100 biotechnology companies, academic 
institutions, state biotechnology centers and related organizations 
across the United States and 31 other nations. BIO members are 
involved in the research and development of healthcare, 
agricultural, industrial and environmental biotechnology products.




-
---
Source: Biotechnology Industry Organization

http://www.arizonabiotech.com/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Curis to Present at the Bear Stearns Boston Biotech Confab

[famouswba]

Curis to Present at the Bear Stearns Boston Biotech Confab 

CAMBRIDGE, Mass.
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, 
today announced that the Company will be presenting at the Bear 
Stearns Boston Biotech Confab on Tuesday, June 28, at the Hyatt 
Regency in Cambridge, Massachusetts. 


Daniel Passeri, Curis' President and Chief Executive Officer, will 
provide an overview of the status of Curis' business and 
collaborations at 3:05 p.m. Eastern. There will be an audio webcast 
of the presentation at: 
customer.talkpoint.com/BEAR002/062805a_cy/default.asp?entity=curis 
(Due to its length, this URL may need to be copied/pasted into your 
Internet browser's address field. Remove the extra space if one 
exists.) 

The presentation will be archived shortly after the live event and 
available for 30 days following the conference. The presentation 
will also be available on the Investor Relations section of Curis' 
website at www.curis.com. 

About Curis, Inc. 

Curis, Inc. is a therapeutic drug development company. The Company's 
technology focus is on regulatory pathways that control repair and 
regeneration. Curis' product development involves the use of 
proteins or small molecules to modulate these pathways. Curis has 
successfully used this technology and product development approach 
to produce several promising drug product candidates in the fields 
of cancer (under collaboration with Genentech, which also includes a 
co-development arrangement for a basal cell carcinoma product 
candidate), kidney disease (licensed to Ortho Biotech Products and 
under development at Centocor, both subsidiaries of Johnson & 
Johnson), neurological disorders (under collaboration with Wyeth), 
hair growth, and cardiovascular disease. For more information, 
please visit the Curis web site at www.curis.com.
  
Contacts  
 
   
 Curis, Inc.
Chief Financial Officer
Michael P. Gray, 617-503-6632
or
Director, Corporate Communications
Megan E. Burling, 617-503-6658 
  
   
 







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Bristol-Myers Squibb Company Signs Manufacturing Agreement With Celltrion

[famouswba]

Bristol-Myers Squibb Company Signs Manufacturing Agreement With 
Celltrion
Tuesday June 21, 10:00 pm ET  
- Celltrion To Produce Select Biologic Products - 


PRINCETON, N.J., June 21 /PRNewswire-FirstCall/ -- Bristol-Myers 
Squibb Company (NYSE: BMY - News) announced today that it has 
completed an agreement with Celltrion, Inc. for Celltrion to 
manufacture biologic products being developed by Bristol-Myers 
Squibb. Commercial terms of the agreement were not disclosed.
ADVERTISEMENT
 
 
"A key element of our company strategy is the expansion of our 
portfolio of biologic products. In support of that goal we must 
continuously assess our manufacturing capabilities," said Carlo de 
Notaristefani, president, Technical Operations, Bristol-Myers 
Squibb. "Bristol-Myers Squibb has several biologic products in 
various stages of development, including the late stage products 
abatacept and belatacept. This agreement increases our biologic 
manufacturing capacity to help ensure sufficient long-term supply of 
our products."

The Celltrion facility, located in Incheon, South Korea, is capable 
of producing multiple products, including abatacept and belatacept. 
This agreement adds to Bristol-Myers Squibb's existing biologic 
manufacturing capacity, which includes a biologic manufacturing 
facility in Syracuse, NY owned and operated by the company and a 
previously announced biologics manufacturing agreement with Lonza 
Biologics PLC.

Bristol-Myers Squibb is a global pharmaceutical and related health 
care products company whose mission is to extend and enhance human 
life.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains certain forward-looking information 
within the meaning of the Private Securities Litigation Reform Act 
of 1995 regarding a product in development and the potential 
efficacy of such product that involves substantial risks and 
uncertainties. Such risks and uncertainties include, among other 
things, the uncertainty of the success of the research and 
development activities; decisions by regulatory authorities 
regarding whether and when to approve any new drug application for a 
product candidate that may result from the research, as well as 
their decisions regarding labeling and other matters that could 
affect the commercial potential of such product candidate; and 
competitive developments. A further list and description of risks 
and uncertainties can be found in the Bristol-Myers Squibb's Annual 
Report on Form 10-K for the fiscal year ended December 31, 2004, and 
in its reports on Form 10-Q and Form 8-K. The Company undertakes no 
obligation to publicly update any forward-looking statement, whether 
as a result of new information, future events or otherwise.




-
---
Source: Bristol-Myers Squibb

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Berna Biotech Announces Two New Collaborations

[famouswba]

Berna Biotech Announces Two New Collaborations



· with the Australian-based biopharmaceutical company CSL regarding 
Aerugen for Australia and New Zealand 


 
· with the Swiss-based biopharmaceutical company Apoxis regarding 
recombinant protein production


BERNE, Switzerland, June 22, 2005--Berna Biotech Ltd (SWX: BBIN) 
announced today two new collaborations:

With CSL an exclusive commercialisation and licence agreement for 
AerugenÒ in Australia and New Zealand was signed. AerugenÒ is a 
vaccine for the prophylaxis of Pseudomonas aeruginosa infections in 
cystic fibrosis patients and is expected to be launched in Europe in 
the year 2007.

CSL Limited is a global, specialty biopharmaceutical company that 
develops, manufactures and markets products to treat and prevent 
serious human medical conditions; Headquartered in Melbourne 
Australia, the CSL Group includes CSL Bioplasma, CSL Pharmaceutical 
and ZLB Behring incorporating ZLB Plasma Services.

With Apoxis an agreement for clinical-grade, recombinant protein 
production and supply was signed: Berna will apply its mammalian-
cell process development expertise and state-of-the-art 
manufacturing facility to the production of Apoxis' recombinant 
MegaFasL product for phase I clinical trials in oncology.

Apoxis SA is a Swiss-based biopharmaceutical company. Apoxis 
develops novel therapeutic proteins able to modulate apoptotic cell 
death (cell suicide). Apoptosis plays a central role in the 
regulation of cancer and autoimmune disease and its control, through 
agonistic or antagonistic molecules, holds great promise for the 
treatment of life-threatening diseases. For further information see 
http://www.apoxis.com

No financial details were disclosed.

For further information:

Berna Biotech Ltd
Patrik Richard
Corporate Secretary
[EMAIL PROTECTED]
Phone +41 (0) 31 980 64 91
www.bernabiotech.com

CSL Ltd
Dr Rachel David
Director, Public Affairs
[EMAIL PROTECTED]
Phone 0401 775 779
www.csl.com.au

Apoxis SA
Cedric Haenni
Chief Operation Officer
[EMAIL PROTECTED]
Phone: +41 (0)21 620 60 82
www.apoxis.com


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] New Study Shows Embryonic Stem Cell Lines Classified by ``MicroRNA'' Expression;

[famouswba]

New Study Shows Embryonic Stem Cell Lines Classified by ``MicroRNA'' 
Expression; Applied Biosystems TaqMan MicroRNA Assays Quantify 
Minute Changes in MicroRNA Expression during Stem Cell 
Differentiation 

Results May Have Implications in Determining Optimal Stem Cell Lines 
for Therapeutic Research

In conjunction with the International Society for Stem Cell Research 
(ISSCR) Annual Meeting, Applied Biosystems Group (NYSE:ABI), an 
Applera Corporation business, and the University of Colorado today 
presented data using a preliminary version of Applied Biosystems 
TaqMan(R) MicroRNA Assays to profile microRNA (miRNA) expression in 
mouse stem cells. 

The collaborative research study shows embryonic stem cells can be 
classified according to miRNA expression profiles, potentially 
having implications in determining optimal stem cell lines. Using 
TaqMan miRNA assays, researchers were able to accurately determine 
expression levels across a large panel of miRNAs and reveal precise 
changes in individual miRNA expression during stem cell 
differentiation. The assays discriminated between miRNAs differing 
by as little as a single nucleotide and between mature miRNAs and 
their precursors, even in single cells. 

Increasing evidence indicates miRNAs, a recently discovered class of 
small RNA molecules, play a powerful gene regulatory role in cell 
differentiation and developmental biology, cancer, and other 
diseases. 

"The different microRNA expression profiles in embryonic stem cells 
suggest some embryonic cell cultures may contain variable 
subpopulations of spontaneously differentiated cells," said William 
M. Strauss, Ph.D., Assistant Research Professor, Department of 
Molecular, Chemical and Developmental Biology (MCDB), University of 
Colorado, Boulder. "Our newly identified microRNAs could one day be 
used as molecular markers for monitoring differentiation within 
embryonic stem cell lines." 

Researchers examined the expression levels of 252 mouse and human 
miRNAs in four mouse embryonic stem cell lines, differentiated 
embryoid bodies, and six mouse tissues. Preliminary results found 
embryonic stem cells could be accurately classified and 
differentiated from embryoid bodies and adult tissue using their 
distinct miRNA expression signatures. 

"We are excited about the potential of our novel TaqMan(R) MicroRNA 
Assays to provide further insights about the role of miRNAs in cell 
differentiation," said Dennis Gilbert, Ph.D., Chief Scientific 
Officer, Applied Biosystems. "This is the first time a technology 
has been able to quantify miRNAs easily and accurately using 
starting samples as small as a single cell. These findings may hold 
promise for stem cell researchers as they identify optimal cell 
lines for use in therapeutic research." 

In addition, data showed a total of 55 percent (138) of miRNAs 
studied were up-regulated by more than a fold, while only one 
percent (3) were down-regulated during the development of embryonic 
stem cells into embryoid bodies, suggesting miRNA expression levels 
globally increase during embryonic stem cell differentiation and may 
play an important role in activating lineage-specific genes. 

Applied Biosystems TaqMan(R) MicroRNA Assays distinguish between 
mature miRNAs and their precursor form by using a proprietary stem-
loop technology for reverse transcription (RT) of the mature miRNA, 
followed by quantitative real-time PCR. Applied Biosystems currently 
has a large set of the miRNA assays in development and plans to 
commercialize its miRNA assay technology based on TaqMan(R) 5' 
nuclease chemistry for real-time PCR. 

The poster (#53), titled "TaqMan-Based MiRNA Profiles Classify 
Embryonic Stem Cells (ES) and Differentiated Cells," will be 
presented at ISSCR today, June 23, from 5:30 to 7 p.m. and during an 
ISSCR tutorial, titled "Real-Time PCR Applications for Stem Cell 
Research," from 7 to 8 p.m. To register for the tutorial go to 
http://info.appliedbiosystems.com/isscr. A copy of the poster can be 
downloaded at http://miRNA.appliedbiosystems.com. 

About University of Colorado 

The University of Colorado is a three-campus system with campuses in 
Boulder and Colorado Springs, and the recently consolidated Denver 
and Health Sciences Center campuses located in Denver and at the 
former Fitzsimons Army Base in Aurora. For further information, 
please contact Michele McKinney in the CU System Office of 
Institutional Relations at (303) 492-6206. 

About Applera Corporation and Applied Biosystems 

Applera Corporation consists of two operating groups. The Applied 
Biosystems Group serves the life science industry and research 
community by developing and marketing instrument-based systems, 
consumables, software, and services. Customers use these tools to 
analyze nucleic acids (DNA and RNA), small molecules, and proteins 
to make scientific discoveries, develop new pharmaceuticals, and 
conduct standardized testing. Applied Biosystems 

[ biotech news ] Combating Cancer with Gene Therapy

[famouswba]

Combating Cancer with Gene Therapy 

  Frost & Sullivan to Host Interactive Quarterly Analyst Briefing on 
Gene Therapy in the Cancer Treatment Markets on Tuesday, June 28, 
2005.

The Technical Insights group at Frost & Sullivan is pleased to 
announce its exclusive 2005 Quarterly Industry Analyst Briefing on 
gene therapy in the cancer treatment market to be held on Tuesday, 
June 28, 2005 at 1:00pm EDT / 12:00pm CDT. 

The briefing will provide manufacturers, researchers in 
pharmaceutical and biotech companies and other industry participants 
with an overview of the current state of gene-therapy technologies 
focused on the treatment of cancer. The briefing will discuss 
various types of technologies under development for improved gene 
delivery and different gene therapy approaches for selective killing 
of tumor cells. Highlights of the briefing include technology 
overview, industry trends, key drivers, barriers to 
commercialization and an insight into important clinical trails. 

"Cancer continues to be the primary target for gene therapy with 
more than 2.5 million new cases of cancer diagnosed each year 
worldwide. Today an increased knowledge about the role of genes in 
cancer has led to the development of novel cancer therapies," says 
Frost & Sullivan Technical Insights Research Analyst, A.N. Aditya. 

The presentation will discuss some of the latest happenings and 
technology trends in this sector. Government, public and private 
initiatives will also be discussed. This free teleconference will 
cover the overview of the gene therapy in the cancer treatment 
market, the future outlook of emerging technologies and an 
interactive question and answer session. 

Those interested in participating in this exclusive analyst briefing 
should send an email to Danielle White, [EMAIL PROTECTED], with the 
following information for registration: full Name, company name, 
title, telephone number, fax number, city, state, address, and email 
address. Upon receipt of the above information, a confirmation/pass 
code for the live briefing will be emailed to you. 

Frost & Sullivan, a global growth consulting company, has been 
partnering with clients to support the development of innovative 
strategies for more than 40 years. The company's industry expertise 
integrates growth consulting, growth partnership services, and 
corporate management training to identify and develop opportunities. 
Frost & Sullivan serves an extensive clientele that includes Global 
1000 companies, emerging companies, and the investment community by 
providing comprehensive industry coverage that reflects a unique 
global perspective and combines ongoing analysis of markets, 
technologies, econometrics, and demographics. For more information, 
visit http://www.frost.com.
  
Contacts  
 
   
 Frost & Sullivan, San Antonio
Corporate Communications - Healthcare 
Danielle White, 210-247-2403
[EMAIL PROTECTED] 
http://www.frost.com 
  
   
 
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Australia Recognized Globally as Stem Cell Research Hub

[famouswba]

Australia Recognized Globally as Stem Cell Research Hub
Wednesday June 22, 8:08 am ET  
Government funding and supportive legislation backs nation's stem 
cell research excellence 



Australia, known globally for its biotech R&D capabilities and 
strengths in human therapeutics, agribiotech, diagnostics, medical 
devices and biodiscovery, will has some of its best in stem cell 
research capabilities on show at BIO 2005.
While human cloning is currently prohibited in Australia, embryonic 
and adult stem cell research is allowed. Australia continues to lead 
the world in stem cell research with innovative programs now 
underway to develop potential treatments for diabetes, Parkinson's 
and heart disease.

Studies currently underway at Australia's government backed 
Australian Stem Cell Centre [ASCC], and some of its collaborative 
partner institutions, include development of potential therapies for:


 * Congestive cardiac failure
 * Hematological disorders
 * Respiratory diseases
 * Disease and injury of the kidney

The ASCC announced at BIO 2005 that, as testament to the nation's 
standing in the stem cell arena, the International Society for Stem 
Cell Research's annual meeting will, for the first time meet outside 
North America -- in the Australian city of Cairns in the State of 
Queensland, in 2007.

Dr Anna Lavelle, the newly appointed Chief Executive Officer of 
AusBiotech, Australia's peak biotech industry organization, said 
Australia has been actively involved in R&D in this area.

In 1980 the first IVF birth in Australia was reported. In 1983 
Australia announced the world's first egg donor baby and the 
development of embryo freezing technology that resulted in the first 
frozen embryo baby.

"Since then Australian IVF and stem cell research teams have clocked 
advances in this sector with world-class research and solid 
government backing aimed at creating therapies for real health 
issues facing Australians -- and the world," said Dr Lavelle.

To make an appointment with members of the Australian delegation 
please go to Austrade's online diary and select the Business 
Matching service where your request will be confirmed within 24 
hours: www.austrade.gov.au/bio2005/.

For a listing of the 63 Australian exhibitors at BIO2005, please 
visit the Australian Exhibitor section of Invest Australia's BIO 
2005 website at www.investaustralia.gov.au/biotech/bio2005 .

About AusBiotech -- www.ausbiotech.org

AusBiotech is Australia's biotechnology industry organization, which 
represents over 2,400 members, covering the human health, 
agricultural, medical device, environmental and industrial sectors 
in biotechnology.

AusBiotech is dedicated to the development, growth and prosperity of 
the Australian biotechnology sector, by providing initiatives to 
drive sustainability and growth, outreach and access to markets, and 
representation and support for members nationally and around the 
world.

AusBiotech has representation in each Australian State and provides 
the foundation to bring together all the relevant players to 
facilitate the commercialization of Australian bioscience in the 
national and international marketplaces. The structure is a not-for-
profit limited guarantee company managed by a Board elected by 
members, under a constitution that is available on request from 
National Office.

AusBiotech's membership base includes biotechnology companies, 
ranging from start-ups to mature multinationals, research institutes 
and universities, specialist service professionals, corporate, 
institutional, individual and student members from Australia and 
globally.

About Invest Australia -- www.investaustralia.gov.au/biotech

Invest Australia is Australia's national inward investment agency, 
set up by the Australian Federal Government in 1997, to attract 
productive foreign direct investment into Australia to support 
sustainable industry growth and development. Invest Australia has 
investment advisory specialists in 11 locations around the world, 
including San Francisco and New York, to provide investors with on-
the-ground support and investment advice, including free and 
confidential advice to firms to help find the right business 
partners and identify commercial opportunities. In the past two 
financial years, to June 2004, Invest Australia has played a role in 
attracting 105 projects worth US$11.1 billion, involving 9,470 jobs.

About Austrade -- www.austrade.gov.au

The Australian Trade Commission, Austrade, is the Federal Government 
agency that helps Australian companies win overseas business for 
their products and service by reducing the time, cost and risk 
involved in selecting and developing international markets. 
Biotechnology is as a major source of growth for Australian industry 
and as such Austrade has established a specialist Biotech team.

Austrade, with seven offices in the US, can assist international 
biotechnology companies to partner with Australia's

[ biotech news ] Generex Biotechnology Begins Research Collaboration on Novel Allergy Therapy Wit

[famouswba]

Generex Biotechnology Begins Research Collaboration on Novel Allergy 
Therapy With Major European Company

Stallergenes, a Principal European Allergy Firm Near Paris, Tests 
Novel Approach to Immunotherapy of Allergy and Asthma Designed by 
Antigen Express 



Generex Biotechnology Corporation (Nasdaq: GNBT - News) today 
announced that a Research Collaboration Agreement has been signed by 
its subsidiary Antigen Express, Inc. with Stallergenes, S.A. a major 
European firm in immunological treatments for allergy and asthma.
 
The studies are to design and test Ii-Key/allergen epitope hybrid 
peptides to create a novel approach for the control of both 
dangerous forms of asthma and functionally disabling allergic 
reactions. A large number of individuals in both North America and 
Europe suffer from various forms of allergic responses. These range 
from allergic rhinitis to cat dander, to ragweed hayfever, to 
potentially fatal asthmatic attacks from bee sting or peanut 
allergens.

Antigen Express scientists have discovered that a segment of the 
immunoregulatory protein called Ii, acts on the HLA-DR molecules, 
which present antigenic peptide epitopes of allergens to T 
regulatory lymphocytes. By coupling this Ii-Key peptide covalently 
to the antigenic epitope peptides, the potency of the HLA-DR 
presented epitope is increased about 200 times in cell culture 
experiments and about 8 to 10 times after injecting animals.

Allergists have been seeking a method to stimulate T helper cells in 
a manner that directs the immune response away from the allergic 
pattern. Allergy symptoms arise when a T helper cell type 2 (TH2) 
response occurs to an environmental antigen, stimulating production 
of immunoglobulin E (IgE). When IgE is crosslinked by recognition of 
an allergen protein, on the surface of mast cells and basophils, 
histamine and other mediators of allergy are released. A wide range 
of responses can be found ranging from local redness and swelling in 
the skin, itchy nose, ears, roof of mouth, watery eyes and sneezing, 
to severe bronchoconstriction requiring powerful medicines and 
potentially intubation and respiratory support.

Antigen Express scientists have found that their established 
approach to stimulating responses to cancer and infectious disease 
antigens stimulates a strong TH1 response, away from a TH2 response. 
That is exactly the pattern sought in research studies to tune down 
allergic reactions. This method of treatment goes directly to the 
cause of the allergic response, rather than just treatment of 
symptoms.

"Since my days in the Allergy Clinic of the Bethesda Naval Hospital, 
trying to help patients with moderate to severe forms of allergy and 
asthma, I have followed the scientific and clinical literature 
toward making some better product," said Robert Humphreys, M.D., 
Ph.D., the Chief Scientific Officer of Antigen Express. He feels now 
that he might just have that better product to control allergic 
reactions. Nevertheless, "A lot of work lies ahead, in collaboration 
with skilled researchers and clinicians working in allergy."

In collaboration with Dr. Philippe Moingeon, Director of Research 
and Development at Stallergenes, Dr. Humphreys has designed a series 
of

Ii-Key/allergic epitope hybrid peptides for assays in France, using 
both lymphocytes from allergic patients and in mouse animal models. 
Dr. Moingeon said, "Bob Humphreys has developed a novel approach to 
controlling allergy. We seek to test it further in the laboratory, 
to see if basic biological mechanisms support further work toward 
clinical trials. Potential advantages lie in the use of peptide 
fragments of the allergen, not recognized by IgE, and in the 
enhanced potency of the epitope so that therapy can be at very small 
doses."

About Generex

Generex is engaged in the research and development of drug delivery 
systems and technologies. Generex has developed a proprietary 
platform technology for the delivery of drugs into the human body 
through the oral cavity (with no deposit in the lungs). The 
Company's proprietary liquid formulations allow drugs typically 
administered by injection to be absorbed into the body by the lining 
of the inner mouth using the Company's proprietary RapidMist(TM) 
device. The Company's flagship product, oral insulin (Oral- lyn
(TM)), which has been approved for commercial sale in Ecuador for 
the treatment of patients with Type-1 and Type-2 diabetes, is in 
various stages of clinical trials around the world. Generex acquired 
Antigen Express in August, 2003. The core platform technologies of 
Antigen Express comprise immunotherapeutics for the treatment of 
malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at 
http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from 
time to time by Generex representatives concerning the same subject 
matter may contain "forward-looking

[ biotech news ] Osiris Raises $50 Million to Commercialize First Stem Cell Products; Proceeds wi

[famouswba]

Osiris Raises $50 Million to Commercialize First Stem Cell Products; 
Proceeds will advance three promising treatments currently in human 
trials 


Osiris Therapeutics, Inc. announces that it has finalized a $50 
million aggregate private investment round through equity and 
convertible debt. The financing will fund the company's three 
ongoing clinical trial programs using their proprietary adult stem 
cell technology platform. The round was arranged by Swiss investment 
firm Friedli Corporate Finance, Inc. 


"With this successful funding round and the progress being made in 
the three clinical trials, Osiris continues to demonstrate its 
ability to execute its commercialization plan," said Chairman of the 
Board, Peter Friedli. Mr. Friedli is one of the founders of Osiris 
and was instrumental in arranging the current financing. 

"This level of support signifies the confidence our investors have 
in Osiris to be the first company to bring a stem cell therapy to 
market," said C. Randal Mills, PhD, President and CEO of Osiris. "As 
always, we are pleased with the unwavering support of our loyal 
investors, and we welcome the new investors who participated in the 
round. The proceeds will be used to aggressively advance our product 
commercialization plans and bring these revolutionary treatments to 
patients in need." 

The first product, Prochymal(TM), now in Phase II clinical trials, 
is a formulation of adult stem cells to treat Graft versus Host 
Disease (GvHD), a life threatening disease afflicting leukemia 
patients who have received a bone marrow transplant. Osiris has 
recently enrolled several prominent cancer centers in the trial 
including the M.D. Anderson Cancer Center in Houston, Texas, one of 
the world's leading bone marrow transplant facilities. "We are 
hopeful that this therapy may be a viable treatment option for 
patients suffering from this direct complication of 
transplantation," said Partow Kebriaei, MD, Assistant Professor, 
Blood and Marrow Transplantation at M.D. Anderson. "The treatments 
available to us currently for Gastrointestinal GvHD are marginally 
effective at best, which makes Prochymal a potentially significant 
breakthrough." 

The second product, Provacel(TM), a formulation of stem cells to 
repair damaged heart tissue following heart attack, is enrolling 
patients in a Phase I clinical trial. In preclinical studies, 
Provacel reversed the damage caused by a heart attack and 
significantly improved cardiac function. "This is a landmark study 
that could ultimately benefit hundreds of thousands of patients a 
year" said Nabil Dib, MD, Chief of Cardiovascular Research at the 
Arizona Heart Institute. "The aim is to develop a stem cell product 
that will repair the damage caused by a heart attack and prevent the 
progression to heart failure." 

Most recently, Osiris won approval from FDA to begin a Phase I/II 
study for its third product, Chondrogen(TM), an injection of stem 
cells formulated to repair damaged tissue in the knee joint and 
prevent the progression of arthritis. Chondrogen, in development at 
Osiris since 1999, has shown encouraging preclinical results that 
served as the basis for FDA's decision. "The product has undergone 
rigorous preclinical testing over the past six years and has shown 
the ability to regrow functional meniscal tissue in as little as six 
weeks," said C. Thomas Vangsness Jr., MD, Professor of Orthopedic 
Surgery and Chief of Sports Medicine at the University of Southern 
California's Keck School of Medicine. "More importantly, the product 
prevented the progression of osteoarthritis in the knee." 

Further portions of the proceeds will fund the continued enrichment 
of the company's product pipeline and expand the company's extensive 
intellectual property portfolio. The company currently holds more 
than one hundred issued domestic and foreign patents, with over a 
hundred more in various stages of approval. "Maintaining our current 
patent portfolio and seeing our applications through to patent 
grants will further solidify our already dominant intellectual 
property position," said Cary J. Claiborne, Osiris' CFO. "This will 
be especially critical as we begin to commercialize our stem cell 
products and assert our considerable intellectual property rights." 

About Osiris Therapeutics 

Osiris Therapeutics, Inc. is the leader in adult stem cell therapy. 
The stem cells produced by Osiris are obtained from adult volunteer 
donors, avoiding the technical problems and controversy surrounding 
other stem cell technologies. Using proprietary methods, these cells 
are grown in culture to very high numbers, allowing a single donor's 
cells to treat thousands of patients. These cells are universal in 
that they can be used in patients unrelated to the donor, without 
rejection, eliminating the need for donor matching and recipient 
immune suppression. Once transplanted, the cells promote healing of 
damaged or diseased tissues. 

Ab

[ biotech news ] TGen Awarded $7.1 Million to Accelerate Brain Disease Research

[famouswba]

TGen Awarded $7.1 Million to Accelerate Brain Disease Research


10,000 investigators now have access to the latest genetic scanning 
technologies

June 17, 2005

The Translational Genomics Research Institute (TGen) today announced 
the receipt of a $7.1 million grant from the National Institutes of 
Health (NIH) to continue a project designed to uncover the genetic 
causes of neurological and mental health disorders using 
sophisticated genetic scanning technologies. This award is part of a 
greater $25 million grant that TGen will share with three other 
microarray centers that are part of the NIH Neuroscience Microarray 
Consortium supported by the NIH Neuroscience Blueprint 
(neuroscienceblueprint.nih.gov). 
The Microarray Consortium was initially funded in 2002 by the 
National Institute of Neurological Disorders and Stroke (NINDS; 
www.ninds.nih.gov) and the National Institute of Mental Health 
(NIMH; www.nimh.nih.gov). The new award is supported by these two 
institutes as well as the thirteen other NIH Neuroscience Blueprint 
institutes. The consortium combines technology resources from TGen, 
Duke University in Durham, NC, and the University of California in 
Los Angeles. Because of the consortium's success and an expanding 
need for consortium services in neuroscience, a fourth research 
center, Yale University in New Haven, Connecticut, will be added to 
the program in June. 

About 10,000 investigators from the 15 different NIH institutes that 
are part of the NIH Neuroscience Blueprint will have access to the 
technology and expertise within the consortium. These investigators 
will be able to further their research through the use of microarray 
technology used for scanning through the entire human genome (3 
billion letters) and all of the genes for which it encodes (30,000-
40,000 genes). 

"The application of the newest and most sophisticated genome 
scanning technologies will allow us to unlock the mysteries of how 
the brain functions normally, as well as what causes common human 
disorders like Alzheimer's disease, multiple sclerosis, and others," 
said Dr. Dietrich A. Stephan, Director of the Neurogenomics Division 
at the Translational Genomics Research Institute. 

Genomic scanning technologies make use of the human genome sequence 
to visualize how gene flavors or aberrant amounts of genes can cause 
human disease. The consortium centers specialize in technologies 
which provide information about the genes turned on or off in the 
diseased tissues being studied. Scientists use these microarray 
technologies to compare genetic patterns between an individual with 
a disease and an unaffected person. Using this information, 
investigators can identify the root causes responsible for certain 
disorders so that diagnostics and treatments can be developed that 
have a direct impact on the disease mechanisms. 

The Microarray Consortium initially received $9 million from the NIH 
from June 2002 to June 2005, and the new funding will be 
approximately $25 million over the next five years. 

"It is exciting to have the microarray consortium expanded in 
capacity and expertise to serve the entire community of 
neuroscientists funded by NIH institutes. The application of genomic 
technologies in neuroscience is an important step in the development 
of future therapies for diseases and disorders of the nervous 
system," said Dr. Thomas Miller, Program Director of Extramural 
Research Programs at the NINDS. 

The consortium worked with 5 AM solutions, a software development 
company in Phoenix, to create a central database for data generated 
by the consortium. These data are freely available so the entire 
scientific community can benefit from this publicly funded endeavor. 

The Neuroscience Blueprint institutes are components of the National 
Institutes of Health in Bethesda, Maryland and are the nation's 
primary supporters of basic and applied biomedical research on the 
brain and nervous system. Additional information about the NIH 
Neuroscience Microarray Consortium can be accessed at 
arrayconsortium.tgen.org. 


# # # 

About TGen The mission of the Translational Genomics Research 
Institute (TGen) is to make and translate genomic discoveries into 
advances in human health. Translational genomics research is a 
relatively new field employing innovative advances arising from the 
Human Genome Project and applying them to the development of 
diagnostics, prognostics and therapies for cancer, neurological 
disorders, diabetes and other complex diseases. TGen is focused on 
personalized medicine and plans to accomplish its goals through 
robust and disease-focused research programs and its state-of-the-
art bioinformatics and computational biology facilities. 

About Duke The consortium's site at Duke University will operate in 
concert with the Institute for Genome Sciences and Policy (IGSP). 
The IGSP, established in 2000 with $200 million in institutional 
funds, represents Duke Universi

[ biotech news ] UCLA awarded more than $6 million for biodefense and infectious disease researc

[famouswba]

 UCLA awarded more than $6 million for biodefense and infectious 
disease research 

UCLA has been awarded more than $6 million over four years by the 
National Institute of Allergy and Infectious Diseases to support 
research for countering threats from bioterrorism agents and 
infectious diseases. UCLA will be a major component of the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases 
Research, a consortium of more than a dozen universities and 
research institutes in California, Arizona, Nevada and Hawaii.  

"Our hope is to increase fundamental knowledge on bacterial and 
viral pathogens and help mitigate the bioterrorism threat," said 
Jeffery F. Miller, professor and chair of microbiology, immunology 
and molecular genetics at UCLA, and the center's associate director 
for basic research. 

Miller's laboratory will focus on bacterial pathogens and will study 
an environmental organism that causes pneumonia and septicemia, and 
is a potential bioterror threat. Numerous safety precautions will be 
in effect, as required under federal regulations. The researchers 
will work with the organism under tightly controlled conditions, 
with high security and extensive oversight by the university and 
federal agencies. 

"This bacterium has a large genome and is largely unexplored," said 
Miller, who holds UCLA's M. Philip Davis Chair in Microbiology and 
Immunology. "We will work to learn the fundamental mechanisms of its 
cell biology and how it causes disease. It enters cells and injects 
proteins into cells using a molecular syringe." 

"Our center will bring together some of the country's best basic 
scientists and engineers for the common goal of preventing illness 
by developing more accurate tests to detect infections and new 
vaccines to protect people," said Alan Barbour, professor of 
medicine and microbiology at the University of California, Irvine, 
who will serve as director of the new center. Barbour is 
internationally known as a co-discoverer of the bacterium that 
causes Lyme disease; he also identified the protein that became an 
approved vaccine against the disease. 

While the center's goals include scientific applications to detect, 
prevent and treat diseases and bio-agents -- including developing 
vaccines -- Miller and Barbour also emphasized the importance of 
basic scientific research in providing the foundation for creating a 
defense against diseases and potential bioterrorism agents. 

"Basic research is essential, and provides a foundation for future 
applications," said Miller, a member of both UCLA's David Geffen 
School of Medicine and the UCLA College. "We will study the 
fundamental mechanisms of how bacterial pathogens work and cause 
disease." 

Miller noted that the discovery of restriction enzymes, a 
fundamental tool for pharmaceutical and biotechnology companies, was 
the result of pure intellectual curiosity. 

"Restriction enzymes were discovered years ago not by biochemists or 
geneticists looking for something practical, but because a bacterial 
virus would infect one strain of E. coli, but not another; the 
strain the virus would not infect expressed these enzymes that would 
chop apart the bacterial virus' DNA. The researchers who made this 
discovery had no immediate practical applications in mind, and yet 
what came from that discovery is an indispensable tool in the 
pharmaceutical and biotechnology industry. 

"In addition, knowledge of the genomes of bacterial pathogens 
required many years of research on model organisms such as E. coli," 
he added. "There are many such examples of the essential role basic 
science has played in leading to essential medical applications." 

Overall, the National Institute of Allergy and Infectious Diseases 
has awarded $40 million over four years to establish the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases 
Research, which will be based at the University of California, 
Irvine. The institute is part of the National Institutes of Health. 

The center is one of only 10 federally funded regional centers 
dedicated to research for countering threats from bioterrorism 
agents and infectious diseases. Its mission will be to bolster basic 
biomedical research into bioterrorism agents, such as those that 
cause anthrax and botulism, and naturally occurring infectious 
diseases, including West Nile virus, hantavirus and dengue, which 
affect increasing numbers of people worldwide. It also will provide 
scientific support, expertise and facilities in response to a 
national emergency, such as a terrorist attack or an epidemic of a 
new infectious disease, like the SARS virus. 

The center also will create a clinical trials unit for evaluating 
new vaccines. In addition, the center will support a detailed 
analysis of proteins and DNA that are key to understanding 
infectious diseases and bioterrorism agents, and lead efforts to 
apply recent computer and engineering advances toward 

[ biotech news ] Biotech Question of the Week: Got Space?

[famouswba]

Biotech Question of the Week: Got Space?

Postcard Campaign Seeking to Find Lab Space for Startups
By MARION WEBB

San Diego Business Journal Staff

Hundreds of San Diego-based biotechnologies will receive postcards 
this week with an unusual proposition: Got space? 

The Burnham Life Sciences Group, a specialty arm of San Diego-based 
Burnham Real Estate, will drop some 700 postcards in the mail 
encouraging local companies to lease access or temporary laboratory 
space to fledgling companies having a tough time getting started.

"The space requirements for young biotech companies are challenging 
in that they need facilities that can accommodate their research, 
but generally at a size that is too small to be listed," said Brent 
Jacobs, senior vice president of Burnham's Life Sciences Group. "Of 
the 15 million square feet of lab space in San Diego County, nearly 
all of the available space is 10,000 square feet or larger — far 
more than the 1,000 to 3,000 square feet of wet lab space typically 
required by startup companies."

Greg Bisconti, a partner with Burnham's Life Sciences Group, said 
few landlords are willing to sign month-to-month, six-month or 12-
month leases that startups on tight budgets and risky scientific 
projects can afford to sign.


http://www.sdbj.com/article.asp?aID=`162971.2745761.1160926.8983597.86472502.120&aID2=‰293



http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Asian `biotech hotbeds' must develop USP: E&Y report

[famouswba]

Asian `biotech hotbeds' must develop USP: E&Y report 
P.T. Jyothi Datta 




Mumbai , June 25 

IT may still puzzle analysts why biotechnology is trusted when used 
in medicine, but viewed with suspicion when used in agriculture. But 
be it medicine or agriculture, Japan, China and India are the 
emerging "biotech hotbeds," says an Ernst and Young (E&Y) report, 
released recently at Bio 2005 in Philadelphia. 

Nevertheless, "each country has to have its USP (unique selling 
proposition), otherwise me-too products will be developed. And the 
USP has to be matched with the bio-diversity of each country," says 
E&Y's Mr Utkarsh Palnitkar, who presented the report at Bio 2005. 

India's strengths are in processing, fermentation, informatics and 
its vaccine manufacturing capacity. By 2010, the country will be the 
largest manufacturer of vaccines in the world, Mr Palniktar told 
Business Line. Also, in terms of the neglected diseases seen in 
Africa, South-America and India — it makes sense to research 
diseases in India, he said. 

China's strengths are in bio-processing, and Korea has made strides 
in stem-cell research. 

In Korea, the legislation has moved in tandem with therapeutic 
cloning and, as a result, companies such as LG and Samsung have 
become large filers of patents, said Mr Palnitkar. 

Singapore has the regulatory environment and infrastructure in 
place, but it has to look outwards for people to man these, he said. 

The support of the governments in India, Singapore, China and Korea, 
in terms of infrastructure and policy, has given an impetus to the 
biotech segment in these regions, said Mr Palnitkar, Health Sciences 
leader with E&Y in India. 




http://www.thehindubusinessline.com/2005/06/26/stories/2005062601390500.htm

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] BIO 2006

[famouswba]

BIO 2006

http://www.bio.org/events/2006/



http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Genome study of beneficial microbe may help boost plant health

[famouswba]

Genome study of beneficial microbe may help boost plant health

ROCKVILLE, Md - In a study expected to greatly benefit crop plants, 
scientists have deciphered the genome of a root- and seed-dwelling 
bacterium that protects plants from diseases. 

The research provides clues to better explain how the helpful 
microbe, Pseudomonas fluorescens Pf-5, naturally safeguards roots 
and seeds from infection by harmful microbes that cause plant 
diseases. The genome paper will be published in Nature Biotechnology 
and was scheduled to be posted online on June 26. 

"The genome sequence has helped us identify new chemical pathways 
that the microbe apparently uses to create what are known 
as 'secondary metabolites' – possibly including new antibiotic 
compounds," says Ian Paulsen. He led the sequencing at The Institute 
for Genomic Research (TIGR), Rockville, Md., and is the study's 
first author. 

The use of naturally-occurring, beneficial microbes such as P. 
fluorescens to control plant pathogens is called "biological 
control." That method is gaining momentum as a way to grow healthy 
plants without using synthetic fungicides. In all, about three dozen 
beneficial microbes are currently used as an environmentally-
friendly way to fight plant diseases. 

Joyce E. Loper, senior author of the genome paper and an expert on 
P. fluorescens Pf-5, predicts that the new genomic data will help 
scientists more quickly develop new ways to boost the effectiveness 
of beneficial microbes in fighting plant diseases. 

"This genomic sequence reveals previously unknown traits of P. 
fluorescens that increase its potential for biological control," 
says Loper. She is a plant pathologist with USDA's Agricultural 
Research Service (ARS) and is based at Oregon State University, 
Corvallis. The P. fluorescens genome was sequenced at TIGR and 
analyzed by scientists there and at ARS and Oregon State University, 
with contributions by researchers at Rutgers, Washington State 
University and the University of Arizona. The project was funded by 
a grant from the USDA's Cooperative State Research, Education and 
Extension Service. 

The article in Nature Biotechnology presents the first complete 
genome sequence of a biological control agent for combating plant 
diseases. 

P. fluorescens Pf-5 was discovered two decades ago by Charles R. 
Howell, a plant pathologist with the ARS in Texas, who showed that 
the microbe suppressed two major cotton diseases. Since then, plant 
pathologists around the world have used this strain as a laboratory 
model to study beneficial microbes. 

Paulsen says the P. fluorescens project also pioneered a new 
methodology. This novel approach relies on the analysis of repeated 
regions of the DNA sequence to help identify segments of the genome 
that appear to have been transferred from other microbes or viruses, 
known as phages, that infect bacteria. 

Says Paulsen: "We found exciting evidence that P. fluorescens may 
have acquired new clusters of genes, called genomic islands, by 
means of lateral transfer from phages or other microbes." 


###
The Institute for Genomic Research (TIGR) is a not-for-profit 
research institute based in Rockville, Maryland. TIGR, which 
sequenced the first complete genome of a free-living organism in 
1995, has been at the forefront of the genomic revolution since the 
institute was founded in 1992. TIGR conducts research involving the 
structural, functional, and comparative analysis of genomes and gene 
products in viruses, bacteria, archaea, and eukaryotes. 

As the principal in-house research arm of the U.S. Department of 
Agriculture, the Agricultural Research Service (ARS) conducts 
research to develop and transfer solutions to agricultural problems 
of high national priority and provides information access and 
dissemination to ensure high-quality, safe food and other 
agricultural products, assess the nutritional needs of Americans, 
sustain a competitive agricultural economy, enhance the natural 
resource base and the environment, and provide economic 
opportunities for rural citizens, communities, and society as a 
whole. 

Oregon State University is known nationally and internationally for 
the quality of its academic programs, its research excellence and 
its service and outreach. OSU is one of only two universities in the 
nation that are designated land grant, sea grant, space grant and 
sun grant institutions. 


http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech

Biotechnology Forums:  http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://gro

[ biotech news ] Galapagos and Celera Genomics Sign Gene Function Analysis Agreement

[famouswba]

Galapagos and Celera Genomics Sign Gene Function Analysis Agreement 
 

ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005 
Galapagos today announced that it has entered into a services 
agreement with Celera Genomics Group (NYSE:CRA), an Applera 
Corporation business. Under the agreement, Galapagos' services 
division Galadeno will provide technology and adenoviral reagents 
enabling Celera to analyze gene function in human cells and validate 
potential drug targets. Galadeno will receive payments related to 
its services and technology.Under the terms of the agreement, 
Galadeno will construct recombinant adenoviruses harboring genes 
selected by Celera. These custom-made viruses will be used to 
introduce the genes into various cell types to evaluate their 
function within biological pathways. 

 
 
 
 
"We are delighted that Celera has decided to take advantage of 
Galapagos' adenoviral technology. This service agreement will allow 
Celera to utilize Galapagos' technology platform to perform cellular 
assays and target validation studies in a very beneficial way," says 
Onno van de Stolpe, CEO of Galapagos. "Our adenoviral platforms have 
proven to deliver functionally validated drug targets for our 
partners, opening significant opportunities for continued 
collaboration. We are pleased that Celera has joined the growing 
number of companies that choose Galapagos technology to study gene 
function in human cells." 

About Celera Genomics and Applera Corporation Applera Corporation 
consists of two operating groups. The Celera Genomics Group is 
engaged principally in the discovery and development of targeted 
therapeutics for cancer, autoimmune and inflammatory diseases. 
Celera Genomics is leveraging its proteomic, bioinformatic, and 
genomic capabilities to identify and validate drug targets, and to 
discover and develop small molecule therapeutics. It is also seeking 
to advance therapeutic antibody and selected small molecule drug 
programs in collaboration with global technology and market leaders. 
The Applied Biosystems Group (NYSE:ABI) serves the life science 
industry and research community by developing and marketing 
instrument-based systems, consumables, software, and services. 
Customers use these tools to analyze nucleic acids (DNA and RNA), 
small molecules, and proteins to make scientific discoveries, 
develop new pharmaceuticals, and conduct standardized testing. 
Applied Biosystems is headquartered in Foster City, CA, and reported 
sales of $1.7 billion during fiscal 2004. Celera Diagnostics, a 
50/50 joint venture between Applied Biosystems and Celera Genomics, 
is focused on discovery, development, and commercialization of 
diagnostic products. Information about Applera Corporation, 
including reports and other information filed by the company with 
the Securities and Exchange Commission, is available at 
www.applera.com, or by telephoning +1.800.762.6923. Information 
about Celera Genomics is available at www.celera.com. 

About Galapagos 

Galapagos is a publicly traded, genomics-based drug discovery 
company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that 
has successfully discovered and validated novel targets in the bone 
and joint diseases - osteoarthritis, osteoporosis and rheumatoid 
arthritis, as well as in asthma and Alzheimer's disease. Proprietary 
targets and compounds resulting from these programs are used for 
Galapagos' internal drug discovery programs, combined with selected 
out-licensing and partnering of projects during development. 
Galadeno, Galapagos' services unit, provides reagents and functional 
screens to leading pharmaceutical, biotech and nutraceutical 
companies for rapid identification and validation of novel drug 
targets. Galapagos currently employs 69 people, including 17 PhDs, 
and occupies facilities in Mechelen, Belgium, and Leiden, The 
Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene, 
GlaxoSmithKline, Vertex and Wyeth. 




http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study Published i

[famouswba]

Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study 
Published in Nature Genetics Shows

- Novel approach identifies 89 novel new human microRNAs, nearly 
doubling the number of human microRNAs sequenced to date, and 
predicts number exceeds 800. 
- First report of large number of primate specific microRNA, 
postulated to play an important role in differentiation and 
evolution. 


REHOVOT, Israel, In a study published online this week and to be 
published as a cover story in the July issue of Nature Genetics, 
Rosetta Genomics' scientists report identification of hundreds of 
human microRNA genes, including the first report of primate specific 
microRNAs. Using a novel methodology, the researchers successfully 
cloned and sequenced 89 human microRNAs, nearly doubling the number 
sequenced in man to date.
MicroRNAs are a recently discovered class of tiny regulatory genes, 
comprised in the 98% of the genome that does not encode proteins, 
which until recently were considered 'Junk DNA'. Numerous recent 
studies have shown microRNA genes, far from being 'junk', are in 
fact of central importance, regulating at least 30% of all proteins, 
and involved in a wide range of diseases, including diabetes, 
obesity, viral diseases, and various types of cancer.

"The finding of large numbers of primate specific microRNAs is 
exciting because it supports the notion that microRNAs may indeed 
play an important role in the evolution of complexity of higher 
organisms," said Aaron Ciechanover, Nobel prize laureate 2004, and 
Chairman of Rosetta Genomics' Scientific Advisory Board. "We believe 
that these genes may serve as an important basis for next generation 
diagnostics and therapeutics."

"We are extremely pleased to report our success in nearly doubling 
the number of human microRNAs sequenced to date, results which we 
believe establish Rosetta Genomics as a leading player in discovery 
of microRNA genes," said Isaac Bentwich MD, founder and chairman of 
Rosetta Genomics and lead investigator of the study. "We are now 
aggressively pursuing partnerships for development of diagnostics 
and therapeutics based on this huge group of novel microRNAs."

About microRNAs

MicroRNAs are a recently discovered group of non-protein-coding 
regulatory genes, shown to be involved in a wide range of diseases 
in addition to neuronal and stem-cell differentiation. MicroRNAs 
currently are an intensely researched area, and are believed 
potentially to be the basis for a new class of therapeutic and 
diagnostic products.

About Rosetta Genomics

Rosetta Genomics is a privately held genomics company, pioneering 
the discovery and commercialization of microRNAs - a novel group of 
regulatory genes, shown to be involved in a wide range of diseases 
including diabetes, obesity and various types of cancer. Rosetta has 
discovered and filed patents for the majority of microRNAs found to 
date, and is in the process of developing diagnostics and 
therapeutics based on these microRNAs, by both internal development 
and collaborative partnerships.


 Rachel Spielman  Sharon Kaspi
 Ruder Finn   Rosetta Genomics Media Relations
 Tel+1 212 583 2714   Tel+1 201 255 5900
 Mobile +1 646 872 2985   Mobile +1 201 255 5914
 [EMAIL PROTECTED]  [EMAIL PROTECTED]




-
---
Source: Rosetta Genomics

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Teva and Active Biotech Announce the Submission of an IND to the FDA

[famouswba]

Teva and Active Biotech Announce the Submission of an IND to the FDA 
for Laquinimod, an Oral Product for the Treatment of Relapsing MS 

JERUSALEM & LUND, Sweden
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active 
Biotech AB (Stockholm: ACTI.ST) announced today the submission of an 
investigational new drug application (IND) to the U.S. Food and Drug 
Administration (FDA) to initiate a clinical trial in the U.S. with 
laquinimod to assess drug-drug interaction. Based on the results of 
this study and of the ongoing phase IIb study in Europe (see below), 
the phase III clinical program to confirm the efficacy and safety of 
laquinimod in relapsing forms of MS, is planned to start in 2006. 


Laquinimod is a novel orally administered immunomodulatory 
substance, developed by Active Biotech and recently licensed to 
Teva. 

"I am pleased to report on this significant milestone," said Israel 
Makov, President and CEO of Teva. "This IND filing is an important 
step towards the initiation of pivotal studies with laquinimod 
which, along with Teva's development of an oral form of Copaxone(R), 
enhance the likelihood that Teva will be the first to market an oral 
treatment. This further demonstrates our commitment to developing 
new and improved therapies for multiple sclerosis patients in order 
to help treat their disease and improve their quality of life". 

"We are very pleased to see how Teva's development program is 
diligently progressing towards starting phase III studies in the 
U.S. and Europe," said Sven Andreasson, President & CEO of Active 
Biotech. "Laquinimod has a profile that meets the need for a safe 
and efficacious oral MS drug suitable for long term treatment." 

Laquinimod has the potential to be the first orally-administered 
disease modifying treatment for multiple sclerosis, both as a single 
agent therapy and in combination with Copaxone(R), Teva's well-
established and leading product on the market today. 

A double-blind, placebo-controlled multi center phase IIb clinical 
study is currently on-going in several European countries, in which 
the effects of laquinimod, administered orally, once-daily, at dose 
levels of 0.3 and 0.6 mg/day, are compared to those of placebo over 
9 months of treatment. 

About laquinimod 

Laquinimod is a novel immunomodulatory substance developed as an 
orally bio-available disease modifying treatment of MS. Laquinimod 
is the lead candidate drug identified from Active Biotech's SAIK 
research program, in which the safety/activity ratio has been 
optimized. 

In a completed randomized, double-blind, placebo-controlled, multi-
center phase II trial, 209 patients received either laquinimod, at 
dose levels of 0.1 or 0.3mg/day, or placebo, orally, once daily for 
24 weeks. Laquinimod, at the dose of 0.3mg/day, reduced disease 
activity (as measured by MRI) by 44%. In a sub-group of patients 
with active MRI brain lesions prior to treatment initiation, the 
same dose of laquinimod reduced disease activity by 52%. In this 
study, laquinimod demonstrated a very favorable safety profile, 
suitable for long-term treatment (Neurology 2005; vol 64, No. 6 p 
987). 

About Multiple Sclerosis (MS) 

Multiple sclerosis (MS) is a chronic, progressive disease of the 
central nervous system. It is the most common neurological disease 
causing disability in young adults. It has been described as an 
autoimmune disease because it is one of many diseases in which the 
immune system attacks healthy areas of the body as if they were 
foreign. In MS, these attacks are aimed at the central nervous 
system. The central nervous system is made up of nerves covered by a 
substance called myelin, which is similar to insulation protecting 
electrical wires because it surrounds and protects nerve fibers. 
When myelin or the nerve fiber is destroyed or damaged, the nerves 
cannot send electrical impulses to and from the brain, causing the 
onset of MS symptoms. 

About Teva: 

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is 
among the top 20 pharmaceutical companies and among the largest 
generic pharmaceutical companies in the world. The company develops, 
manufactures and markets generic and innovative human 
pharmaceuticals and active pharmaceutical ingredients. Close to 90% 
of Teva's sales are in North America and Europe. Teva's innovative 
R&D focuses on developing novel drugs for diseases of the central 
nervous system. 

About Active Biotech 

Active Biotech AB is a biotechnology company focusing on research 
and development of pharmaceuticals. Active Biotech has a strong R&D 
portfolio with pipeline products focused on autoimmune/inflammatory 
diseases and cancer. Its most advanced projects are laquinimod, an 
orally administered small molecule with unique immunomodulatory 
properties for the treatment of multiple sclerosis, as well as 
ANYARA for use in cancer immunotherapy with the primary indication 
non-small cell lung cancer. Further key project

[ biotech news ] Research and Markets: Introducing a 29-Question Survey of More than 600 Life Sci

[famouswba]

Research and Markets: Introducing a 29-Question Survey of More than 
600 Life Scientists in North America 

http://www.arizonabiotech.com/

Research and Markets 
(http://www.researchandmarkets.com/reports/c19899) has announced the 
addition of Information Technology in the Life Sciences: An 
Examination of Genomics Researchers to their offering. 


The bottleneck in many labs is data integration and analysis, and 
poor data integration often leads to reduced productivity. Because 
scientists are increasingly compiling data from multiple sources and 
instrument platforms that were never intended to be compatible, 
instrumentation suppliers and IT vendors are challenged to provide 
solutions that integrate this data. These companies are also faced 
with the challenges of disseminating this data to other institutions 
as well as improving user interfaces to accommodate scientists with 
little IT background. These IT challenges provide many market 
opportunities. Instrument companies are developing new applications, 
and independent software vendors are creating software that keeps up 
with increased demands for better throughput and compatibility. 
Finally, IT vendors are venturing into new markets. All of these 
companies must keep up with the demands and needs of life scientists 
in order to remain competitive. 

Based on a 29-question survey of more than 600 life scientists in 
North America, Information Technology in the Life Sciences: An 
Examination of Genomics Researchers will help instrumentation 
suppliers and IT vendors understand how academic and industrial 
scientists use IT tools from start to finish in their genomics 
experiments. It explores both researchers' use of, and satisfaction 
with, various types of software and hardware. Additionally, the 
report will assist companies in identifying future opportunities as 
well as provide them with information that can be used to expand 
their internal capacity by forming strategic alliances and 
partnerships. 

The major objectives of this report are as follows: 

-- Measure the current usage patterns for the IT systems used in 
genomics research. 

-- Ascertain differences between researchers in the academic and 
industrial market segments in their usage of genomics hardware and 
software. 

-- Evaluate levels of satisfaction with components of IT systems for 
genomics research. 

-- Determine future opportunities regarding high performance 
computing, collaborative tools and storage area networks. 

A preview of key findings derived from just a few of the survey 
questions: 

-- Applied Biosystems is the most frequently cited supplier of 
fragment analysis/genotyping systems and real-time PCR instruments 
used to generate genomics data. (Question 6) 

-- Regardless of the instrument used to generate genomics data, more 
than two-thirds of respondents analyze their data using software 
embedded on it. (Question 7) 

-- More than half of the scientists surveyed (59%) obtain software 
used to analyze/integrate their data through a commercial third 
party. (Question 9) 

-- According to respondents, Dell and Apple are the leading 
suppliers of desktop computer/workstation hardware used to study 
genomics data. (Question 16) 

-- Roughly one-third of respondents believe high performance 
(distributed/grid/clusters) computing will be highly useful (a score 
of 6 or 7 on a 7-point scale where 7=very useful) in their research 
within the next 12 to 24 months. (Question 20) 

-- Most respondents perceive IBM to be the best qualified provider 
of collaborative software at their institutions. (Question 25) 




http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Mayo Clinic Collaborative Research Building Opens on Scottsdale Campus

[famouswba]

Mayo Clinic Collaborative Research Building Opens on Scottsdale 
Campus


Collaboration with TGen brings hope for cancer cures

06-29-2005

SCOTTSDALE, Ariz. -- A major milestone in the advancement of cancer 
research for residents of Arizona and beyond will be realized later 
this week with the dedication of a new biomedical scientific 
facility that joins Mayo Clinic and the Translational Genomics 
Research Institute (TGen) in a unique strategic partnership. The 
partners' combined technological, academic, research and clinical 
expertise will help bring innovative research findings directly to 
the bedside of patients. 
The physical manifestation of this ambitious research collaboration 
is the new Mayo Clinic Collaborative Research Building (MCCRB), a 
110,000 square-foot facility that will officially open on Thursday, 
June 30, on the Scottsdale campus of Mayo Clinic. The $25 million 
facility was funded by Scottsdale developer Tom Hornaday of Hornaday 
Development. The building is the first of its kind for Mayo Clinic 
in that it brings multiple strategic partners under one roof 
dedicated to scientific discovery and therapeutics to ease the 
burden of disease for the people of Arizona and around the world. 

Ground was broken in February 2004 for the MCCRB, which is located 
south of the main clinic facility and directly north of the S.C. 
Johnson Research Building. The collaboration represents a broadening 
of the scope of research between the Mayo Clinic and TGen extending 
beyond it's initial focus on melanoma. Tenants of the building thus 
far include: 

Mayo Clinic research business offices 
Mayo Clinic researchers, including investigational labs for 
hematologic malignancies, multiple myeloma and pancreatic cancer 
TGen's Cancer Drug Development Laboratory (CDDL) and the TGen 
subsidiary, TGen Drug Development (TD2) 
Jeffrey M. Trent, Ph.D., is president and scientific director of 
TGen. Dr. Daniel Von Hoff, TGen executive vice president, is also 
director for TGen's Translational Research Division and the director 
of TD2. In addition to leading TGen's clinical enterprise, Von 
Hoff's team is involved in translating basic genetic, molecular and 
biochemical observations to create therapies for patients with 
pancreatic cancer. 

The CDDL provides a centralized set of resources for investigators 
interested in the recent explosion in molecular medicine and 
genomics-based diagnostics and treatment methods. The combination of 
world-class researchers and the latest technologies create a highly 
collaborative multidisciplinary research environment. The goal is to 
develop innovative preclinical research products based on an 
individual's disease and associated molecular profiles that are 
brought to bear on cancer as quickly as possible. 

Mayo Clinic, headed by Dr. Victor F. Trastek, chair of the Board of 
Governors, has research investigators who work closely with 
clinicians to translate discoveries into therapies for patients. 
Specifically, their work supports the Mayo Clinic Cancer Center, one 
of only 38 U.S. medical centers named a National Cancer Institute 
(NCI)-designated Comprehensive Cancer Center. Mayo's clinical and 
research experts join forces to address the complex needs of 
oncology patients. 

The principal collaborative partners who will be housed at the MCCRB 
partners share a passion for cooperation among institutions and 
individuals to bring advances to cancer research. But they also 
share something more -- compelling personal stories reflective of 
their commitment to cancer research. 

Developer Hornaday and his wife, Ruth Ann, lost their daughter, 
Kristi, 26, to melanoma. Hornaday's mother died at age 52 of breast 
cancer. "My hope, my prayer and my belief is that the research 
conducted in this building will result in cures so others will not 
experience these kinds of untimely losses," notes Hornaday. 

Speakers at the opening will include Trastek, Trent, Von Hoff and 
Hornaday, as well as Scottsdale Mayor Mary Manross and Dr. Laurence 
Miller, deputy director of the Mayo Clinic Cancer Center. Both Trent 
and Von Hoff share Hornaday's passion for finding a cure. They 
experienced the loss of a close friend and mentor when founding 
Arizona Cancer Center director, Dr. Sydney Salmon, passed away in 
2002. 

Trastek is a thoracic surgeon who has witnessed more than his share 
of cancer-related diseases. At one time in his practice he chaired a 
committee of the Society of Thoracic Surgeons whose charge was a 
high-profile public campaign to encourage smoking cessation. 

"Pursuing joint research strategies and building strong partnerships 
with researchers at TGen helps advance Mayo Clinic's mission of 
integrating research and education with clinical medicine to provide 
optimal health care for our patients and patients everywhere," said 
Trastek. 

"The TGen-Mayo Clinic collaboration signifies a milestone, both in 
terms of Arizona's leadership in bringing the best

[ biotech news ] Molecular Profiling Institute, Inc. Acquires NanoBiomics, Inc.

[famouswba]

Molecular Profiling Institute, Inc. Acquires NanoBiomics, Inc. 


Developing a platform to commercialize novel genomics-based products

06-29-2005

Phoenix, AZ, June 29, 2005—The Molecular Profiling Institute, Inc. 
(Molecular Profiling) today announced the acquisition of the assets 
of NanoBiomics, Inc. NanoBiomics is an early-stage company whose 
mission is to develop and commercialize genomic-based diagnostics 
utilizing nanoscale-processing technologies created at the Applied 
Nanobioscience Center at ASU. Nanobiomics was recently recognized as 
the "Startup Biotechnology Company of the Year" from the Arizona 
BioIndustry Association at the Arizona Bio Expo 2005. 
NanoBiomics was formed by the Translational Genomics Research 
Institute (TGen) and Arizona Technology Enterprises (AzTE) with the 
intention to commercialize technology from both organizations. 
Molecular Profiling, a collaboration between TGen and the 
International Genomics Consortium (IGC), is a specialty reference 
laboratory and a leader in using genetic signatures to help tailor 
medical therapy. Molecular Profiling is the first for-profit spin-
off venture for TGen and IGC. 

"The acquisition provides Molecular Profiling with a platform for 
commercializing novel, genomic-based diagnostic products in the 
future," said Richard Love, acting president of NanoBiomics and 
Managing Director of TGen Accelerators. "Molecular Profiling is 
currently driving physician adoption of such tests in the reference 
lab setting. As these tests are accepted into the practice of 
medicine, NanoBiomics' technologies will help enable lower cost 
diagnostic products to be produced and commercialized more broadly." 

Molecular Profiling will work closely with Dr. Frederic Zenhausern, 
Director of the Applied Nanobioscience Center at ASU's Biodesign 
Institute. "Dr. Zenhausern is a pioneer in using nanoscale 
processing technologies to perform complex biological processes on 
cartridges the size of credit cards," said Dr. Robert Penny, CEO of 
Molecular Profiling. "These technologies will ultimately drive down 
the cost of genomic-based diagnostic testing and this transactions 
will provide a commercial focus for the collaboration to enhance the 
collaboration between TGen, IGC and ASU at Molecular Profiling." 

According to Zenhausern, "The goal of developing the technologies 
behind NanoBiomics is to be able to one day provide better 
diagnostic platforms for physicians to better diagnose and treat 
complex diseases." 

The acquisition brings together the diagnostic platform developed by 
ASU, the diverse and extensive database of DNA signatures and 
scientific leadership from TGen, and the reference laboratory 
expertise and market access offered by Molecular Profiling. 

"The complementary technologies that Molecular Profiling, TGen and 
NanoBiomics bring to bear create a stronger molecular diagnostics 
products and services company with a clear commercialization path," 
said Peter Slate, the CEO of AzTE. "This is a case where the sum is 
worth substantially more than the individual parts." 

The terms of the acquisition have not been disclosed. 

# # # 

About the Molecular Profiling Institute Inc.
The Molecular Profiling Institute, Inc. (Molecular Profiling) is a 
specialty reference laboratory that helps cancer patients worldwide 
by applying the discoveries of the Human Genome Project to 
personalized medicine. Molecular Profiling provides cutting-edge 
testing facilities, products, and resources for genomic and 
proteomic profiling and treatment of cancers. Molecular Profiling 
has strategic relationships and alliances with the Translational 
Genomics Research Institute (TGen), the International Genomics 
Consortium (IGC), IBM and AmeriPath. 

About NanoBiomics, Inc.
NanoBiomics' mission is to improve healthcare by developing 
molecular diagnostics that increase the physician's ability to 
accurately determine the medical diagnosis and medical prognosis of 
the patient. NanoBiomics targets the rapidly growing field of 
molecular diagnostics. The company's primary focus is the 
commercialization of molecular diagnostics based primarily upon gene 
expression signature sets that offer substantial predictive or 
prognostic value for disease outcome. The value gained from these 
diagnostics will be to increase the survival rates of patients by 
tailoring the therapeutic regiment to the genomic profile of a 
disease. 

About Arizona Technology Enterprises
Arizona Technology Enterprises at Arizona State University works 
with university inventors and industry to transform scientific 
innovations into products, services and other technology-based 
ventures. Arizona Technology Enterprises mines university research, 
negotiates transactions, and markets inventions based on university 
research. AzTE activities benefit the public by contributing to new 
product creation and new economic opportunities. For more 
information, visit www.azte.com. 

Media Contact

[ biotech news ] Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma

[famouswba]

Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma



Cougar Biotechnology, Inc., a privately held biotechnology company, 
today announced that it has licensed the worldwide, exclusive rights 
to seocalcitol (EB1089) from LEO Pharma A/S (Ballerup, Denmark). 
Seocalcitol (EB1089) is a synthetic analog of vitamin D (1-alpha,25
(OH2)D3) that has been clinically tested in a number of different 
cancer indications. 

The results of in vivo and in vitro studies have shown that vitamin 
D and analogs of vitamin D have anticancer activity in a wide range 
of tumor types. The results of preclinical studies have shown that 
seocalcitol (EB1089) is 50-200 times more potent than 1-alpha,25(OH2)
D3 with respect to regulation of cell growth and differentiation in 
in vitro and in vivo tumor models. Importantly, because seocalcitol 
has shown reduced calcemic activity compared to 1-alpha,25(OH2)D3, 
this increase in antitumor activity is seen without inducing 
unacceptable levels of hypercalcemia. 


 
"Vitamin D analogs represent an emerging class of potentially 
promising drugs for the treatment of prostate cancer," said Dr. Arie 
Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of 
Cougar Biotechnology. "Based on the preclinical and clinical studies 
that have been completed with seocalcitol (EB1089), we believe that 
the drug may represent a potentially novel treatment option for 
patients with hormone refractory prostate cancer." 

"We are pleased to be able to complete this licensing agreement with 
LEO Pharma," said Alan H. Auerbach, chief executive officer and 
president of Cougar Biotechnology. "Seocalcitol (EB1089) is the 
third drug that Cougar has in-licensed since the company was founded 
approximately two years ago. We view it as an important addition to 
Cougar's pipeline and as an intriguing new potential treatment for 
prostate cancer." 

Under the terms of the licensing agreement, LEO Pharma received an 
upfront payment and will receive milestone payments as seocalcitol 
progresses through clinical development as well as a royalty on 
sales. Detailed financial terms were not disclosed. 

About Cougar Biotechnology 

Cougar Biotechnology, Inc. is a Los Angeles-based private 
biotechnology company established to in-license and develop clinical 
stage drugs, with a specific focus on the field of oncology. 
Cougar's oncology portfolio includes CB7630, which has completed 
Phase I clinical trials in prostate cancer, and CB3304, which is 
currently being tested in a Phase I trial in non-Hodgkin's lymphoma. 
Further information about Cougar Biotechnology can be found at 
www.cougarbiotechnology.com. 

About LEO Pharma A/S 

LEO Pharma A/S is a research-based, fully integrated pharmaceutical 
company among the world's leading players in topical dermatology and 
parenteral treatment of thrombotic disorders. The foundation-owned 
company is headquartered in Denmark, markets its products in 90 
countries and employs 3,300 people in 40 countries. Further 
information about LEO Pharma can be found at www.leo-pharma.com. 

Contact Cougar Biotechnology, Inc. Alan H. Auerbach, 310-443-4209


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/resources.htm







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Thomas H. McLain Appointed to the Biotechnology Industry Organization's Board of

[famouswba]

Thomas H. McLain Appointed to the Biotechnology Industry 
Organization's Board of Directors

Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today that 
its chairman, chief executive officer and president, Thomas H. 
McLain, has been appointed to the Board of Directors of the 
Biotechnology Industry Organization (BIO), effective June 21, 2005. 
Mr. McLain is one of eleven new Board members, who will each serve 
two-year terms.

 
 
BIO represents more than 1,000 biotechnology companies, academic 
institutions, state biotechnology centers and related organizations 
in all 50 U.S. states and 33 other nations. BIO members are involved 
in the research and development of healthcare, agricultural, 
industrial and environmental biotechnology products.

"Biotechnology's impact on human health has never been greater; its 
discoveries are beginning to realize their great promise. I am 
honored to accept this Board position, as our industry continues to 
serve as a leading force in the advancement of 21st century 
medicine," said Mr. McLain.

Mr. McLain joined Nabi Biopharmaceuticals in 1998 and today serves 
as chairman, chief executive officer and president of the company. 
>From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb, 
Incorporated. He earned his B.A. in Economics at College of the Holy 
Cross and an M.B.A. from the William E. Simon Graduate School of 
Business at the University of Rochester. He is a member of the Board 
of Directors of Eastman Chemical Company and serves as the Chairman 
of BioFlorida.

"Tom McLain is a widely recognized leader in the emerging life 
sciences arena both nationally and internationally," said Florida 
Governor Jeb Bush. "As Florida is increasingly positioned at the 
epicenter of this industry, we are fortunate to have someone of 
Tom's caliber contributing on a national scale. I applaud BIO's 
decision to recognize Tom's commitment to and noted achievements in 
biotechnology, and look forward to his ongoing leadership to escort 
the industry to new heights."

"Tom McLain's knowledge, experience and vision make him an ideal 
addition to our Board of Directors," said BIO President James 
Greenwood. "In particular, we value his expertise in vaccines and 
his role in the emergence of biotech in Florida."

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in 
powering the immune system to develop and market products that fight 
serious medical conditions. We are poised to capture large, 
commercial opportunities in our four core business areas: Gram-
positive bacterial infections, hepatitis, kidney disease 
(nephrology), and nicotine addiction. We have three products on the 
market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B 
Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for 
injection)] and a number of products in various stages of clinical 
and preclinical development. The company filed its Marketing 
Authorization Application in Europe for its product candidate, 
StaphVAX® [Staphylococcus aureus Polysaccharide Conjugate Vaccine], 
in December 2004. The application was accepted for review in January 
2005. StaphVAX is currently in a confirmatory Phase III clinical 
trial in the U.S. StaphVAX is designed to prevent the most dangerous 
and prevalent strains of Staphylococcus aureus bacterial infections. 
S. aureus bacteria are a major cause of hospital-acquired infections 
and are becoming increasingly resistant to antibiotics. The 
company's other products in development include Altastaph(TM) 
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an 
antibody for prevention and treatment of S. aureus infections, NicVAX
(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine 
addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an 
antibody for preventing hepatitis C virus re-infection in liver 
transplant patients. For additional information on Nabi 
Biopharmaceuticals, please visit our website at: 
http://www.nabi.com .

This press release contains forward-looking statements that reflect 
the company's current expectations regarding future events. Any such 
forward- looking statements are not guarantees of future performance 
and involve significant risks and uncertainties. Actual results may 
differ significantly from those in the forward-looking statements as 
a result of any number of factors, including, but not limited to, 
risks relating to the possibility that our confirmatory Phase III 
clinical trial for StaphVAX or our plans to commercialize StaphVAX 
in the European Union and United States may not be successful; the 
possibility that we may not realize the value of our acquisition of 
PhosLo; the company's ability to raise additional capital on 
acceptable terms; the company's dependence upon third parties to 
manufacture its products; the company's ability to utilize the full 
capacity of its manufacturing facility; the impact on sales of Nabi-
HB from

[ biotech news ] Biotechnology Companies Have to Insure against Failures in the Research & Develo

[famouswba]

Biotechnology Companies Have to Insure against Failures in the 
Research & Development Stages


Both biotechnology and pharmaceutical companies are feeling the 
pressure created by the immense hype around the biotechnology 
industry. Its extraordinary popularity creates unreasonable 
expectations, wherein even common molecule failure in the research 
and development (R&D) stages result in loss of both investor 
confidence and funds for further research. 

Such unrealistic expectations can be especially crippling to new 
companies. The biotechnology sector will suffer more than 
pharmaceuticals, as it does not have many established companies that 
can absorb the burden of failed ventures. 


 
If you are interested in a virtual brochure, which provides 
manufacturers, end users, and other industry participants with an 
overview of the Cost Benefit Analysis of Research and Development of 
Top 10 Biotechnology Companies, then send an e-mail to Melina 
Gonzalez, Corporate Communications, at [EMAIL PROTECTED], 
with the following information: your full name, company name, title, 
telephone number, fax number, and e-mail address. Upon receipt of 
the above information, an overview will be sent to you through e-
mail. 

As a drug moves through more advanced stages of R&D, the losses 
associated with failure will tend to naturally increase. To counter 
this situation, biotech companies could enter into licensing deals 
and implement risk management solutions. 

The industry trends point toward an increase in such deals and 
partnerships between companies. By sharing the risks and profits, 
they can eliminate or decrease the jeopardy associated with 
failures. 

"The partnerships between big pharma and biotech companies are 
likely to be the trendsetters in the industry," says Frost & 
Sullivan Research Analyst Barath Shankar S. "With the technical 
expertise of biotechnology companies and the marketing skills of big 
pharmas, the collaborations are expected to be very successful." 

Such strategic moves and plans have seen the top ten biotechnology 
companies in the United States have 186 products in R&D, and of 
these, nearly 20 percent are in phase III of development. These 
products are likely to have substantial impact on market growth in 
the next two to three years. 

The biotechnology industry is optimistic about market growth despite 
the recent spate of drug recalls, which wiped out billion's of 
dollars of market capital. Since the fundamentals of product 
development are sound, the companies are confident of overcoming 
these setbacks and accelerating growth. 

This positive attitude is a huge advantage in the biotechnology 
industry, since it thrives on risk taking. From 1994 to 2005, the 
top ten companies have returned an exceptional figure of close to 27 
percent on stock price appreciation. In the next year, this number 
is expected to reach 24-25 percent, despite a few setbacks. 

Established companies such as Amgen, Chiron, Genentech, and Genzyme 
are expected to continue leading the market. Such high returns from 
biotechnology stocks are likely to sustain investor interest in the 
industry and maintain focus on new R&D projects. 

"Biogen IDEC, which has delivered the highest returns of 43.5 
percent from 1994 to 2005, has a risk rating of 'moderate/high'," 
says Barath Shankar. "Similarly, Gilead which has returned 29.5 
percent, much above the industry average, has the highest risk 
rating of 'very risky'." 

Cost Benefit Analysis of Research and Development of Top 10 
Biotechnology Companies is part of the pharmaceuticals and clinical 
diagnostics subscription and examines the risk-return and cost-
benefit profiles of research and development of the top ten 
biotechnology companies in the United States. The study incorporates 
a model to evaluate and provide an outlook for each of these 
companies. It also analyzes the possible blockbuster products in the 
product pipelines. Analyst interviews are available to the press. 

Frost & Sullivan, a global growth consulting company, has been 
partnering with clients to support the development of innovative 
strategies for more than 40 years. The company's industry expertise 
integrates growth consulting, growth partnership services and 
corporate management training to identify and develop opportunities. 
Frost & Sullivan serves an extensive clientele that includes Global 
1000 companies, emerging companies, and the investment community, by 
providing comprehensive industry coverage that reflects a unique 
global perspective and combines ongoing analysis of markets, 
technologies, econometrics, and demographics. For more information, 
visit http://www.frost.com 

Cost Benefit Analysis of Research and Development of Top 10 
Biotechnology Companies 

F246 

Keywords in this release: biotech companies, cost benefit analysis, 
research and development, R&D, United States, Amgen, Chiron, 
Genentech, Genzyme, Biogen IDEC, research, information, market, 

[ biotech news ] Organon Launches Global Research and Biotechnology Initiative

[famouswba]

Organon Launches Global Research and Biotechnology Initiative

- Organon's Biotechnology Day Attracts Over 100 Boston-area 
Biotechnology and Licensing Executives - 



Organon, the human healthcare business of Akzo Nobel (Nasdaq: AKZOY -
 News), announced that the Company is launching a global 
biotechnology discovery research initiative with a Boston seminar 
and open house to discuss R&D strategy and collaborative 
opportunities.

 
 
"Organon is expanding upon its current biotechnology programs with a 
global discovery research initiative aimed at diversifying our 
therapeutic areas of focus and bringing the next generation of 
biopharmaceutical products to market," stated David Nicholson, 
Executive Vice President Global Research at Organon. "Organon 
fosters innovation and entrepreneurship with its unique approach to 
discovery research by giving our scientists the ability to explore 
interesting targets and compounds without being restricted to a 
specific therapeutic area of focus. When successful, our global 
pharmaceutical operations will provide the infrastructure and know-
how needed to rapidly find an appropriate partner or move promising 
new programs towards the market."

Organon's strategy in biotechnology is to develop and market 
biological entities that represent new therapeutic approaches within 
areas of interest including immunology, oncology and osteoporosis. 
Organon will leverage its proprietary monoclonal antibody technology 
and is committed to partnering with academia for early research, and 
with biotechnology and pharmaceutical companies for product 
development programs and for access to the best discovery 
technologies. The new Cambridge research center, which officially 
opened on June 29th, will be the hub of its interface with 
innovative institutes and companies in the USA.

Organon's Biotechnology Day, that has attracted over 100 local 
biotechnology and licensing executives, will include discussions of 
Organon's research and partnering strategy by members of Organon's 
senior management including Toon Wilderbeek, President of Organon 
International; David Nicholson, and Wiebe Olijve Ph.D., Vice 
President Research at Organon. Additional talks will focus on doing 
business with Organon from Mark Gessler, CEO and President of Gene 
Logic Inc.; Aaron Hsueh, Ph.D., Professor at Stanford University; 
and Arthur Sands, M.D., Ph.D., CEO and President of Lexicon Genetics.

Organon and Biotechnology

Organon and its sister businesses in Diosynth Biotechnology and 
Intervet have a strong heritage in biotechnology. Organon's 
capabilities cover all aspects of drug discovery and development, 
from early research through clinical development and large scale 
manufacturing. The companies are actively involved in developing 
recombinant fertility treatments (Organon), recombinant vaccines 
(Intervet) and recombinant protein API's (Diosynth Biotechnology). 
Organon's lead product today is the biologic Follistim® (USA), 
Puregon® (Europe) and biotech now represents over 20% of revenues. 
Organon is also one of the largest global contract manufacturers of 
Active Biopharmaceutical Ingredients through Diosynth Biotechnology.

Research at Organon

Organon has a strong commitment to research and development with 
approximately 19% of revenues budgeted annually to R&D. The Company 
maintains discovery research facilities in Oss, The Netherlands; 
Newhouse, Scotland; and Cambridge, Mass., USA. Research programs 
encompass both biotherapeutic and small molecule discovery with over 
20% of budgets committed to external collaborations. Current 
discovery collaborations involve over 50 biotech and academic groups 
worldwide. The new Organon Research Center in Cambridge will 
discover novel biologicals and will be the hub of interface with 
innovative institutes and biotechnology companies in the USA.

About Organon

Organon -- with shared head offices in Roseland, NJ, USA and Oss, 
The Netherlands -- creates, manufactures and markets prescription 
medicines that improve the health and quality of human life. Through 
a combination of independent growth and business partnerships, 
Organon strives to remain or become one of the leading 
pharmaceutical companies in each of its core therapeutic fields: 
reproductive medicine, psychiatry and anesthesia. Organon also 
actively pursues the discovery of both chemical and novel biological 
entities. In so doing, Organon seeks to exploit and further develop 
its basic discovery and production expertise in biotechnology. 
Organon products are sold in over 100 countries, of which more than 
60 have an Organon subsidiary. Organon is the human health care 
business unit of Akzo Nobel. Additional information about Organon is 
available through its corporate website, http://www.organon.com.


For more information
Contact for Organon:
 Monique Mols Kari Lampka
 Associate Director, Media Relations  MacDougall Biomedical 
Co

[ biotech news ] Millennium Announces New CEO

[famouswba]

Millennium Announces New CEO

-- Head of Novartis North American Oncology Business to drive 
Millennium toward long-term growth and near-term profitability -- 



Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today 
announced that Deborah Dunsire, M.D., an accomplished pharmaceutical 
executive and head of Novartis Pharmaceuticals Corporation's North 
American Oncology Operations, has been named as the new president 
and chief executive officer of Millennium. Dr. Dunsire will also be 
elected to the Company's Board of Directors. She plans to assume her 
duties by August 1, 2005. Dr. Dunsire will succeed Mr. Mark Levin, 
co-founder and CEO since the Company's inception. Mr. Kenneth Weg, a 
member of the Board of Directors since 2001, will become the new non-
executive chairman. Mr. Levin will remain an active member of the 
Board.

 
"Deborah has an impressive track record in building and motivating 
multi- functional organizations to deliver significant revenues and 
sustainable growth, two key goals for Millennium," said Mr. 
Weg. "Her depth of experience and proven leadership in the 
pharmaceutical industry and repeated success in commercializing 
products will enable Millennium to optimize the potential of its 
novel therapies and capitalize on the Company's strengths in 
innovative drug discovery and development."

Dr. Dunsire has nearly 20 years of experience in the commercial, 
operational, clinical and scientific aspects of a world-leading 
pharmaceutical business. She led the Novartis U.S. Oncology Business 
in a competitive market, achieving more than 25 percent compounded 
annual growth rate over the last eight years. While at Novartis, Dr. 
Dunsire also played a critical role in the broad development and 
successful launch of a number of products including Zometa, Femara 
and Gleevec, and evaluated and implemented key business development 
initiatives. She was also responsible for managing the merger and 
significant growth of the combined Sandoz Pharmaceuticals and Ciba- 
Geigy oncology businesses.

"Millennium is poised for continued growth and I'm excited to be 
joining at such a pivotal point in the Company's development," said 
Dr. Dunsire. "Widely recognized for scientific leadership, 
entrepreneurial culture and visionary management, Millennium can 
command a strong commercial presence and leverage its robust product 
pipeline. I look forward to building on the Company's rich legacy 
and track record in bringing breakthrough medicines to patients, 
while fulfilling its goal of non-GAAP profitability in 2006 and long-
term growth."

Dr. Dunsire has served on the U.S. pharmaceutical executive 
committee at Novartis, was a designated member of the corporate 
executive group, and a member of the operating committee charged 
with defining corporate strategy, managing operations and assessing 
executive performance.

Earlier in her career, Dr. Dunsire was a clinical researcher 
responsible for the implementation of global phase II and phase III 
studies across multiple therapeutic areas such as immunology, 
endocrinology, neurology, dermatology, oncology and transplantation. 
She has also been a practicing physician.

"Deborah shares an unwavering commitment to making a difference in 
patients' lives, the Company's mission since day one," said Mark 
Levin. "She is dedicated to building a leading biopharmaceutical 
company and has the commercial and business experience to make it 
happen for our stockholders, employees, partners and patients."

Acknowledging the exceptional contributions of Mark Levin, Mr. Weg 
stated, "Mark has been one of the great visionaries in the biotech 
industry and his passion for the business, amazing energy and 
ability to motivate people at Millennium has been no less than 
remarkable. I would like to express the Board's sincerest 
appreciation for Mark's dedication to the Company over the past 12 
years, his commitment to patients to deliver breakthrough medicines, 
and his promise to build value for shareholders."

Mr. Weg has had more than 30 years of experience in the 
pharmaceutical industry including significant leadership roles at 
Merck & Co., Inc. and Bristol-Myers Squibb Company (BMS). At BMS he 
was elected to the Board of Directors in 1995 and became vice 
chairman in 1999. He also served as president, Worldwide Medicines 
Group; president, Pharmaceuticals Group; and president of 
Pharmaceutical Operations. Currently, Ken is chairman of Clearview 
Projects, a consulting firm which provides partnering and 
transactional services to biopharmaceutical companies and academic 
institutions.

Conference Call Information

In conjunction with this news release, Millennium will host a live 
webcast of its conference call today, Wednesday, June 29, 2005 at 
8:00 AM ET. This webcast can be accessed by visiting the Investors 
section of the Company's website, http://www.millennium.com. 
Following the webcast, an archived version of the call will be 
availabl

[ biotech news ] 5AM Solutions Grows Users by 5,000; Develops a D.C. Presence

[famouswba]

5AM Solutions Grows Users by 5,000; Develops a D.C. Presence 
An additional five thousand researchers studying neurological and 
mental health disorders gained access to 5AM Solutions" Microarray 
Enterprise Manager (MEM) this month. MEM provides researchers with a 
tool to speed their access to microarray technology 
 
Phoenix, Arizona June 29, 2005 -- An additional five thousand 
researchers studying neurological and mental health disorders gained 
access to 5AM Solutions" Microarray Enterprise Manager (MEM) this 
month. MEM provides researchers with a tool to speed their access to 
microarray technology available through the NIH Neuroscience 
Microarray Consortium, and allows them to collaborate with other NIH-
funded researchers and the consortium"s Institutes of Excellence. 
The Phoenix, Arizona-based 5AM Solutions also announced that the 
firm has opened an office in the Washington, DC area to serve 
clients and access their network of talent and contacts on the East 
Coast. 

In 2002, the National Institute of Neurological Disorders and Stroke 
(NINDS) and the National Institute of Mental Health (NIMH) awarded a 
grant to the consortium to make microarray technology available to 
neuroscientists whose research was funded by the two institutes. At 
that time, the consortium, which included the Translational Genomics 
Research Institute (TGen), UCLA, and Duke University, needed 
a "bridge" between it and scientists seeking to take advantage of 
sophisticated technology that allows them to compare genes in normal 
and diseased tissues. 5AM Solutions developed an internet-based tool 
that manages workflow, collaboration, and communication between the 
scientists and the consortium.

In June 2005, NINDS, NIMH, and thirteen other institutes that 
comprise the NIH Neuroscience Blueprint 
(neuroscienceblueprint.nih.gov/) awarded a $25 million grant to the 
consortium which included funds to bring microarray technology to an 
additional five thousand grant holders, added Yale University as a 
Center of Excellence and renamed the consortium to reflect its 
broader scope. 5AM Solutions Chief Architect Eric Tavela was pleased 
to learn that the consortium would continue to use MEM and 5AM to 
support their efforts. "Building a national, completely web-based 
enterprise solution guided by leaders in the field of neuroscience 
research and microarray technology was extremely rewarding." 5AM CEO 
Brent Gendleman said, "Knowing that we contributed to their 
management and informatics efforts and that they have been rewarded 
with additional funding confirms that we are delivering quantifiable 
return on investment." 

Dietrich Stephan Ph.D., chairman of the consortium and director of 
the Neurogenomics Division at the Translational Genomics Research 
Institute (TGen), was enthusiastic about expanding access to the 
consortium"s microarray technology. "The 5AM team has been dedicated 
to serving the entire consortium from day one, enabling us to 
collect, monitor and share our results and grant access to the 
exciting technology and collective expertise to a national 
audience." 

5AM Solutions" new Northern Virginia office reflects the firm"s 
growth. According to VP Operations Susan Mason, "Northern Virginia 
is an ideal base for us to better serve our East Coast clients. We 
are actively seeking teaming opportunities and have established 
deals with GSA Schedule holders to make it easy for our target 
clients to access our talent. There are ample opportunities for us 
to apply our software development expertise to the wide range of 
established industries – including the DC-area"s biotech market – 
and use our software assets such as MEM to support customization 
services."

About 5AM Solutions
5AM builds software solutions for the life sciences. Web-based, 
interoperable solutions that integrate with third-party systems, 
support industry guidelines and standards, and grant insight into 
the complex data produced by the genomic revolution represent a core 
of 5AM"s expertise. 5AM shares a common passion to advance medicine 
and science by contributing state-of-the-art software engineering 
services. www.5amsolutions.com

About the NIH Neuroscience Microarray Consortium
The Consortium is comprised of microarray core facilities at TGen, 
UCLA, Yale, and Duke University. These institutes collectively 
provide advanced microarray technology and other resources to 
researchers who are committed to curing pervasive neurological and 
mental disorders and diseases and whose work is funded by any of the 
NIH Neuroscience Blueprint Institutes.
arrayconsortium.tgen.org

 
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biote

[ biotech news ] TGen's Dr. Paul Keim Appointed to National Biosecurity Board

[famouswba]

TGen's Dr. Paul Keim Appointed to National Biosecurity Board 


Keim provides expertise on the genetics of weaponized pathogens 

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research 
Institute (TGen) today announced that Dr. Paul Keim, Director of the 
institute's Pathogen Genomics Division, has been appointed to the 
National Science Advisory Board for Biosecurity (NSABB), a group of 
25 experts who will assess issues of biosafety in life sciences 
research. 
The NSABB will provide advice, guidance and leadership regarding 
biological research that has the potential for misuse and could pose 
a threat to public health or national security. The NSABB will 
advise all federal departments and agencies that conduct or support 
life science research. 

"Dr. Keim's groundbreaking research with lethal biological agents 
like plague and anthrax allows him to bring a unique perspective to 
the board," said TGen President and Scientific Director Dr. Jeffrey 
Trent. 

"I am honored to serve my country by providing insight and expertise 
about potential biological threats," said Dr. Keim. 

In addition to his appointment at TGen, Dr. Keim is a professor of 
biology and Cowden Endowed Chair in Microbiology at Northern Arizona 
University (NAU). Keim and his NAU team are involved with protecting 
America against anthrax and other dangerous microbes by analyzing 
deadly agents that may be used in a biological attack at the genetic 
level. The group is also developing molecular identification tools 
for public health related pathogens, which cause illness in billions 
of individuals worldwide. 

Dr. Keim's nomination was supported by members of the Arizona 
Congressional delegation, including Senators Jon Kyl and John 
McCain, and Representatives Rick Renzi, John Shadegg and J.D. 
Hayworth. 

"It is a fitting tribute for Dr. Keim to be appointed to this 
biosecurity board," said Senator Kyl. "The appointment is testimony 
to Dr. Keim's work with pathogen genomics and his expertise will 
help positively shape the future of public health policy. His 
efforts on the NSABB will impact all of the nation, as well as 
TGen's research efforts." 

"Dr. Keim has done a phenomenal job of collecting and studying 
biological threats from around the world," said Arizona Congressman 
Rick Renzi. "His appointment to the NSABB will help keep America 
safe and secure, and bring acclaim to Northern Arizona University." 

# # # 

About TGen
The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a relatively new field 
employing innovative advances arising from the Human Genome Project 
and applying them to the development of diagnostics, prognostics and 
therapies for cancer, neurological disorders, diabetes and other 
complex diseases. TGen is focused on personalized medicine and plans 
to accomplish its goals through robust and disease-focused research 
programs and its state-of-the-art bioinformatics and computational 
biology facilities. 

About Northern Arizona University
Northern Arizona University (NAU) has a student population of about 
18,000 at its main campus in Flagstaff and at 30 sites across the 
state. NAU has earned a solid reputation as a university with all 
the features of a large institution but with a personal touch. NAU 
carefully balances teaching, scholarship and service with a faculty 
and staff dedicated to each student's success. While our emphasis is 
undergraduate education, we offer a wide range of graduate programs 
and research that extend to such national concerns as forest health 


http://groups.yahoo.com/group/biotech-news/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] TGen Drug Development Services (“TD2”) Opens on Mayo Campus

[famouswba]

TGen Drug Development Services ("TD2") Opens on Mayo Campus


TD2 integrates genomic technologies to advance drug development

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research 
Institute (TGen) today announced the official opening of its drug 
development services unit known as TD2. Located at the new Mayo 
Clinic Collaborative Research Building on the Scottsdale campus of 
Mayo Clinic, TD2 has over 10,000 square feet of wet and dry 
laboratory space. 
Advances in genomic discoveries and technologies are bringing in a 
new era of personalized medicine, and in the process, transforming 
the nature of drug development. TD2 is designed to integrate these 
genomic advances with progressive drug development strategies aimed 
at developing targeted therapies for patients with cancer. 

"With more than 1,000 new drug candidates in development for cancer, 
there is a tremendous need to bring the latest technologies to bear 
on preclinical and clinical development programs," said Richard 
Love, Managing Director TGen Accelerators. "TD2 expects to be on the 
leading edge of utilizing genomic tools to guide the drug 
development process and ultimately match the right drug with the 
right patient." 

TD2 helps investigators from research institutions, biotech and 
pharmaceutical companies evaluate the efficacy of their drug 
candidate by using preclinical models, genomic tools and 
coordination of Phase I clinical trials at various clinical 
facilities, including Mayo Clinic Scottsdale, Scottsdale Healthcare, 
the Arizona Cancer Center, and U.S. Oncology. TD2 also provides 
central coordination of an international team of investigators who 
are conducting studies in patients with pancreatic cancer. Although 
initially focused in oncology, TD2 expects to expand its 
capabilities to other disease areas including neurological diseases 
and diabetes. 

TD2 is led by noted scientist and physician, Dr. Dan Von Hoff, 
TGen's Director of Translational Research. "We are extraordinarily 
fortunate to have the leadership of Dr. Von Hoff," said Steve Marsh, 
General Manager of TD2. "He has led teams bringing more than 200 new 
anticancer drugs into clinical development and has played a pivotal 
role in getting many new anticancer drugs approved by the FDA." 

### 

About TGen
The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a relatively new field 
employing innovative advances arising from the Human Genome Project 
and applying them to the development of diagnostics, prognostics and 
therapies for cancer, neurological disorders, diabetes and other 
complex diseases. TGen is focused on personalized medicine and plans 
to accomplish its goals through robust and disease-focused research 
programs and its state-of-the-art bioinformatics and computational 
biology facilities. 





http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] TGen’s Cancer Drug Discovery Laboratory Relocates to Mayo Clinic Collaborative R

[famouswba]

TGen's Cancer Drug Discovery Laboratory Relocates to Mayo Clinic 
Collaborative Research Building


Move enhances multidisciplinary environment, accelerates research

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research 
Institute (TGen) today announced the transition of its Cancer Drug 
Discovery Laboratory (CDDL) from their Gaithersburg, MD, facility to 
the new Mayo Clinic Collaborative Research Building on the 
Scottsdale campus of the Mayo Clinic. The CDDL was established as 
TGen's drug discovery and development arm. 
Co-locating CDDL and TGen's Drug Development (TD2) Services Unit 
with researchers at the Mayo Clinic is a key component of TGen's 
patient-centered research approach. The combination of world-class 
researchers and the latest technologies creates a highly 
collaborative multidisciplinary research environment, ensuring that 
innovative preclinical research products will be moved from the lab 
to the patient as quickly as possible. This will hopefully 
ultimately improve and extend the lives of patients living with 
cancer. 

"The TGen-Mayo Clinic collaboration signifies a milestone, both in 
terms of Arizona's leadership in bringing the best that biomedicine 
has to offer to patients nationally and internationally and the 
potential that research results between these two institutions will 
have toward defeating cancer," said Sen. John McCain. 

CDDL investigators are a multi-disciplinary team of scientists with 
expertise ranging from cell biology to bioinformatics. The lab uses 
a powerful cutting-edge technology called RNA interference (RNAi) 
technology to accelerate their research. The area of RNAi opens up a 
new field for drug discovery and will allow researchers to develop 
specific and potent drugs. RNAi technology centers on understanding 
how genes are turned on and off in cells and what the effect is on 
those cells. 

"The CDDL team has assembled some of the most sophisticated and high-
throughput technology in the world for studying cancer cells," said 
Dr. Spyro Mousses, Director of CDDL. "Our RNAi technology should 
greatly accelerate the discovery of new anti-cancer compounds." 

The move to the Mayo Clinic Collaborative Research Building will 
nearly triple CDDL's current capacity. The new building, which 
officially opens its doors today, is an 110,000-square-foot facility 
specifically devoted to developing and supporting medical research 
that will help patients in Arizona and beyond. 

"The CDDL's proximity to our researchers and clinicians accelerates 
our joint pursuit of identifying strategies to defeat all forms of 
cancer and further strengthens the Mayo Clinic mission of 
integrating research and educational efforts with clinical medicine 
to provide the best care for our patients," said Victor F. Trastek, 
MD, Chair, Board of Governors at Mayo Clinic. 

Mousses and his team are settling into the lab over the next few 
months and will be completely moved in by early next year. 

"CDDL's move to Arizona strengthens TGen's attack on cancer. The 
addition of these researchers not only bolsters the translational 
arm of TGen's discovery work, but proves that good science is 
happening right here in Arizona, and with it comes the hope of 
finding new ways to stop cancer in its tracks," said Dr. Jeffrey 
Trent, TGen's President and Scientific Director. 

# # # 

About TGen
The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a relatively new field 
employing innovative advances arising from the Human Genome Project 
and applying them to the development of diagnostics, prognostics and 
therapies for cancer, neurological disorders, diabetes and other 
complex diseases. TGen is focused on personalized medicine and plans 
to accomplish its goals through robust and disease-focused research 
programs and its state-of-the-art bioinformatics and computational 
biology facilities. 

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yah

[ biotech news ] Arizona Biotech Funding News

[famouswba]

Arizona Biotech Funding News

AmpliMed Secures $5 Million Series B Financing 

TUCSON, Arizona

AmpliMed, Amplimexon and Amplizone are United States trademarks of 
AmpliMed Corporation.

Oncology Drug Development Company to Use Funds to Develop and Expand 
Portfolio of Anti-Cancer Therapies and Bring Drugs into Clinical 
Trials

AmpliMed Corporation today announced the completion of a Series B 
Preferred private placement of approximately $5 million. Led by 
Biotech Insight Ventures, previous investors including InvestBio 
Ventures, Valley Ventures and Solstice Capital also participated in 
the round. To date, AmpliMed has raised more than $14 million in 
financing. 

"AmpliMed's impressive management team and outstanding group of 
scientists have accomplished significant milestones in the research 
and development of anti-cancer drugs, including the recent 
initiation of Phase I/II clinical trials for its lead drug Amplimexon
(TM) for pancreatic cancer. We are delighted to participate again in 
this second round of financing," said Joel R. Smolen, Managing 
General Partner at Biotech Insight Management, L.L.C., which manages 
Biotech Insight Ventures L.P. 

"The fact that our investors continue to support AmpliMed 
underscores their commitment to our clinical development program and 
our pipeline of anti-cancer therapies. This is an exciting time for 
the company as our Amplimexon(TM) clinical development program is 
expanding rapidly and we plan to bring additional new drugs into 
clinical trials in the near future," said Robert A. Ashley, 
Chairman, President and Chief Executive Officer of AmpliMed. "This 
funding will help us to continue these efforts as well as research 
additional late-stage clinical development opportunities." 

AmpliMed recently began a multi-center Phase I/II study to evaluate 
the safety and effectiveness of a combination of gemcitabine and 
Amplimexon in previously-untreated patients with advanced pancreatic 
adenocarcinoma. Additional trials in patients with malignant 
melanoma, multiple myeloma, breast, lung and prostate cancer are 
planned in 2005. 

About Amplimexon(TM) 

Amplimexon is Amplimed's trademarked name for imexon injection, an 
injectable formulation of a cyanoaziridine compound which showed 
tantalizing evidence of activity in limited studies in lung cancer, 
melanoma and breast cancer that were documented in publications in 
the 1980s. The potential of imexon as a cancer drug was never fully 
explored, until 1994, when AmpliMed co-founding scientists Drs. Evan 
Hersh, David Alberts, Robert Dorr and William Remers initiated a 
program to decipher Amplimexon's novel mechanism of action. They 
discovered that the drug disrupted mitochondria, the energy 
producing factories of the cancer cells, resulting in the leakage of 
toxic substances which ultimately resulted in cell death. This led 
to the initiation in 2003 of an ongoing Phase I clinical study of 
the drug as a stand-alone therapy in late-stage cancer patients. 
Further preclinical research revealed that the combined use of 
Amplimexon and certain other chemotherapeutics resulted in a 
significant increase in efficacy compared to either drug alone. 
These findings are now being translated into a series of Phase I/II 
clinical studies of combination therapy in patients with various 
types of cancer. 

About AmpliMed Corporation 

AmpliMed Corporation was founded in 1989 with the support of the 
University of Arizona Technology Development Corporation and is 
focused on the clinical development of chemotherapeutic agents for 
cancer. AmpliMed's strategy is to develop anti-cancer drugs with 
novel mechanisms of action designed to overcome some of the 
limitations, such as myelosuppression (suppression of blood cell 
counts), multi-drug resistance (treatment-induced resistance to many 
cancer drugs) and cardiac toxicity, frequently associated with 
current cancer therapy. The company's lead product, Amplimexon(TM) 
(imexon inj.), is undergoing NDA-directed clinical development. 
Other products in the company's portfolio include Amplizone(TM), 
which is anticipated to enter the clinic early in 2006, and a 
portfolio of derivatives of both lead compounds for future 
development. AmpliMed Corporation is based in Tucson, Arizona and is 
on the Web at www.amplimed.com. 

AmpliMed, Amplimexon and Amplizone are United States trademarks of 
AmpliMed Corporation.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php





http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit 

[ biotech news ] Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In P

[famouswba]

Human Genome Sciences Reports Results of Phase 2 Clinical Trial of 
HGS-ETR1 In Patients With Non-Small Cell Lung Cancer

- Results support continued study of HGS-ETR1 in combination with 
chemotherapy in non-small cell lung cancer - 



Human Genome Sciences, Inc. (Nasdaq: HGSI - News) announced today 
that the results of a Phase 2 clinical trial demonstrate that HGS-
ETR1 (mapatumumab) is well tolerated and can be administered safely 
in patients with advanced non-small cell lung cancer (NSCLC).(1) 
Stable disease was observed in a number of patients.


Data on 32 patients were presented yesterday in Barcelona, Spain, at 
the 11th World Conference on Lung Cancer in a poster 
entitled "Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human 
Monoclonal Antibody to TRAIL Receptor 1) in Subjects with 
Relapsed/Recurrent Non-Small Cell Lung Cancer." The trial, which was 
conducted in the United States, was a multi-center, open-label study 
to evaluate the efficacy, safety and tolerability of HGS-ETR1 in 
patients with relapsed or refractory non-small cell lung cancer.(2) 
Patients enrolled in the trial received 10 mg/kg doses of HGS-ETR1 
administered as an intravenous infusion 21 days apart in the absence 
of disease progression. The primary objective of the study was to 
evaluate tumor response. The secondary objectives were to evaluate 
the safety and tolerability of HGS-ETR1, and to determine plasma 
concentrations of HGS-ETR1 for use in a population pharmacokinetic 
analysis.

Patients participating in the study had previously received up to 7 
different cancer treatment regimens (median of 3). The data 
presented demonstrated that HGS-ETR1 was well tolerated, with no 
patients discontinuing therapy due to drug-related toxicity, and 
that HGS-ETR1 can safely be administered intravenously every 21 days 
at doses of 10 mg/kg. No immunogenic responses were observed. Stable 
disease was observed in 29% (9/32) of the patients treated, with 8 
patients receiving at least 4 cycles of therapy. Plasma 
concentrations in the NSCLC study population were within the range 
expected based on previous Phase 1/2 experience.

F. Anthony Greco, M.D., a study investigator and Medical Director of 
The Sarah Cannon Research Institute, Nashville, said, "The results 
of the Phase 2 study of HGS-ETR1 in heavily treated patients with 
advanced non-small cell lung cancer support further evaluation of 
HGS-ETR1 in this indication in combination with chemotherapeutic 
agents. Non-small cell lung cancer represents a significant medical 
need. Fewer than half of the patients who are newly diagnosed with 
non-small cell lung cancer are candidates for surgery. The majority 
of these patients present with incurable locally advanced or 
metastatic disease. (3-4) We look forward to continuing to evaluate 
the potential of HGS-ETR1 in non-small cell lung cancer in 
combination with chemotherapeutic agents."

David C. Stump, M.D., Executive Vice President, Drug Development, 
said, "HGS-ETR1 is the subject of a broadening program of clinical 
study. We are pleased to have available the results of the Phase 2 
trial in patients with advanced non-small cell lung cancer. The data 
presented demonstrate that HGS- ETR1 can be safely and repetitively 
administered to these patients. We note that stable disease was 
observed in a number of these very ill patients who had received 
multiple regimens of anti-cancer therapy before entering the study 
of HGS-ETR1. We recently reported the positive interim results of a 
separate Phase 2 clinical trial of HGS-ETR1 in advanced non-
Hodgkin's lymphoma and look forward to presentation of the complete 
results of that study at an appropriate scientific meeting later in 
2005.(5) The results of an ongoing Phase 2 study in patients with 
advanced colorectal cancer are also expected later this year.(6) In 
addition, we continue to enroll patients into two Phase 1b trials of 
HGS-ETR1 in combination with chemotherapy."

Human Genome Sciences, using genomic techniques, originally 
identified the TRAIL receptor-1 and TRAIL receptor-2 proteins as 
members of the tumor necrosis factor receptor super-family. The 
company's own studies, as well as those conducted by others, show 
that TRAIL receptor 1 and TRAIL receptor 2 play a key role in 
triggering apoptosis, or programmed cell death, in tumors. Human 
Genome Sciences took the approach of developing human monoclonal 
antibodies that would bind to specific TRAIL receptors and stimulate 
the TRAIL receptor-1 and TRAIL receptor-2 proteins to trigger 
apoptosis in cancer cells, in much the same way that the native 
TRAIL ligand (tumor necrosis factor- related apoptosis-inducing 
ligand) triggers it, but with the advantage of a longer half-life 
and an exclusive specificity for TRAIL receptor 1 or TRAIL receptor 
2, respectively. Human Genome Sciences' own clinical and preclinical 
studies, along with published results in the scientific literature, 
demonstrate that a

[ biotech news ] Millipore Acquires European Contract Testing Lab; Acquisition Adds Expertise in

[famouswba]

Millipore Acquires European Contract Testing Lab; Acquisition Adds 
Expertise in Virus, Mycoplasma and Bacteria Testing and Strengthens 
Millipore's Growing Services Business 

Millipore Corporation (NYSE:MIL) today announced it has completed 
the acquisition of MicroSafe, B.V., for approximately $9.3M. 
MicroSafe is a contract laboratory that develops assays and provides 
a range of testing services to help leading European biotech and 
pharmaceutical customers monitor for quality and compliance in the 
drug manufacturing process. The company employs thirty professionals 
and is based in Leiden, The Netherlands. 


Martin D. Madaus, Millipore's Chairman, CEO and President noted: "We 
are very pleased that MircoSafe is becoming part of Millipore. They 
have a loyal client base and the expertise that will help us expand 
the scope of service we offer to our biotech and pharmaceutical 
customers, particularly in the area of virus and mycoplasma testing. 
Their application knowledge will also help us accelerate development 
of products and systems for rapid process monitoring." 

Fathia Methnani, Managing Director of MicroSafe, B.V., 
commented: "With Millipore's market presence in Europe and 
scientists and applications specialists in the field we will be able 
to bring our services to more clients and we'll be able to expand 
those service offerings." Ms. Methnani will continue to direct 
MicroSafe operations. 

MicroSafe, with annual revenues of $4 million, has received GMP and 
GLP approvals and is currently expanding its capabilities to meet 
growing customer needs. 

About Millipore 

Millipore is a leading bioprocess and bioscience products and 
services company, organized into two divisions. The Bioprocess 
division offers solutions that optimize development and 
manufacturing of biologics. The Bioscience division provides high 
performance products and application insights that improve 
laboratory productivity. Millipore has a deep understanding of its 
customers' research and manufacturing process needs, and offers 
reliable and innovative tools, technologies and services. The 
Company employs approximately 4,500 people worldwide and posted 
revenues of $883 million in 2004. 

For additional information on Millipore Corporation, please visit 
its website at: www.millipore.com 

Forward Looking Statements: 

The matters discussed herein, as well as in future oral and written 
statements by management of Millipore Corporation that are forward-
looking statements, are based on current management expectations 
that involve substantial risks and uncertainties which could cause 
actual results to differ materially from the results expressed in, 
or implied by, these forward-looking statements. Potential risks and 
uncertainties that could affect Millipore's future operating results 
include, without limitation, foreign exchange rates; regulatory 
delay in the approval of new therapeutics and their ultimate 
commercial success; further consolidation of drug manufacturers; 
competitive factors such as new membrane technology; lack of 
availability of raw materials or component products on a timely 
basis; inventory risks due to shifts in market demand; change in 
product mix; conditions in the economy in general and in the 
bioscience and bioprocess markets in particular; potential 
environmental liabilities; the inability to utilize technology in 
current or planned products due to overriding rights by third 
parties; difficulties inherent in research and development 
activities; and the risk factors listed from time to time in 
Millipore's filings with the SEC.


http://www.arizonabiotech.com/
http://www.azhttp.com/seo.htm
http://www.arizonaentrepreneurs.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Amazon Biotech, Inc. Announces the Appointment of Meir Spear, CPA as the Company

[famouswba]

Amazon Biotech, Inc. Announces the Appointment of Meir Spear, CPA as 
the Company's Internal Accountant

Amazon Biotech, Inc. (OTC Bulletin Board: AMZB - News), a 
pharmaceutical company developing and producing a potential 
immunomodulator drug, developed for use in the treatment of the HIV 
virus, today announced that it has retained the services of Meir 
Spear, CPA from the firm of Spear & Co. CPAs as Amazon Biotech's 
internal accountant (not independent auditors).
Meir Spear received his Bachelors of Science in Accounting from 
Touro College, NY. He has over 9 years of experience in public 
accounting and 4 years of experience working for one of New York's 
top 15 accounting firms, servicing the needs of large and small 
businesses with their tax and accounting needs.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, 
primarily developing immune modulator drugs. AMZ 0026 is the 
company's first such drug, to be used for the treatment of HIV/AIDS. 
The company intends to initiate Phase I/II clinical studies of AMZ 
0026 shortly, with an eventual goal of a joint venture with a major 
pharmaceutical company in Phase III trials, or to seek to qualify 
for the FDA Fast Track program to market. Amazon Biotech specializes 
in natural plant pharmaceutical drugs and is focused on bringing 
healthier pharmaceutical drugs to market. Additional information on 
Amazon Biotech may be found at http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation 
Reform Act of 1995. This press release contains forward-looking 
information within the meaning of Section 21E of the Securities 
Exchange Act of 1934, including statements regarding any potential 
sales of products as well as statements that include the 
words "believes," "expects," "anticipates," or similar expressions. 
Such forward-looking statements involve known and unknown risks, 
uncertainties and other factors that may cause the actual results, 
performance or achievements of Amazon Biotech, to differ materially 
from those implied or expressed by such forward-looking statements. 
Such factors include, among others, the risk factors included in 
Amazon Biotech's reports filed with the Securities and Exchange 
Commission under the Exchange Act. This press release speaks as of 
the date first set forth above and Amazon Biotech assumes no 
responsibility to update the information included herein for events 
occurring after the date hereof.

You may register to receive Amazon Biotech's future press releases 
and to be added to the Company's distribution list by visiting: 
http://www.roiny.com/form.php.


Investor Relations Contact:
 Andrea Costa   Robert Giordano
 ROI Group Associates, Inc. ROI Group Associates, Inc.
 Phone: (212) 495-0200 x14  Phone: (212) 495-0200 x10
 Fax: (212) 495-0746Fax: (212) 495-0746
 [EMAIL PROTECTED]   [EMAIL PROTECTED]
 http://www.roiny.com




-
---
Source: Amazon Biotech, Inc.


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] GPC Biotech Announces Phase 1 Trial Evaluating Satraplatin in Combination with T

[famouswba]

GPC Biotech Announces Phase 1 Trial Evaluating Satraplatin in 
Combination with TAXOTERE(R) in Patients with Advanced Solid Tumors 
Opens for Accrual



MARTINSRIED/MUNICH, Germany and U.S. Research and Development 
Facilities in WALTHAM/BOSTON, Mass. and PRINCETON, N.J., 

-- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; 
Nasdaq: GPCB) today announced that a Phase 1 study evaluating the 
Company's lead drug candidate, satraplatin, in combination with 
TAXOTERE® (docetaxel) in patients with advanced solid tumors has 
opened for accrual. Satraplatin is currently in a Phase 3 
registrational trial as a second-line chemotherapy treatment for 
patients with hormone-refractory prostate cancer.

 
 
The Phase 1 study is an open label, single center study being led by 
Lynn Van Ummersen, M.D. Assistant Professor and George Wilding, 
M.D., Professor at the University of Wisconsin Comprehensive Cancer 
Center (UWCCC), Madison, Wisconsin. The primary objectives of this 
study are to assess toxicity, determine maximum tolerated doses, and 
recommend Phase II dosage for this combination. The objective 
response in those patients with measurable disease will also be 
assessed. The study is expected to enroll up to 48 patients.

"I am excited to have the opportunity for the UWCCC to conduct this 
clinical study to develop a treatment regimen combining satraplatin 
and TAXOTERE," said Dr. Wilding. "The favorable safety profile and 
clinical activity of satraplatin in several solid tumor types and 
the proven efficacy of TAXOTERE in various cancers make this a 
treatment regimen that has the potential to help many patients with 
cancer."

"We are pleased to have Dr. Van Ummersen and Dr. Wilding run this 
trial. They have extensive experience in conducting Phase 1 cancer 
studies and the UWCCC is a leader in the oncology field," said 
Marcel Rozencweig, M.D., Senior Vice President, Drug Development at 
GPC Biotech. "This study is part of our strategy to initiate a 
number of studies to explore the potential of satraplatin in 
combination with other anticancer therapies and for the treatment of 
other cancers beyond the initial indication of second-line hormone-
refractory prostate cancer."

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum 
family of compounds. Over the past two decades, platinum-based drugs 
have become a critical part of modern chemotherapy treatments and 
are used to treat a wide variety of cancers. Worldwide sales of 
these drugs exceeded $2.2 billion in 2004. Unlike the platinum drugs 
currently on the market, all of which require intravenous 
administration, satraplatin is an orally bioavailable compound and 
is given as capsules that patients can take at home. An oral 
platinum drug could offer key advantages, including ease of 
administration and patient convenience, in a variety of 
applications. Additionally, satraplatin is the only platinum-based 
compound to have shown efficacy in a randomized clinical trial in 
prostate cancer. Prostate cancer is the most common cancer among men 
in the U.S. and Europe. The number of patients with this disease is 
expected to increase with the aging population. As the disease 
advances, patients are often treated with hormone therapy. Once 
patients fail hormone therapy, becoming hormone-refractory, follow-
on treatment involves a limited number of options, including 
chemotherapy. For patients who then fail first-line chemotherapy, 
there are currently no approved second-line chemotherapy regimens. 
Satraplatin is in a Phase 3 registrational trial -- the SPARC trial -
- as a second-line chemotherapy treatment for hormone-refractory 
prostate cancer (HRPC). GPC Biotech has successfully completed a 
Special Protocol Assessment with the U.S. FDA and has received a 
Scientific Advice letter from the European regulatory authority, the 
European Medicines Agency (EMEA). The FDA has also granted fast 
track designation to satraplatin for this indication.

Phase 2 trials have been completed in HRPC, ovarian cancer and small-
cell lung cancer. Promising early clinical results have also been 
shown when satraplatin is combined with radiation therapy, and a 
Phase 1/2 study evaluating this combination in patients with non-
small cell lung cancer has been initiated. Additional studies 
evaluating satraplatin in combination with other therapies in 
various cancers are planned. Further information on satraplatin can 
be found in the Anticancer Programs section of the Company's Web 
site at www.gpc-biotech.com.

GPC Biotech AG is a biopharmaceutical company discovering and 
developing new anticancer drugs. The Company's lead product 
candidate -- satraplatin -- is currently in a Phase 3 registrational 
trial as a second-line chemotherapy treatment in hormone-refractory 
prostate cancer following successful completion of a Special 
Protocol Assessment by the U.S. FDA and receipt of a Scientific 
Advice letter from the Europea

[ biotech news ] Using the genomic shortcut to predict bacterial behavior

[famouswba]

Using the genomic shortcut to predict bacterial behavior


-
The common flea can carry Rickettsia felis bacteria in its cells 

-

How do you study a pathogen that can't survive outside its host's 
cells? In a new study published in the open access journal PLoS 
Biology, Hiroyuki Ogata and colleagues show that sequencing and 
analyzing the genome of the bacteria Rickettsia felis provide 
valuable insights into the biology and behavior of this 
intracellular pathogen. The researchers discovered that the 
parasitic bacterium has the standard large circular chromosome plus 
two unexpected plasmids, small circular pieces of DNA that can 
replicate on their own. This discovery may lead to novel techniques 
for study. "The newly identified plasmids may become a basis of a 
new tool, such as for efficiently producing rickettsial proteins," 
explains Ogata. 

Other Rickettsia species include the pathogens responsible for 
typhus and Rocky Mountain spotted fever. "Up to now, due to the lack 
of appropriate genetic transformation tools for rickettsiae, 
detailed molecular studies were difficult for these bacteria," says 
Ogata. But with new tools and "because of the medical importance of 
this group of bacteria, different teams of researchers are 
sequencing the genomes of different species of Rickettsia felis. We 
determined the genome sequence of Rickettsia felis, which is the 
fourth Rickettsia genome completely determined." R. felis is the 
only species known to have a plasmid. 

Ogata and colleagues also made surprising discoveries about sexual 
activity in these bacteria. The larger plasmid encoded proteins 
typically associated with bacterial sex, called conjugation. The 
researchers also observed pilli, the bacterial conjugation bridge. 
Previously, researchers believed that intracellular bacteria did not 
exchange genetic material with each other. But Ogata explains that 
the new findings "forced us to change this static view." 

In addition to conjugation, the researchers found evidence of other 
mechanisms for the bacterium to reshuffle its DNA. The R. felis 
genome encodes a large number of transposases, enzymes that cut and 
paste chromosomal DNA, and bears traces of multiple types of mobile 
gene elements and acquisition of genes from other, non-rickettsial, 
bacteria. 

The research demonstrates that genomic analysis can provide new 
information about an organism efficiently. "Our study demonstrates 
the importance of sequencing a bacterial genome, even if several 
closely related genomes have been already determined. It is very 
difficult to correctly forejudge the diversity of bacterial 
genomes," Ogata says. "Thus we have to sequence more." 


###
Citation: Ogata H, Renesto P, Audic S, Robert C, Blanc G, et al. 
(2005) The genome sequence of Rickettsia felis identifies the first 
putative conjugative plasmid in an obligate intracellular parasite. 
PLoS Biol 3(8): e248. 

CONTACT:
Hiroyuki Ogata
CNRS UPR 2589
31 Chemin Joseph Aiguier 
Marseille, France 13402 Cedex 20
33-491-16-4548
33-491-16-4549 (fax)
[EMAIL PROTECTED] 

Source: PLoS Biology (www.plosbiology.org)



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Active Biotech's New Share Issue Oversubscribed

[famouswba]

Active Biotech's New Share Issue Oversubscribed
STOCKHOLM, Sweden, July 7, 2005 

Active Biotech announces that, following the close of the 
subscription period for its share issue of approximately SEK 169 M 
(18 Million Euro), the issue was oversubscribed by 43 percent.98.5 
percent of the shares offered, were subscribed based on subscription 
rights. Shares offered, which were not subscribed with the support 
of subscription rights, will be allocated proportionally to those 
who have subscribed for shares beyond their subscription right. 

Through the new share issue, the number of shares in Active Biotech 
will increase by 5,623,426 to a total of 39,363,983 shares. 

Active Biotech's new share issue will be concluded according to the 
following time schedule: 

Notification of possible allocation of shares without the support of 
subscription rights on or about July 8 

Payment for shares allocated without the support of subscription 
rights on or about July 13 

First day of trading in new shares on or about July 25 

The conversion price for existing convertible debentures, issued in 
December 2004, will as a consequence of current new share issue be 
adjusted accordingly and hence amount to 38.39 SEK. 


 Active Biotech AB (publ)
 Sven Andreasson President & CEO

Active Biotech AB is a biotechnology company focusing on research 
and development of pharmaceuticals. Active Biotech has a strong R&D 
portfolio with pipeline products focused on autoimmune/inflammatory 
diseases and cancer. Most advanced projects are laquinimod, an 
orally administered small molecule with unique immunomodulatory 
properties for the treatment of multiple sclerosis, as well as 
ANYARA for use in cancer immunotherapy with the primary indication 
non-small cell lung cancer. Further key projects in clinical 
development comprise the three orally administered compounds TASQ 
for prostate cancer 57-57 for SLE and RhuDex(R) for RA. 

Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax: 
+46 46-19 20 50 www.activebiotech.com 


http://www.auntiebelhams.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Successful Large Scale Biotech Project Nearly Complete

[famouswba]

Successful Large Scale Biotech Project Nearly Complete
Thursday July 7, 12:25 pm ET 


ROCKVILLE, Md., July 7 

Human Genome Sciences awarded their Large Scale Manufacturing 
Facility process piping contract to Kinetics in February, 2004. The 
project is located within the Belward Research Center in Rockville, 
Maryland and will greatly increase Human Genome Sciences' capacity 
for production of protein and antibody drugs discovered through 
genomics-based research.

 
Piping systems in the contract scope include purified water, two WFI 
loops, process, clean-in-place, clean steam, CIP chemicals, ethanol, 
process vents and condensate, biowaste and process waste drains. The 
$20 million contract is currently 99% complete.

Engineering design of process piping by Lockwood Greene Engineers 
was released for construction in stages beginning in January and 
completed in October 2004. Coordination and teamwork between the 
owner, engineer, and construction manager Gilbane Building Company, 
Kinetics and project trade contractors was phenomenal and key to the 
successful completion of the project.

As with most projects undertaken by Kinetics, off-site 
prefabrication was maximized to reduce over-crowding and trade 
stacking in the field. This is particularly important on such a 
large biotech project. Modeled isometric piping drawings issued to 
Kinetics were field verified, submitted, and approved by the owner 
before being prefabricated at Kinetics fabrication shop in New 
Berlinville, PA. Kinetics' jobsite manpower eventually peaked at 128 
pipefitters through UA Local #602, plus supervision, draftsmen, 
QA/QC and management personnel.

In March, 2005 Kinetics was awarded the 2004 Trade Contractor Award 
by Gilbane Building Company "In Recognition of Excellence in 
Performance" on the HGS Large Scale Manufacturing Facility project.

About Kinetics: Kinetics is a global provider of process and 
mechanical solutions to the electronics, biopharmaceutical and 
general industries. Kinetics combines support equipment assembly, 
design, global installation capability and on-going service and 
support for complete process system installations around the world. 
The company has 32 offices and over 3000 employees, located 
strategically in high-technology areas where semiconductor fabs and 
biopharmaceutical manufacturing facilities are built. Kinetics is 
based in Union City, California. For more information, visit 
http://www.kineticsgroup.com .




-
---
Source: Kinetics


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech Crops Reach Billionth Acre

[famouswba]

Biotech Crops Reach Billionth Acre

Ten years ago, U.S. farmers planted crops produced from 
biotechnology for the first time. The first genetically engineered 
crops carried genes that allowed them to survive certain herbicides 
to provide farmers more economical weed control options that 
required less soil tillage and were better for the environment. 
Since then, biotech crops have been introduced which are resistant 
to major plant diseases and some of the most crop-damaging insects.

2005 Marks Ten Year Anniversary of Biotech Crops


June 2005 

Ten years ago U.S. farmers planted crops produced from biotechnology 
for the first time. The first genetically engineered crops carried 
genes that allowed them to survive certain herbicides to provide 
farmers more economical weed control options that required less soil 
tillage and were better for the environment. Since then, biotech 
crops have been introduced which are resistant to major plant 
diseases and some of the most crop-damaging insects. 

Today, an estimated 75 percent of the processed foods consumers buy 
from grocery store shelves contain at least one ingredient resulting 
from a biotech crop. And consumers can find high-quality, 
unblemished biotech vegetables and fruits -- ranging from insect-
resistant sweet corn to disease-resistant papaya -- in the produce 
aisle. 

While providing consumers a safe and more abundant food supply, 
biotech crops have become the most rapidly adopted technology in 
agriculture's history. Now, a decade later, the one-billionth acre 
of biotech crops is maturing somewhere in the world. It's an apt 
time to look at some of the ways biotechnology is impacting the 
world's food and fiber supply. 

When the U.S. Department of Agriculture (USDA) releases its 2005 
Crop Production Acreage Report at 8:30 a.m. Eastern on Thursday, 
June 30, biotech crops -- including corn, soybeans and cotton -- are 
expected to have continued expanding their share of crop acres as 
the technology has each year for the past decade. Report to be 
available at: 
http://usda.mannlib.cornell.edu/reports/nassr/field/pcp-bba/

At their commercial introduction, proponents of biotech said the 
crops would boost productivity and help feed a growing world 
population. Last year, for the first time, biotech crop area in 
developing countries grew faster than in developed countries, 
further indicating the important economic, health and social 
benefits realized by small, resource-poor farmers. 

Dr. Clive James, founder and chairman of the International Service 
for the Acquisition of Agri-Biotech Applications, a non-profit 
organization addressing global hunger and poverty through technology 
transfer to resource-poor farmers, and Thandiwe Myeni, a small-scale 
farmer growing insect-resistant biotech cotton in KwaZulu-Natal, 
South Africa, can bring global perspective to the latest USDA 
biotech crop report. For more information on how biotechnology is 
providing a more economical and abundant food supply for the world, 
while protecting the environment, go to www.isaaa.org


-
---

Produced for Council for Biotechnology Information


Thandiwe Myeni, a biotech cotton farmer in KwaZulu-Natal, South 
Africa explains how biotechnology has helped improve her farm's crop 
yield.

Video:  http://tinyurl.com/c9cbx

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Visual Numerics(R) and Aegis Help Major Pharmaceutical and Biotech Companies

[famouswba]

Visual Numerics(R) and Aegis Help Major Pharmaceutical and Biotech 
Companies Optimize Manufacturing Processes, Save Millions of Dollars
Visual Numerics' IMSL(TM) C Numerical Library Brings Unrivaled 
Analytical Power to Aegis Discoverant GlobalVantage(R) Solution for 
Process Manufacturing Intelligence and FDA Compliance 

SAN RAMON, CA -- 07/12/2005 -- Visual Numerics Inc., a leading 
provider of numerical analysis and visualization software, announced 
today that Aegis Analytical Corporation, a provider of enterprise 
software and expertise for pharmaceutical and biotechnology 
manufacturers, will utilize its IMSL C Numerical Library more 
extensively to help major pharmaceutical and biotechnology companies 
better monitor, analyze and manage their pharmaceutical 
manufacturing practices to prevent costly mistakes. 

Pharmaceutical manufacturing can be a high-risk process, in which 
one unexpected deviation on the production line can cost a company 
millions of dollars. Monitoring manufacturing operations require 
that hundreds of key process parameters are tracked continuously, 
resulting in a generous amount of data that must be monitored and 
analyzed to ensure consistent quality. Aegis is embedding Visual 
Numerics' IMSL C Numerical Libraries into its flagship product, 
Discoverant, a suite of software products that enable pharmaceutical 
and biotech companies to obtain direct access to all the data 
collected from multiple locations throughout the manufacturing 
enterprise -- in a framework that allows decision-makers to quickly 
translate data into usable intelligence. 

By using Visual Numerics' IMSL C Numerical Libraries as a part of 
Discoverant, users will gain powerful analytical capabilities to 
improve process monitoring and predictability, reduce manufacturing 
downtime and waste as well as resolve and prevent compliance issues. 
Companies today are saving millions of dollars by using Discoverant 
with the IMSL C Numerical Library to pinpoint the exact factor 
responsible for the success or failure of their manufacturing 
processes. 

"The Visual Numerics' IMSL C Numerical Library is an important 
component of our Discoverant product suite, which provides the 
reliability, scalability and validation our customers need to 
optimize their drug manufacturing processes and comply with 
regulatory standards," said Justin Neway, chief science officer, 
Aegis Analytical Corporation. "The breadth of algorithm coverage 
from the Visual Numerics IMSL C Libraries and ease of integration in 
our application development, allows us to respond to market needs 
quickly." 

"Application developers in Life Sciences are increasingly turning to 
Visual Numerics to meet their most data-intensive computational 
needs," said Phil Fraher, president and CEO of Visual Numerics. "By 
incorporating our 'gold standard' analytic capabilities, developers 
save significant development time and costs while offering their 
customers the very best analytical tools to navigate easily through 
extremely complicated numerical environments." 

IMSL™ Numerical Library Product Family 

The IMSL™ Numerical Libraries have been the cornerstone of high-
performance computing and predictive analytic applications in 
science, technical and business environments for over three decades. 
Regarded as the most sophisticated, flexible, scalable and 
accessible technology available in the most important mainstream 
programming environments today, the IMSL Libraries provide users 
with the software and technical expertise needed to develop and 
execute advanced numerical analysis applications. The IMSL Libraries 
save development time by providing pre-written mathematical and 
statistical algorithms that can be embedded into C, C# for .NET, 
Java™, and Fortran applications, significantly impacting return on 
investment and programmer productivity. 

About Aegis Analytical Corporation 

Aegis Analytical Corporation provides manufacturing software and 
expertise that helps pharmaceutical and biotech companies improve 
compliance, increase profits and gain competitive advantage. 
Discoverant, an enterprise software application, gathers data from 
multiple sources and quickly transforms it into useable 
intelligence. More information about Aegis Analytical Corporation 
can be found at www.aegiscorp.com. For a streaming video demo 
of Discoverant, visit: www.aegiscorp.com/product/demo.asp. 

About Visual Numerics® 

Visual Numerics has provided technical software solutions for 
numerical analysis and visualization for more than three decades. 
The company's software products help users understand complex data 
from a variety of sources and build business-critical applications. 
Visual Numerics offers two product lines: the IMSL Numerical 
Libraries for powerful mathematical and statistical analysis and the 
PV-WAVE® visual data analysis development environment. Visual 
Numerics also offers customized professional services for 
applications that in

[ biotech news ] Substituting blood transfusions

[famouswba]

Substituting blood transfusions
New research to substitute blood in transfusions
Do you have a rare blood group or are you concerned about 
contracting a disease such as HIV from a blood transfusion? The 
first ever European Blood Substitutes project 
('EuroBloodSubstitutes') is designing molecules which will be able 
to replace the need for blood during transfusions in the future. 
Researchers are modifying the genes of the oxygen-carrying part of 
the blood (haemoglobin) and using cell factories to mass produce 
artificial molecules which will be able to oxygenate the body's 
cells as efficiently, but without the possibility of contamination 
with disease. 
Dr Ken Lowe (University of Nottingham, UK) who is coordinating the 
project says "We are using genomics to modify the haemoglobin as 
well as looking at ways to attach it to large molecules so that it 
stays in the body longer during transfusions. We are aiming to find 
the optimum molecules for oxygen-binding and transport as well as 
the best culture conditions for mass producing it for the future." 
Dr Lowe will be reporting his results at the Society for 
Experimental Biology Annual Meeting in Barcelona on Tuesday 14th 
July [session E3.2]. 

This initiative is set to revolutionise blood transfusions which 
will become largely safe especially in emerging countries such as 
Eastern Europe and Africa where there are still relatively high 
risks of contamination. 



http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
http://www.arizonabiotech.com/index.php";>Biotechnology News 
Forums




http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] 14th annual report: Top 100 biotechnology companies back to table of contents

[famouswba]

14th annual report: Top 100 biotechnology companies back to table of contents   
 
 
http://www.pharmalive.com/magazines/medad/view.cfm?articleID=2302";>Med 
Ad News

  Over the Line: As the biotechnology industry outpaces traditional 
pharmaceuticals, the biotechnology leaders are taking top spots from big pharma 
peers. At the other end, small, emerging biotechnology companies struggle to 
find funding among risk-averse investors.

by Med Ad News Staff  


Notes to Charts 

Methodology 

REVENUE: Top 100 biotechnology companies (table) 

RESEARCH & DEVELOPMENT: Top 100 biotechnology companies (table) 

EMPLOYEES: Top 100 biotechnology companies (table) 

LOCATION, YEAR ESTABLISHED: Top 100 biotechnology companies (table)  
 
 
 
As biotechnology companies merge and grow, they are rising in the ranks of the 
top companies overall. Traditional pharmaceutical companies, meanwhile, are 
partnering with the biotechnology sector to fill dry pipelines and to replace 
the dwindling blockbusters. Industry analysts believe that the growth of the 
biotechnology industry, led by Amgen Inc. and Genentech Inc., will continue to 
outpace that of pharmaceutical companies.

According to Wood Mackenzie analysts, the seven largest biotechnology companies 
are growing at rates faster than the pharmaceutical industry’s 9.1% average. 
Amgen is now ranked among the top 20 global pharmaceutical companies in the 
world and will break into the top 10 by 2008, Wood Mackenzie analysts say. In 
addition, five of the 10 largest mergers and acquisitions in 2003 were within 
the biotechnology sector, indicating continued growth and maturity.

"Our research shows what the industry has suspected: biotechnology companies 
have truly come into their own," says Jim Hall, life-sciences president, Wood 
Mackenzie (woodmac.com). "As biotechs increasingly retain ownership of their 
developmental compounds and create more targeted blockbuster drugs, they will 
grow faster than pharmaceutical companies."

Biotechnology companies will continue to take prominent positions among the top 
pharmaceutical companies, according to James A. Lebovitz, partner and chair, 
the business and technology group, Dechert LLP (dechert.com), and a member of 
Dechert’s health law group. "Right now, you can distinguish between the Pfizers 
and the Mercks, and the Amgens, Biogen Idecs, and Genentechs, but the 
distinctions are becoming fewer and fewer," he says. "As more biotech companies 
get bigger products that are just huge revenue generators, they will start to 
be mentioned in the same breath as those pharmaceutical companies."

 


http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
http://www.arizonabiotech.com/index.php";>Biotechnology News 
Forums







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] SRI International and European Bioinformatics Institute Significantly Expand

[famouswba]

SRI International and European Bioinformatics Institute 
Significantly Expand BioCyc Collection of Pathway/Genome Databases 


SRI International, an independent, nonprofit research and 
development organization, has significantly expanded its BioCyc 
collection (biocyc.org/) of pathway/genome databases to now include 
databases for 160 organisms. The BioCyc collection has grown from 18 
to 160 organisms and now includes databases for most eukaryotic and 
prokaryotic species whose genomes have been completely sequenced to 
date. 


The BioCyc pathway/genome databases contain information about 
biochemical pathways: the network of interaction between proteins 
and small molecules that forms the biochemical factory of a cell. 
Understanding these pathways is critical in the development of 
pharmaceuticals, which mostly operate by blocking or enhancing 
interactions in particular pathways. The BioCyc collection is a 
forum for the open sharing of this fundamental biological knowledge 
that will have a significant impact on the future of biology. 

Biomedical researchers are encouraged to adopt BioCyc databases for 
organisms within their expertise for refinement and further 
updating, and to redistribute those databases within the biomedical 
research community. The process is akin to the development of 
powerful open source software, leveraging the expertise of many to 
create exponential progress in the human understanding of biology. 

"No one group can curate all the world's genomes," said Peter Karp, 
Ph.D., director of SRI International's Bioinformatics Research 
Group. "It is imperative to involve many scientists in the updating 
of genome databases. Ideally, BioCyc databases are adopted, and then 
updated, by a group of scientists that share an interest in a 
specific organism or a related group of organisms." 

SRI collaborated with the Computational Genomics Group at the 
European Bioinformatics Institute (EBI), a part of the European 
Molecular Biology Laboratory, to add 142 new databases to the BioCyc 
collection. Each pathway/genome database describes the genome and 
predicted metabolic network of a single organism, as inferred from 
the related SRI MetaCyc (metacyc.org/) database of metabolic 
pathways from multiple organisms. BioCyc is a unique resource for 
researchers in genomics, bioinformatics, and systems biology that 
combines new information inferred from each genome with a powerful 
collection of query and visualization tools. 

"The combined use of a sophisticated software suite such as Pathway 
Tools from SRI and a highly curated protein database such as 
UniProtKB/SwissProt from the EBI has allowed the team to develop the 
world's most comprehensive set of pathway databases," said Christos 
Ouzounis, head of the Computational Genomics Group at the 
EBI. "BioCyc provides both breadth and depth of coverage, enabling 
researchers to put the vast body of data that has emerged from the 
genome sequencing projects into the context of what gene products 
are really doing in the cell. This type of work would have been 
unthinkable even a few years ago." 

To accelerate sharing of these databases once they have been 
adopted, SRI has established a registry of pathway/genome databases 
to allow scientists to register and share the databases that they 
curate. The adoption and database-sharing approaches will maximize 
the accuracy of the rapidly evolving knowledge about the genome and 
biochemical networks of each organism. Most BioCyc pathway/genome 
databases are openly available for updating and redistribution 
without intellectual property restrictions. Adopters can update 
adopted pathway/genome databases and publish them on their own Web 
sites, using the same Pathway Tools 
(bioinformatics.ai.sri.com/ptools/) software that powers the BioCyc 
Web site. 

BioCyc databases are organized into three tiers according to the 
degree of curation they have undergone to date. For example, the 
Tier 1 EcoCyc database (ecocyc.org) is a thoroughly curated 
encyclopedia of E. coli (Escherichia coli K12) genes and metabolism. 
Tier 2 pathway/genome databases have received moderate amounts of 
curation, whereas Tier 3 pathway/genome databases were 
computationally generated and received no curation. 

BioCyc databases exist for most of the bacteria that are the 
subjects of biodefense research, as well as bacteria that are being 
studied for use in environmental remediation and the sequestration 
of carbon from the atmosphere to reduce global warming. 

BioCyc extracts new information from each of its component genomes 
by predicting their metabolic pathways and, for bacteria, their 
operons. Scientists use the Pathway Tools Omics viewer 
(biocyc.org/ov-expr.shtml), available through the BioCyc Web site, 
to visualize combinations of gene expression, proteomics and 
metabolomics data on a wiring diagram for the metabolic network of a 
cell. The software creates animated displays of time-series omics 
dat

[ biotech news ] Japan External Trade Organization Sets Biotech Mission to Yokohama, Japan

[famouswba]

Japan External Trade Organization Sets Biotech Mission to Yokohama, 
Japan for September 4-10

CHICAGO, July 12 
The Japan External Trade Organization (JETRO) has announced the 
latest of its business-to-business missions to Japan, this one 
supporting collaboration between North American and Japanese 
biotechnology industries. Representatives from business, academia 
and government on both sides of the Pacific will come face-to-face 
to explore partnership opportunities during the bio-mission to 
Yokohama, Japan, September 4 through 10.


During the BioMission, JETRO will provide companies and 
organizations with opportunities to forge strong connections within 
Japan's biotechnology sector. Mission activities include 
participation in BioJapan 2005, one of Asia's largest biotechnology 
trade shows, as well as the BioLink Forum 2005, a day- long event 
where companies will gain insights on recent trends in the 
biotechnology sector during sessions led by industry experts and 
analysts.

More than 100 companies joined the inaugural BioMission to Japan in 
2004, learning of the market, meeting with potential partners, and 
for many, doing deals and realizing their goal of expanding to 
Japan. The networking opportunities and business meetings from the 
2004 BioMission has already led to solid business results for many.

"Japan's growing biotechnology market has made it very attractive 
for U.S. companies seeking expansion and partnership. Japanese 
biotech and pharmaceutical businesses have demonstrated a strong 
interest in meeting with companies traveling with JETRO bio-
missions," commented Takashi Tsuchiya, Chief Executive Director of 
JETRO's Chicago office. "We expect that companies participating in 
this latest mission will experience an unprecedented introduction to 
the Japanese market, leading to successful business development."

Pharmaceuticals, medical devices, chemicals and agri-bio form the 
cornerstones of the Japanese market, and North American companies 
and organizations are increasingly seeking ways to expand their 
presence as Japan's market continues to grow. New business practices 
in Japan, such as a shift from out-licensing to independent sales, 
increased M&A activity, and a quicker drug approval process have 
opened the way for new collaborations.

JETRO is subsidizing conference fees and expenses to provide mission 
programming free of charge to mission members. Program includes: 
BioLink Forum participation; BioJapan 2005 admission; business 
matching; along with additional networking opportunities. JETRO is 
arranging one-on-one meetings between mission members and Japanese 
companies, however space is limited.

Application deadline for companies wishing to arrange one-on-one 
meetings in Japan is Wednesday, July 20, 2005. The cost of this 
mission is $905 US, excluding airfare. Mission space is limited. 
Those interested in participating should contact Kelly Denewellis at 
312-832-6000 ext. 203, or [EMAIL PROTECTED] Additional 
information can be found at http://www.jetro.org/biomission2005.

About JETRO

JETRO has provided information and support to American companies 
entering the Japanese market for over 50 years. Through a local 
network of six offices in the United States, JETRO provides a wide-
range of services, such as timely market intelligence, extensive 
business development support, and relevant business events, all 
designed to encourage business partnerships between American 
companies and Japan. For information visit http://www.jetro.org.




-
---
Source: Japan External Trade Organization (JETRO)

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Re: hello everyone

[famouswba]

--- In biotech-news@yahoogroups.com, "samreen_btech" 
<[EMAIL PROTECTED]> wrote:
> hello
> 
> iam samreen doin my engg frm in biotechnology
> 
> i just wanna know the top 100 universities offering biotech course 
for 
> ms in usa
> 
> bubye

Here are a couple of places to start looking:

Arizona Biodesign Institute at Arizona State University 

http://www.biodesign.org/

and the Institute for Biomedical Science and Biotechnology at 
University of Arizona. 

http://bio5.org/


Bill Austin
http://www.arizonabiotech.com/







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Deadly Parasites Have Common Genetic Core - THE INSTITUTE FOR GENOMIC RESEARCH

[famouswba]

Deadly Parasites Have Common Genetic Core 

THE INSTITUTE FOR GENOMIC RESEARCH

Deadly Parasites Have Common Genetic Core;
Studies May Help Target New Drugs to Fight Them 

Scientists decipher, compare the genomes of parasites that threaten 
half a billion people, causing Chagas disease, Sleeping Sickness and 
Leishmaniasis

One parasite causes a deadly sleeping sickness in Africa. The second 
damages the internal organs of millions of Latin Americans. The 
third causes terrible lesions on the face or limbs of victims from 
Brazil to India.

The three parasites – the culprits behind African sleeping sickness, 
Chagas disease and leishmaniasis – cause markedly varying diseases 
and are carried by different insect vectors. But scientists have 
found that the pathogens have a core of about 6,200 conserved genes. 
Their genetic similarities far outweigh their differences.

"This common core of genes is extremely important because it may 
provide targets for a new generation of drugs that might fight all 
three parasites, which threaten millions of people worldwide," says 
Najib El-Sayed, the first author of two of the parasite papers that 
appear in the July 15 issue of Science and senior author of a third 
paper. "At the moment, there are no vaccines and only a few 
inadequate drugs to fight these devastating and neglected diseases."

El-Sayed is a molecular biologist at The Institute for Genomic 
Research (TIGR), of Rockville, Maryland, which conducted the genome 
sequencing and analysis along with scientists at the Wellcome Trust 
Sanger Institute in Hinxton, U.K.; the Seattle Biomedical Research 
Institute (SBRI); and the Karolinska Institutet, in Stockholm, 
Sweden. 

The Science issue includes several related papers, including genome 
studies of Trypanosoma cruzi, which causes Chagas disease; 
Trypanosoma brucei, which causes African trypanosomiasis, also known 
as sleeping sickness; and Leishmania major, which causes the skin 
disease leishmaniasis and an internal disease known as kala azar. 
Another paper compares the three related genomes.
  By determining the shared genes and focusing on those that differ, 
the comparative study sheds important new light on the genetic basis 
for the differences between the parasites – including how they 
infect people, how they cause human disease, and why they are 
carried by different insects. (T. cruzi is carried by blood-sucking 
triatomine insects; T. brucei by the tsetse flies; and L. major by 
sand flies.)

The comparison found dozens of genes found in all three parasites 
that may have been acquired from bacteria through lateral gene 
transfer. In addition, studies of the parasites' Variant Surface 
Glycoproteins (VSGs) found T. brucei to have the most complex 
genetic apparatus for avoiding host immune systems and, at the same 
time, to be the most dependent of the parasites on the host's 
metabolism. Scientists also discovered that many of the genes 
specific to each species are found in so-called sub-telomeric 
regions near the ends of chromosomes – areas where the genome tends 
to be more changeable.

An important finding in the T. cruzi genome study was the discovery 
of a novel and large set of 1,300 genes (called the "mucin-
associated surface protein," or MASP, genes) that may play a role in 
the parasite's evasion of the human immune system or in its ability 
to survive in the variety of hosts that it infects.

The T. cruzi project was funded by the National Institute of Allergy 
and Infectious Diseases (NIAID), part of the U.S. National 
Institutes of Health. The major funders of the T. brucei and L. 
major genome projects were The Wellcome Trust and the NIAID.

Matthew Berriman of Sanger, the first author of the T. brucei genome 
paper, predicts that the genome sequences will help advance research 
into diseases that have been "neglected" in the past. "Genome 
sequences allow ideas to be tested and more quickly turned into 
reality," Berriman says. "The basic building blocks of all three 
parasites are now known."  

Peter J. Myler of SBRI, who shared the first authorship with El-
Sayed on two of the papers, says: "Now that the genes of these 
parasites are mapped out, it's much easier to identify genes that 
are critical for parasite survival. Genes encoding proteins that are 
involved in critical biological processes often serve as drug 
targets."

Much of the world's population in tropical and sub-tropical areas is 
at risk of contracting one or more of the diseases. Chagas disease – 
which may have infected Charles Darwin – infects as many as 18 
million people and threatens about 100 million others in Latin 
America, according to the World Health Organization. African 
sleeping sickness (trypanosomiasis) infects between 300,000 and 
500,000 persons and threatens more than 60 million people in 36 
countries in sub-Saharan Africa. Leishmaniasis (which also can be 
caused 
  by related parasites) is endemic in 88 countries and may threaten 
as m

[ biotech news ] Arizona Biotech is now listed in Science > Biology > Biotechnology

[famouswba]

Arizona Biotech is now listed in Science > Biology > Biotechnology 
in the Yahoo Directory
http://dir.yahoo.com/Science/Biology/Biotechnology/ 
>Arizona Biotech is now listed in Science > Biology > 
Biotechnology in the Yahoo! Directory


http://dir.yahoo.com/new/20050609/Science/ >Ariona 
Biotech Yahoo! Directory - New Additions in Science for Thursday 
Jun 9, 2005

Directory > Science Directory > Biology > Biotechnology
http://www.arizonabiotech.com/ >Arizona Biotech - 
includes news and information on Arizona Biotechnology, genomics, 
biotech companies, genetic engineering, biotech research, and 
biology. 

http://www.arizonabiotech.com/ >Arizona Biotech



http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs

[famouswba]

Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs
http://www.biohealthmatics.com/

Biohealthmatics.com provides career resources and services for health 
informatics and biotechnology professionals and employers.





http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Trinity Biotech Completes Acquisition of Primus Corporation

[famouswba]

Trinity Biotech Completes Acquisition of Primus Corporation
DUBLIN, IRELAND -- 

07/21/2005 -- Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a 
leading developer and manufacturer of diagnostic products for the 
point-of-care and clinical laboratory markets, today announced that 
it has completed the acquisition of Primus Corporation, a leader in 
the field of in vitro diagnostic testing for haemoglobin A1c and 
haemoglobin variants. 

Trinity Biotech has acquired Primus for US$12 million, consisting of 
a cash consideration of US$9 million and a one-year promissory note 
of US$3 million. The shareholders of Primus will also be entitled to 
an additional consideration of up to US$4.6 million depending on the 
growth of the business during the remainder of 2005. The transaction 
is being funded entirely with bank borrowings, thereby leaving 
Trinity's cash balances available for future potential acquisitions. 

Primus, a Kansas City, Missouri based corporation advised by 
Crosstree Capital Partners, was founded in 1989 and employs 36 
people in the manufacture of glycohaemoglobin instruments and 
reagents to serve customers from physicians' offices to the largest 
reference laboratories worldwide. Trinity is committed to further 
developing the business from the Kansas City location. 

Primus has demonstrated consistent sales and profit growth. Sales 
increased from $3.6 million for the year 2001 to $7.9 million for 
the year 2004, a compound annual growth rate of 30%. The acquisition 
will be earnings positive for Trinity Biotech in 2005. As part of 
the transaction, Primus CEO and founder, Tom Reidy, will remain with 
the Company and continue to direct the operations of Primus within 
the Trinity Group. 

Ronan O'Caoimh, Trinity Biotech CEO, commented, "We are delighted to 
acquire Primus which has a strong track record of growth and a 
unique patented technology in the field of A1c testing. In 
particular, Primus has a strong position in the US market for 
variant A1c testing with an estimated market share of 35%. Trinity's 
distribution network through direct sales and worldwide distributors 
can further expand the Primus sales effort and ultimately result in 
a significant increase in the number of instruments placed above the 
current level of approximately three hundred. We are also excited 
about the new Primus Rapid Gel product which is currently awaiting 
FDA approval which we expect will be granted in early 2006. The 
Rapid Gel product will compete in the US$100 million point-of-care 
A1c market and is based on the Company's unique boronate affinity 
methodology. We are confident that Primus will make a significant 
contribution to Trinity's growth in future years." 

Tom Reidy, CEO and founder of Primus, commented, "The acquisition of 
Primus by Trinity will provide the company with access to the wider 
distribution base and technical support infrastructure of Trinity's 
direct sales operations in the USA, Germany and the UK and to its 
worldwide distributor network. We are very excited at the 
opportunities this will present to continue the growth profile of 
our business and to better serve our customers." 

Trinity will provide additional information regarding the 
acquisition during its second quarter earnings conference call on 
Thursday 28th July at 11.00am EST. 

Trinity Biotech develops, acquires, manufactures and markets over 
500 diagnostic products for the point-of-care and clinical 
laboratory segments of the diagnostic market. The broad line of test 
kits are used to detect infectious diseases, sexually transmitted 
diseases, blood coagulation disorders, and autoimmune diseases. 
Trinity Biotech sells worldwide in over 80 countries through its own 
salesforce and a network of international distributors and strategic 
partners. For further information please see the company's website: 
www.trinitybiotech.com. 

Forward-looking statements in this release are made pursuant to 
the "safe harbor" provision of the Private Securities Litigation 
Reform Act of 1995. Investors are cautioned that such forward-
looking statements involve risks and uncertainties including, but 
not limited to, the results of research and development efforts, the 
effect of regulation by the United States Food and Drug 
Administration and other agencies, the impact of competitive 
products, product development commercialisation and technological 
difficulties, and other risks detailed in the Company's periodic 
reports filed with the Securities and Exchange Commission. 




 
-
---


SOURCE:  Trinity Biotech 

http://www.arizonabiotech.com
http://groups.yahoo.com/group/biotech-news
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/gro

[ biotech news ] Rubicon Genomics Signs Agreement with the Genome Institute of Singapore for Retr

[famouswba]

Rubicon Genomics Signs Agreement with the Genome Institute of 
Singapore for Retrospective Studies of Serum

Serum Archive Converted to Valuable Genetic Resource to Fight 
Hepatitis B 


ANN ARBOR, Mich., July 21 

Rubicon Genomics, Inc. today announced an agreement with the Genome 
Institute of Singapore to use Rubicon molecular diagnostics 
technology to recover genetic information from clinical serum 
samples for a large study of the immune response to vaccination 
against the hepatitis B virus.
 
 
The Genome Institute of Singapore (GIS) has chosen Rubicon to 
isolate and amplify very small amounts of genomic DNA in archived 
serum samples from 5,000 participants in a hepatitis B vaccine 
trial. Later this year, GIS will use the amplified DNA in an 
international study with colleagues in Indonesia and the Netherlands 
to discover genes important for hepatitis B prevention and treatment.

"These DNA isolation and amplification methods were originally 
developed for sensitive non-invasive screening for cancer from 
patient serum and other fluids," said Dr. John Langmore, Vice 
President of Commercial Development, Rubicon Genomics. "The 
enthusiasm of our diagnostic partners has been noticed by 
pharmaceutical companies and institutions, who want the same 
sensitive, accurate, and repeatable results for clinical trials, 
pharmacogenomics, drug discovery and epidemiology."

Modern genetic research and diagnostic tests require large amounts 
of DNA from millions of cells; however, the most common clinical 
samples such as serum and urine rarely contain these amounts of DNA. 
The proprietary Rubicon technology efficiently isolates and 
amplifies DNA from 10 - 100 cells -- making faithful copies 
equivalent to millions of cells.

Rubicon is developing diagnostic tests capable of detecting the 
presence of fewer than 10 cancer cells in less than three hours 
using DNA or methylated DNA tumor markers. Amplified DNA from one 
half milliliter of serum is sufficient for unlimited genetic or 
epigenetic research assays. Rubicon uses these same technologies to 
discover novel biomarkers, including DNA methylation markers that it 
will use in more sensitive, specific and inexpensive tests for 
cancer.

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, Mich., USA, develops and 
commercializes proprietary OmniPlex(TM) technology for molecular 
diagnostics and research. In projects with commercial partners, 
Rubicon discovers novel methylation markers using microarrays and 
uses them to develop more sensitive and specific non-invasive 
diagnostic and prognostic tests for cancer from serum, urine and 
biopsies. Rubicon also has large-scale contracts to amplify and 
analyze DNA and RNA from sera and biopsies for pharmaceutical 
companies, academic institutions, and tissue repositories. More 
information can be found at http://www.rubicongenomics.com.

The Genome Institute of Singapore

The Genome Institute of Singapore (GIS) is a member of the Agency 
for Science, Technology and Research (A*STAR). Established in 2001, 
the research institute's mission is to be a world-class genomics 
institute and a centre for genomic discovery. GIS pursues the 
integration of technology, genetics, and biology towards the goal of 
individualized medicine. The genomics infrastructure at GIS is 
utilized to train new scientific talent, to act as a bridge between 
academic and industrial research and explore scientific questions of 
high impact. More information can be found at http://www.gis.a-
star.edu.sg and http://www.a-star.edu.sg.




-
---
Source: Rubicon Genomics, Inc.


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Ag Biotech News Being Presented at AFBF Conference

[famouswba]

Ag Biotech News Being Presented at AFBF Conference

http://www.fb.org/news/nr/nr2005/nr0629a.html

WASHINGTON D.C., June 29, 2005 – The AFBF Biotechnology Conference 
will be held July 29 at the Indiana Farm Bureau headquarters in 
Indianapolis.

"The conference is appropriate for anyone with an interest in the 
current biotechnology situation in the United States and around the 
world, as well as the outlook for agricultural biotechnology," says 
Mark Maslyn, AFBF executive director of public policy.

There is no registrations fee for this national conference, but 
those wishing to attend should email Donna Jackson at [EMAIL PROTECTED] 
or call (202) 406-3679. For hotel accommodations the suggested hotel 
nearby to contact is the Hampton Inn at telephone number 317-261-
1200.

Scheduled speakers include Cindy Smith, deputy administrator for 
Biotechnology Regulatory Services under the Animal and Plant Health 
Inspection Service of the Agriculture Department; Bobby Richey, 
deputy director of the Foreign Agriculture Services Biotech Group at 
USDA; Paul Green, international trade consultant; Barb Glenn, 
director of animal biotechnology with the Biotechnology Industry 
Organization; Michael Dykes, vice president, government affairs at 
Monsanto; Jeff Stein, director of regulatory affairs at Syngenta 
Seeds; and Mark Janis, professor of law at the University of Iowa 
College of Law.

"First-hand, I know that our speakers have a great amount of 
knowledge and information that they will share to enlighten 
attendees," said Michelle Gorman, AFBF regulatory relations director 
for biotechnology.

In general, topics being covered during the conference include 
government regulations, non-food and feed uses for agricultural 
biotechnology, animal biotechnology, ag biotechnology and trade, 
technology fees and products in the pipeline.

Maslyn said, "Having the conference centrally located in the country 
should make attendance easy and affordable for more of our members. 
Additionally, the Indiana Farm Bureau office is an excellent meeting 
facility."


http://www.azhttp.com/
http://www.arizonabiotech.com/
http://www.stoneagedesigns.net/
http://www.navending.com/
http://www.progressive-network.com/
http://www.sell2us.net/
http://smsac.blogspot.com/
http://groups.yahoo.com/group/biotech-news/
http://www.auntiebelhams.com/
http://www.serenitygroup.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] The Sixth European Biotechnology Symposium November 13 - 15 2005

[famouswba]

The Sixth European Biotechnology Symposium November 13 - 15 2005; 
Competitive Biotechnology: Advanced Biologics Manufacturing and 
Closing the Deal: Joint Ventures and Partnership 

NEW ROCHELLE, N.Y. July 22, 2005--Sponsored by GENETIC ENGINEERING 
NEWS and organized by BioConferences International, Inc., The Sixth 
European Biotechnology Symposium at the Radisson SAS Scandinavia 
Hotel in Copenhagen is the only event in Europe that assembles the 
broadest collection of technical and business expertise from 
Europe's rapidly-growing biomanufacturing sector. 


GEN and BioConferences International will welcome all sponsors, 
exhibitors and attendees at an opening reception in the expo hall on 
the evening of Sunday, November 13, at the Radisson SAS Scandinavia 
Hotel, Copenhagen. 

The Symposium, which begins Monday, November 14, uniquely addresses 
biotech's two principal concerns, technology and business, through 
two consecutive tracks. "Competitive Biotechnology: Advanced 
Biologics Manufacturing" (morning and afternoon, November 14 and 
morning of November 15) features leading European experts in 
biomanufacturing. Speakers include Dr. Prof. Florian Wurm (Swiss 
Federal Institute of Technology, Lausanne) and representatives from 
top biotechnology companies across Europe. "Closing the Deal: Joint 
Ventures and Partnerships" (afternoon of Tuesday, November 15) will 
provide a forum for business and finance experts to share their 
expertise on partnership and funding activities which are critical 
both to companies and the greater biotechnology industry. 

Sponsors for the Sixth European Biotechnology Symposium include Host 
Sponsor: Invest in Denmark, Chairs Cup: Pall Life Sciences, 
Platinum: Sartorius, Diamond: Novozymes, Gold, Hyclone and Silver, 
Stedim, CMC, and Linde. Additional sponsorships are available, as 
well as a few non-commercial speaking opportunities. 

Held approximately every other year, the European Biotechnology 
Symposium has become a favorite stop on the European meeting and 
conference circuit. This year's event promises even greater value 
with the addition of "Closing the Deal". "This Symposium has been 
extremely successful because speakers and attendees alike value the 
intimate atmosphere and informative, non-commercial presentations," 
said Mary Ann Liebert, Publisher of Genetic Engineering News. "With 
the addition of the 'Doing the Deal' session GEN and our partners 
and sponsors hope to create a truly unique conference with broad 
appeal to biotechnology scientists, engineers, and business 
professionals." 

For sponsorship information contact: HMatysko @ bioconferences.com 
Harriet I. Matysko 914-740-2182. 

registration: 914-740-2181 or 1 800 524 6266 Register on-line at 
www.bioconferences.com/ebs.
  
  BioConferences International Inc., New Rochelle
 
 
 
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.science-fairs.com/
http://www.bill-austin.com/








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications

[famouswba]

Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for 
Applications in the Research Products Market


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi 
therapeutics company, announced today that it has granted MWG 
Biotech AG, an established provider of synthetic nucleic acids, a 
non-exclusive license to provide research products and services in 
RNA interference (RNAi) under the Kreutzer-Limmer patent family 
owned by Alnylam. This patent family covers short interfering RNAs 
(siRNAs) and their use to mediate RNAi in mammalian cells. 


 
"This agreement with MWG, an international genomic solution 
provider, continues to highlight the value of the Alnylam-owned 
Kreutzer-Limmer patent family as a critical component of fundamental 
intellectual property in the field of RNAi," said Vincent Miles, 
Ph.D., Senior Vice President, Business Development of Alnylam 
Pharmaceuticals. "By leveraging our portfolio of leading IP, we are 
creating value today and for the future by amassing an increasing 
number of license agreements with leading reagent and service 
providers. To date, fourteen companies have taken licenses for 
therapeutic or research product applications, including eight 
research product suppliers." 

"This license strengthens our siRNA offering and is part of our 
commitment to build a high quality presence in siRNA design and 
production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG. 

About RNA Interference (RNAi) 

RNA interference, or RNAi, is a naturally occurring mechanism within 
cells for selectively silencing and regulating specific genes. Since 
many diseases are caused by the inappropriate activity of specific 
genes, the ability to silence and regulate such genes selectively 
through RNAi could provide a means to treat a wide range of human 
diseases. The discovery of RNAi has been heralded by many as a major 
breakthrough, and the journal Science named RNAi the top scientific 
achievement of 2002, as well as one of the top 10 scientific 
advances of 2003. 

About Alnylam 

Alnylam is a biopharmaceutical company seeking to develop and 
commercialize novel therapeutics based on RNA interference, or RNAi. 
Growing from its foundation as the world's first company focused on 
RNAi therapeutics, the company's leadership in the field of RNAi is 
supported by its preeminent founders and advisors and its strengths 
in fundamental patents, technology, and know-how that underlie the 
commercialization of RNAi therapeutics. Alnylam is developing a 
pipeline of RNAi products using Direct RNAi(TM) to treat ocular, 
central nervous system, and respiratory diseases and Systemic RNAi
(TM) to treat a broad range of diseases, including oncology, 
metabolic, and autoimmune diseases. The company's global 
headquarters are in Cambridge, Massachusetts. For additional 
information, please visit www.alnylam.com. 

About MWG Biotech AG 

MWG Biotech AG (www.mwg-biotech.com) is an international provider of 
DNA sequencing and DNA/siRNA synthesis products and services for 
academic and industrial research from production sites in Germany, 
the US, and India. With strong customer orientation, fast service 
and high quality products the company creates the platform for 
success in the life sciences today and for a better life tomorrow. 
In its siRNA portfolio the company offers, in addition to a range of 
siRNA products, a series of advance siRNA design tools and other 
siRNA services. 

Alnylam Forward-Looking Statements 

Various statements in this release concerning our future 
expectations, plans, prospects and future operating results 
constitute forward-looking statements for the purposes of the safe 
harbor provisions under The Private Securities Litigation Reform Act 
of 1995. Actual results may differ materially from those indicated 
by these forward-looking statements as a result of various important 
factors, including risks related to: our approach to discover and 
develop novel drugs, which is unproven and may never lead to 
marketable products; our ability to obtain additional funding to 
support our business activities; our dependence on third parties for 
development, manufacture, marketing, sales and distribution of our 
products; the successful development of products, all of which are 
in early stages of development; obtaining regulatory approval for 
products; competition from others using technology similar to ours 
and others developing products for similar uses; obtaining, 
maintaining and protecting intellectual property utilized by our 
products; and our short operating history; as well as those risks 
more fully discussed in the "Certain Factors That May Affect Future 
Results" section of our most recent Form 10-Q filed with the 
Securities and Exchange Commission. In addition, any forward-looking 
statements represent our views only as of today and should not be 
relied upon as representing our views as of any subsequent date. We 
do not assume any obl

[ biotech news ] New Report Examines Biotech Giant Amgen’s Success and Future Direction

[famouswba]

New Report Examines Biotech Giant Amgen's Success and Future 
Direction 
  Amgen is the world's largest biotechnology company and the eighth 
largest pharmaceutical company worldwide, with revenues reaching $10 
billion in 2004. Arrowhead Publishers' new report takes a detailed 
look at the company's many successes and its strategy for the 
future. (www.arrowheadpublishers.com/Amgen.html)

Minneapolis, MN July 26, 2005 -- Amgen is the world's largest 
biotechnology company and the eighth largest pharmaceutical company 
worldwide. Revenues have nearly doubled in the last three years, 
going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet the 
majority of revenue is based on twenty-year old technology. Can 
Amgen continue its amazing revenue growth? Or will it fall behind, 
lacking the small molecule therapeutics that are the main stay of 
modern pharmaceuticals?

Arrowhead Publishers' new report entitled "Amgen: Profile, Patents 
and Pipeline" answers these important questions. It provides 
detailed analysis and information concerning Amgen's business 
activities. This report also includes a thorough accounting of the 
company's patents and patent applications.

This report provides an in-depth analysis of Amgen's

•Strategic strengths and weaknesses
•Current therapeutic products and pipeline of future products 
•Financial analysis, including R&D productivity 
•Current patents and patent applications
•Alliances, joint ventures and acquisitions
•Key personnel 

Who should buy this report?

•Biotech and pharmaceutical companies of all sizes interested in 
understanding Amgen's rapid climb to success and its future 
direction 
•Early stage biotechnology companies interested in understanding 
Amgen Ventures strategy for investing its $100 million 
•Financial analysts looking for an in-depth technical analysis 
of Amgen's future revenue sources

Key reasons to purchase this report

•Competitive intelligence
•Benchmark company performance against the leading biotechnology 
company
•Understand what is driving Amgen's growth, and what is holding 
it back

This 81 page up-to-date report, based on information gathered 
through the end of the first quarter 2005, contains five tables on 
Amgen's pipeline; a listing of the last three years of granted 
patents, analyzed by therapeutic area as well as therapeutic form; a 
breakdown of sales for all key products; both U.S. and 
International, as well as a list of all patent applications for 2004 
through the first quarter of 2005.
 
http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
http://www.arizonabiotech.com/index.php";>Biotechnology News 
Forums









http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotech CEOs Seek SBA Fix to Continue Their Medical Research

[famouswba]

281 Biotech CEOs Seek SBA Fix to Continue Their Medical Research



WASHINGTON, July 26, 2005 

To demonstrate its support of H.R.2943 and S.1263, the "Save 
America's Biotechnology Innovative Research (SABIR) Act," the 
Biotechnology Industry Organization (BIO) today submitted a letter 
to Congress endorsed by 281 biotechnology CEOs and senior executives 
who are asking that this legislation be passed. 


 
The legislation, introduced in the House by Sam Graves (R-Mo.) and 
in the Senate by Kit Bond (R-Mo.), corrects the Small Business 
Administration's (SBA) new interpretation of eligibility standards 
related to Small Business Innovation Research (SBIR) grants. 

The Rural Enterprises, Agriculture and Technology Subcommittee of 
the House Small Business Committee is holding a hearing on the issue 
at 2 p.m. Wednesday, July 27 in Room 2360 of the Rayburn House 
Office Building. Douglas A. Doerfler, president and CEO of MaxCyte 
Inc., of Gaithersburg, Md., will testify on behalf of BIO. 

The SBA's action has forced many biotechnology companies to stop or 
curtail research into therapies for many diseases, including HIV, 
lupus, diabetes, leukemia, Alzheimer's and West Nile virus. 

Presently, companies that are 51 percent owned by a group of venture 
capital firms are not eligible for SBIR grants. Most small and 
emerging biotechnology companies, which are years away from owning 
revenue-generating drugs or biologics, must look to the venture 
capital community for investments to fund the very high-cost 
preclinical and clinical research. 

"Prior to the SBA's new interpretation, many small biotechnology 
companies relied on SBIR grants to validate the potential of their 
research as they raised critical start-up investment funds," said 
Jim Greenwood, BIO's president. "In submitting this letter, endorsed 
by 281 CEOs -- many of whom run companies that have been impacted by 
the new interpretation -- we urge Congress to support this new 
legislation and re-start the flow of funds to innovative 
biotechnology companies." 

Doerfler and Morrie Ruffin, BIO's executive vice president of 
capital formation and business development, discuss the impact of 
SBIRs on the biotechnology industry during a BioLive Webcast for BIO 
members. An excerpt can be viewed at 
members.bio.org/biovideos/biolive_0705s.asx. 

BIO represents more than 1,100 biotechnology companies, academic 
institutions, state biotechnology centers and related organizations 
across the United States and 31 other nations. BIO members are 
involved in the research and development of healthcare, 
agricultural, industrial and environmental biotechnology products. 



http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech 
News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
http://www.arizonabiotech.com/index.php";>Biotechnology News 
Forums








http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Prana Biotechnology Strengthens Board With Non-Executive Appointment

[famouswba]

Prana Biotechnology Strengthens Board With Non-Executive Appointment
Friday July 29, 8:00 am ET 


MELBOURNE, Australia, July 29  -- Prana Biotechnology Limited 
(Nasdaq: PRAN, ASX: PBT), is pleased to announce the appointment of 
Peter Marks as a non-executive director. Mr. Marks brings to Prana 
extensive experience in the areas of corporate finance and advice 
and venture capital investment, having specialized in capital 
raisings (for listed and unlisted companies), underwritings and 
initial public offerings in London and Australia.
Mr. Marks currently serves as Executive Chairman of Premier Bionics 
Ltd., an investment company focused on investing in later stage 
Australian-based research and development projects that demonstrate 
strong commercial potential. He has served as an Associate Director 
of McIntosh Securities, now Merrill Lynch Australia, as well as held 
senior corporate finance positions at Barings Securities Ltd. and 
Burdett Buckeridge & Young Ltd. in their Melbourne offices. In his 
roles with these various financial institutions, he was responsible 
for advising a substantial number of listed and unlisted companies 
on issues ranging from corporate and company structure, to 
valuations, business strategies, acquisitions and international 
opportunities.

In addition, Mr. Marks has served as Head of the Melbourne Companies 
Department at the Australian Stock Exchange; been a founding 
Director of Momentum Funds Management Pty Ltd, an Australian venture 
capital firm; and was employed by KPMG Corporate Finance Ltd 
(Australia), where he rose to Director and was responsible for 
heading up the equity capital markets group in Melbourne.

Geoffrey Kempler, chairman and CEO of Prana, said, "Peter brings 
invaluable and highly relevant financial experience to the Board, as 
well as wise counsel. His appointment brings to three the number of 
non-executives on the Board. Peter will serve on the Audit 
Committee, helping to maintain a high level of corporate compliance."

Mr. Marks holds a Bachelor of Economics, Bachelor of Laws and 
Graduate Diploma in Commercial Law from Monash University in 
Melbourne, Australia. He completed his MBA at the Scottish School of 
Business at the University of Edinburgh.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into 
Alzheimer's disease and other major age-related degenerative 
disorders. The company was incorporated in 1997 and listed on the 
Australian Stock Exchange in March 2000 and listed on NASDAQ in 
September 2002. Researchers at prominent international institutions 
including the University of Melbourne and Massachusetts General 
Hospital, a teaching hospital of Harvard Medical School, discovered 
Prana's technology.


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Women in Biotechnology Issues Invitation to 4th Annual Boston Breakfast Meeting

[famouswba]

Women in Biotechnology Issues Invitation to 4th Annual Boston 
Breakfast Meeting Aug. 9, 2005 

Exciting Program Planned on Biotech Public Affairs Issues

The Boston Chapter of Women in Biotechnology issued an invitation 
today to its 4th Annual Breakfast Meeting, which features three 
prominent industry public affairs practitioners exploring the 
theme, "Promoting Your Company's Agenda" regarding public affairs 
issues. The speakers will reflect on how public affairs 
professionals present company and industry positions on products, 
reimbursement and legislative issues, and how to raise the money to 
afford them. The meeting will be held on August 9, 7:30-9:30 AM at 
the D'Arbeloff Suite at Boston's Museum of Science. Continental 
breakfast and networking from 7:30-8 AM. 

The meeting is sponsored by Thermo Electron Corporation, a worldwide 
manufacturer of laboratory, analytical, measurement and control 
instruments and software. 

Program Speakers Will Explore Public Affairs Issues in Biotech 

All three program speakers are respected public affairs 
practitioners who will be imparting a wealth of knowledge on 
product, reimbursement and legislative issues. The speakers are: 

-- Janice Bourque, Senior Vice President, Comerica Incorporated 

-- Susan Zagame Reardon, Esq., Director of Federal Affairs, Johnson 
& Johnson 

-- Janet Trunzo, Executive Vice President for Technology and 
Regulatory Affairs, AdvaMed (Advanced Medical Technology 
Association) 

Meeting Registration Available Online 

Register online for Women in Biotechnology's 4th Annual Breakfast 
Meeting at www.womeninbiotechnogy.com. For questions, please contact 
Kathleen Bernstein at [EMAIL PROTECTED] On-site registration 
will be accepted on a space-available basis, members, $50, non-
members, $80. 

About Women in Biotechnology: Women in Biotechnology is a multi-
disciplinary, global coalition of women looking for an informal 
setting to exchange ideas. Women in Biotechnology meets periodically 
for informational, educational and networking sessions around events 
relevant to our field. Women in Biotechnology founders are Kathleen 
Bernstein of Seidler Bernstein, Inc.; Lena Chow of City of Paris, 
Inc.; and Kathleen Dunn of KFDunn and Associates. In support of the 
professional growth of their peers, the founders of Women in 
Biotechnology encourage ongoing development of new leaders for the 
group. To learn more, visit www.womeninbiotechnology.com.


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] Biotechnology Asia 2005 Expects 6,000 Trade Visitors

[famouswba]

Biotechnology Asia 2005 Expects 6,000 Trade Visitors


KUALA LUMPUR, July 29 (Bernama) -- Biotechnology Asia 2005 
Exhibition and Conference is expected to attract 6,000 trade 
delegates, speakers, policy makers, industry professionals and 
researchers who will gather to discuss opportunities and challenges 
in the fast-booming biotech industry.

Conference organising chairman Dr Abdul Reezal Abdul Latif said last 
year's event had received good response with 5,000 trade visitors 
from 15 countries.

The exhibition this year will be held at the Putra World Trade 
Centre (PWTC) here from August 16 to 18.

At a press conference here today, Abdul Reezal said 45 local and 
international companies have confirmed their participation in the 
exhibition which would showcase an array of products and services.

The inaugural Biotechnology 2005 Innovation Awards will also be 
presented during the event.

http://www.bernama.com.my/bernama/v3/news_business.php?id=147517

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php







http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
 

[ biotech news ] DuPont Announces New Biotechnology Advisory Panel Member

[famouswba]

DuPont Announces New Biotechnology Advisory Panel Member
Thursday July 28, 11:45 am ET 


WILMINGTON, Del., July 28  -- DuPont today announced the addition of 
Mr. Chebet Maikut to its external Biotechnology Advisory Panel. Mr. 
Maikut is the president of the Uganda National Farmers Federation 
(UNFFE), one of the largest farmer organizations in Uganda. He joins 
the ranks of seven other distinguished panel members who bring 
important and diverse viewpoints to the broad area of biotechnology 
and its application in agriculture, food and bio-based materials.
"Chebet Maikut's knowledge of African agriculture will provide 
valuable insight into biotechnology policy and acceptance from the 
perspective of a developing country and market," said DuPont 
Chairman and CEO Charles O. Holliday, Jr. "He brings a strong voice 
that represents both African opinions on biotechnology as well as 
prospective customer segments in this emerging market."

As a farmer in the Kapchorwa District, Uganda, Maikut is no stranger 
to the challenges facing African growers. He has dedicated his 
career to empowering others to create a better quality of life 
through the development of a sustainable African agricultural 
industry. In addition to his role at the UNFFE, Maikut holds several 
other leadership positions, including vice president, Eastern Africa 
Farmers Federation (EAFF) and member of the Interim Panel of Eminent 
Experts to the Global Crop Diversity Trust. He is also an active 
participant of the CGIAR Sub-Saharan Challenge Program.

Formerly, Maikut was chairman of the International Federation of 
Agricultural Producers' Committee on Science and Technology; a 
District Councilor, Constituent Assembly (CAD) and a member of 
Parliament (MP) in the National Assembly of Uganda representing 
Kween in the Kapchorwa District. Before then, he worked with the 
Republic of Uganda Ministry of Agriculture Animal Industry and 
Fisheries (MAAIF).

Established in 2000, the DuPont external Biotechnology Advisory 
Panel is an independent panel charged with providing counsel to 
guide DuPont's actions, help create positions on important issues, 
as well as challenge the organization in the development, testing 
and commercialization of new products based on biotechnology.


In addition to Maikut, the other panel members include:

 -- Dr. Marcelo Carvalho de Andrade, an accomplished advocate of
sustainable community development and environmental 
preservation and
restoration.  He is the founding chairman of Pro-Natura, the 
first
international, nongovernmental organization headquartered in 
the
Southern Hemisphere to specialize in sustainable development.
 -- Professor Chunming Chen, founding president of the Chinese 
Center for
Disease Control and Prevention and currently senior advisor 
and
professor of nutrition.  Professor Chen is an internationally
recognized expert in nutrition.
 -- Dr. Pablo Eyzaguirre, senior scientist for anthropology and 
socio-
economics in the Genetic Resources Science and Technology 
group of the
International Plant Genetic Resources Institute (IPGRI) 
based in Rome.
Dr. Eyzaguirre is a specialist in social and ecological 
anthropology,
tropical farming systems, and agrarian institutions.
 -- Father Kevin T. FitzGerald, S.J., Ph.D., research associate 
professor
in the Department of Oncology at Georgetown University 
Medical Center.
Father FitzGerald is internationally known and sought after 
for his
expertise in human genetic engineering, cloning and stem cell
research.
 -- Carol Tucker Foreman, well-known and respected consumer 
advocate and a
distinguished fellow and director of the Consumer Federation 
of
America's Food Policy Institute.  Foreman has had a major 
impact on
diet and health in the United States over the last 25 years.
 -- Dr. V. Prakash, director of the Central Food Technological 
Research
Institute (CFTRI) in Mysore, India.  He is internationally 
known for
his work in sustainable food and nutrition security.  As a 
scientist
in the area of biotechnology, Dr. Prakash has won a large 
number of
awards and is a member of several international committees.
 -- Dr. Sven Thormahlen, vice president of the Research and 
Development
Organization of the Danone Group, a world leading company in 
the field
of dairy products, biscuits and mineral water.  Thormahlen's
experience covers product research, product development, 
clinical
studies and quality assurance.

The work of the advisory panel is facilitated by the Keystone 
Center, a non-profit organization based in Keystone, Colo., which 
includes a regular audit of DuPont's progress in the biotechnology 
arena. This public report is available at 
http://www2.dupont.com/Biotechnology/en_US/difference/advisory.htm

[ biotech news ] GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT

[famouswba]

GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT 
-
---
 
 17:51 IST  
Lok Sabha 


The Department of Biotechnology provides grant-in-aid support for 
research & development, and capacity building in the area of 
biotechnology to universities, research institutes and not-for-
profit organizations across the country.  In addition grant-in-aid 
is also provided for creation of Centers of Excellence in emerging 
areas.  During the last 5 years more than 2000 R&D Projects have 
been supported; 74 universities have been supported for post-
graduate biotechnology programmes, 60 universities and research 
institutes have been provided support for bioinformatics network 
centers.  In addition 57 biotechnology infrastructure facilities 
have been established across the country for cutting edge basic 
research and process and product development.

To promote excellence in biotechnology it is proposed to 
establish Centers of Excellence in the areas of :

Ø   Transnational research in public health

Ø   Stem Cell
Ø   Marine biotechnology

Ø   Animal biotechnology
Ø   Nutritional genomics and food biotechnology

Ø   Herbal Medicine

Ø   Molecular medicine
Ø   Bio-materials and devices and

Ø   Bio-informatics

In addition centers would also be supported in other frontier 
emerging areas of Biotechnology.

This information was given by Shri Kapil Sibbal, 
Minister of State, Science and Technology and Ocean Development in 
Lok Sabha today.

 

 


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php






http://www.arizonabiotech.com/
http://www.arizonabiotech.com/";>Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
http://groups.yahoo.com/group/biotech-news/";>Biotech News
http://www.arizonaentrepreneurs.com/
http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs
http://www.azhttp.com/
http://www.azhttp.com/";>Arizona High Tech
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/